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1 Summary 
This thesis deals with 
• the investigation of chemically induced cardiomyogenesis of mouse ES cells, 
• a simplified procedure for the synthesis of Takemoto’s catalyst, 
• the development of the first Lewis acid catalysed asymmetric aza-BH reaction. 
1.1 Chemically Induced Cardiomyogenesis of mES Cells 
Cardiomyocytes are used as donor cells in cell replacement therapies to treat serious 
heart damage. Despite the significant demand for heart cells, there exists up to now no 
efficient method for the production of these donor cells. The most promising approach 
so far is the in vitro cardiomyogenesis from embryonic stem (ES) cells induced by small 
molecules. However, with this method, only a small ratio of stem cells evolve into car-
diomyocytes. The design of new and highly selective small molecules is therefore of 
great interest.1  
 
1.1.1 Substance Screening 
 
For the identification of a cardiomyogenesis inducing substance, a rational drug de-
sign (RDD) was performed with a preliminary diversity orientated screening (DOS) 
focused on the synthesis and screening of (thio)urea and cinchona alkaloid based 
libraries. Derivatives of these (thio)ureas and cinchona alkaloids are known to exhibit 
bioactivities correlated to decreased proliferation rates of cancer cells2 or cardiac action 
potential,3 respectively. 
A transgenic murine ES cell lineage, expressing enhanced green fluorescence pro-
tein (EGFP) under the control of the heart specific promoter α-myosine heavy chain 
(pα-MHC), was used to investigate the effects of the test substrates on cardiomyo-
genesis. 
 
Diversity Orientated Screening (DOS). For a preliminary DOS, two substance libraries 
I and II containing (thio)urea (I, 19 compounds) or cinchona-alkaloid (II, 20 compounds) 
derivatives with extensively modified substitution patterns were synthesised and tested 
for their cardiomyogenesis inducing efficiency. 
Among the substrates tested, especially compounds I-6, I-15 and II-16 induced an 
increase of 80 %, 50 % or 60 %, respectively, of the EGFP fluorescence which corre-
lates with a positive cardiomoygenic effect (Scheme 1-1, p. 2). 
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  I-6         I-15     II-16 
 
 
 
 
 
Scheme 1-1 Influence of the compounds I-6, I-15 and II-16 on the expression of EGFP. Both a significant 
increase and decrease of values, compared to controls, represent an effect on the generation of cardiac 
cells. 
 
Rational Drug Design (RDD). On the basis of the three lead structures (I-6, I-15, II-16), 
a focused (thio)urea (III, 8 compounds) and a focused cinchona-alkaloid based library 
(IV, 9 compounds) were created, tested for their cardiomyogenic activity, and analysed 
in a RDD approach.  
The results obtained with the (thio)urea based library did not provide a sufficiently 
solid and reliable basis for a meaningful structure-activity relationship (in this case of 
small molecule induced cardiomyogenesis). 
In contrast, RDD analysis of the physiological screening of the cinchona alkaloid 
based library IV showed that especially variations on the alkoxy group (IV-5) and the 
quarternary ammonium moiety (IV-8) lead to an increased formation of cardiomyocytes 
(Scheme 1-2).  
 
 
 
               IV-5 
        
           II-16      
 
 
                       IV-8 
       
Scheme 1-2 Influence of the variations on the alkoxy and quarternary ammonium substituents 
(compounds IV-5 and IV-8) on the expression of EGFP. Both a significant increase and decrease of 
values, compared to controls, represent an effect on generation of cardiac cells.  
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Based on these positively tested substances (compounds IV-5 and IV-8), a new 
quinidine based substance library V (8, compounds) was developed and screened for 
its cardiomyogenesis inducing effectivity. This library contains substances which differ 
either in the alkoxy group attached to the quinidine moiety, or in the quinuclidine N-sub-
stituent compared to the lead structures IV-5 and IV-8. However, these structural modifi-
cations did not improve the cardiomyogenesis inducing effect of the lead structures.  
 
Conclusion. The substance screenings led to the identification of cardiomyogenesis 
inducing compounds with good (IV-5) to very good activities (II-16, IV-8) determined by 
a 50 to 80 % increase of the EGFP fluorescence compared to untreated cells.  
 
1.1.2 Identification of Signalling Cascades Involved in Cardiomyogenesis  
 
Verapamil rac-6, a cardiomyogensis inducing agent found in previous studies,4 and the 
most active compound identified in the substance screening II-16 were used for the 
identification of signalling cascades involved in the cardiomyogenesis by a time-depen-
dent screening approach. In this method, an increased cardiomyogenesis indicates in-
teraction of the compound tested with a target expressed at a certain point in time du-
ring the application time-frame of the test substrate.  
 
 
 
             rac-6   .       II-16  
Scheme 1-3 Cinchona alkaloid II-16 (left), verapamil rac-6 (racemic mixture, right). 
 
Since both substrates exhibited different cardiomyogenesis inducing profiles in each 
test series, the cardiomyogenesis inducing effect of the tested substrates appeared to 
rely on an interaction of the tested substances with several target proteins expressed at 
different points of time. In this case, time-dependent correlations between cardiomyo-
genesis and concentrations of the substrates are not suitable to limit the number of 
potential targets associated to the various developmental stages.  
 
1.2 A Simplified Synthesis of Takemoto’s Catalyst 
A significant number of C-C couplings can be catalysed enantioselectively by Take-
moto’s bifunctional amino thiourea derivative 51.5 The original synthesis of the amino 
N
CH2
N
OMe
OH
Cl
NMeO
MeO
OMe
OMe
MeiPrNC
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thiourea catalyst 51 consists in the facile addition of isothiocyanate 43 to N,N-dimethyl-
trans-1,2-diaminocyclohexane 11. The preparation of the N,N-dimethyl-trans-1,2-diami-
nocyclohexane building block 52 is a laborious four step procedure (Scheme 1-4).6,7 
NH2
NMe2
N
H NMe2
N
H
S
CF3
F3C
NCS
CF3
F3C
NH2
NH2 2 h, THF, r.t.
51, 63 %11 52
43
 
Scheme 1-4 Synthesis of the amino thiourea 51 developed by Takemoto. 
 
An improved synthesis of Takemoto’s catalyst 51 was realised consisting of only two 
steps: The thiourea moiety was obtained by condensation of 3,5-bistrifluoromethyl-
aniline 68 with phenyl chlorothioformate 71 and subsequent reaction with trans-1,2-
diaminocyclohexane 11, according to a modified reaction protocol of Nagasawa.8 
Subsequent reductive dimethylation using formaldehyd / zinc afforded Takemoto’s 
catalyst in an overall yield of 36 % (Scheme 1-5). 
 
N
H NH2
N
H
S
CF3
F3C N
H NMe2
N
H
S
CF3
F3CNH2
CF3
F3C
PhO
S
Cl
62, 50 % 51, 73 %
Zn / H2CO / AcOH
dioxane, r.t., 72 h
+
1) pyridine
2) diamine 11, 
    Hünig's base
CH2Cl2, r.t., 15 min
68 71  
Scheme 1-5 Improved synthesis of Takemoto’s catalyst 51. 
 
1.3 La-linked BINOL Catalysed Asymmetric aza-BH reaction 
The asymmetric aza-Baylis-Hillman (aza-BH) reaction of achiral imines with acrylates 
provides a direct access to chiral β-amino acid esters, which have gained considerable 
interest due to their important biological properties, their occurrence in natural products, 
and as potential precursors for β-lactams.9 
In this work, the first aza-Baylis-Hillman reaction catalysed by a chiral Lewis acidic 
complex was developed. Diphenylphosphinoyl- (dpp-) protected imines were employed 
as electrophiles, due to the ease of removal of this activating and protecting group. 
In an initial ligand screening with La(OiPr)3 and various (R)-BINOL-based ligands 
(Scheme 1-6, p. 5), high enantioselectivity was achieved with linked-(R,R)-BINOL 97. 
Since raising the ligand to metal ration for (R)-BINOL 101 from 1:1 to 2:1 showed no be-
neficial effect, the increase in enantioselectivity for linked-(R,R)-BINOL 97 complex was 
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discussed as effect of its higher stability compared to the La-(R)-BINOL complex. The 
introduction of sterically more demanding substituents in the (R)-BINOL 3,3’ position 
lead to catalysts with low reactivity and enantioselectivity. 
Ph H
Ndpp
OR
O
DABCO
Ph OR
ONHdpp
CF3F3C
Pr
Pr
iPr
H
OH
OH
R
R
O
HOOH
HOOH
La(OiPr)3
(R)-BINOL-based ligand
35 h, r.t., THF
+
98a 99 100
R =
i
i 105
102
97
103
104101
 
Scheme 1-6 Screening of (R)-BINOL-based ligands. 
 
The La-linked-(R,R)-BINOL complex is well known for its dual reactivity as Lewis acid 
and Brønsted base. However, increasing the basicity of the catalyst by deprotonation 
with KHMDS, NaHMDS or n-BuLi did not result in higher yields or enantioselectivities 
relative to the non-metallated species.  
A variation of the catalyst’s Lewis-acidity by complexation of linked-(R,R)-BINOL 97 
with various M(OiPr)x, identified Ln-complexes as the most efficient catalysts, whereas 
the more Lewis-acidic Ti-complex as well as the more Lewis basic Sr-complex led to 
decreased yields and enantioselectivities. 
An extensive screening of the reaction parameters was performed. The optimised 
conditions are shown in Scheme 1-7. 
Ph H
Ndpp
OMe
O 20 mol% DABCO
Ph OMe
ONHdpp
O
OH
OH
HO
HO
10 mol% La(OiPr)3 / ligand 97
35 h, 40 °C, THF
+
1.0 eq 98a 4.0 eq 99a 100aa 50 %, 90 % ee 97  
Scheme 1-7 Optimised reaction conditions for the aza-BH reaction catalysed by La-linked-BINOL 
 
In a substrate screening, among the acrylates tested, the highest yields were 
achieved with 2-naphthyl acrylate 99d (up to 67 %), while methyl acrylate 99a led to the 
highest enantioselectivities (up to 90 % ee). Comparison of dpp-protected benzald-
imine 98a with its para-Cl-substituted analogue 98b revealed in most cases higher 
enantioselectivities at virtually unchanged yields for the para-Cl-substituted and dpp-
protected benzaldimine 98b. Aliphatic imines were also tested, but only traces of the 
corresponding aza-BH adducts were detected. 
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Hydrolytic deprotection of the aza-Baylis-Hillman products 100 provided single step 
access to the corresponding β-amino acids 106 in up to 75 %  yield (Scheme 1-8). 
 
Ar OR
ONH
dpp
Ar OR
ONH2
100ab R = Ph, Ar = Ph
100ba R = Me, Ar = pClC6H4
75 % 106a Ar = Ph
62 % 106b Ar = pClC6H4
.
20 % HCl
reflux, 6 h
HCl
 
Scheme 1-8 Single step conversion of aza-BH adducts 100 to β-amino acids 106. 
 
Conclusions. It was shown for the first time that the aza-Baylis-Hillman reaction can be 
catalyzed enantioselectively by a chiral Lewis acidic metal complex. Using the La-
linked-(R,R)-BINOL complex as catalyst and dpp-protected imines as substrates the 
corresponding aza-BH adducts could be obtained in up to 68 % yield and up to 
90 % ee. Hydrolytic deprotection of the highly enantio-enriched aza-Baylis-Hillman 
products thus obtained grants access to α-methylene-β-aminoacids in a simple one pot-
procedure. 
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2 Introduction 
In modern sciences, interdisciplinary fields become more and more important. For 
example, organic chemistry and biology are linked by the building blocks of life. 
Chemically, such building blocks of life are small organic molecules (i.e. amino acids, 
sugars and nucleic bases) or polymers (i.e. proteins, nucleic acids, carbonhydrates). 
Biologically, the building blocks of life are cells (Scheme 2-1). 
 
ORGANIC
CHEMISTRY
AGROCHEMICALS
FOOD CHEMISTRY
PHARMACEUTICAL CHEMISTRY
herbicide, fungicide,
insecticide
flavours
pharmaceuticals
genetically
modified
BIOLOGY
yeast
soybeans
ES cells
BUILDING BLOCKS OF LIFE
sugars, amino acids, 
nucleic bases cells
 
Scheme 2-1: Building block of life as interdisciplinary field of organic chemistry and biology and their 
relations to applied chemistry. 
 
Cellular biology, studied since the 1800s, is the basis of current stem cell research. The 
advent of the microscope provided scientists a first look at human cells. At this time 
cells were identified as the building blocks of life, capable of reproducing and different-
tiating into all the cell types that make up the living body.  
Although the history of stem cell research started in the early 1900s with the disco-
very that the various types of blood cells all came from a particular ‘stem cell’, the po-
tential of these stem cells has been discovered in the late 1960s: McCulloch and Till 
detected self-renewing cells in mouse bone marrow10 and Altman as well as Das 
showed that adult neurogenesis was accompanied by stem cell activity in the brain.11 
Stem cell research has basically focused on bone marrow transplants. Since 1950, 
theses transplants have been used in patients additionally treated with radiation and 
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chemotherapy.12 However, first the pioneering discovery by Dausset in 1958, which 
identified the first human histocompatibility antigens, enabled the establishment of this 
stem cell  theraphy.13 
Developments in biotechnology in the 1980s and 1990s afforded techniques for 
targeting and altering genetic material as well as methods for growing human cells in 
the laboratory. These advances opened the doors for stem cell research.14 
In 1998, Thompson isolated cells from the inner cell mass of early embryos, and 
developed the first embryonic stem cell lines.15 The blastocysts used for human stem 
cell research typically originate from in vitro fertilization procedures. 
These discoveries stimulated further research. The growing interest in stem cell 
research is evident from the exponential increase of publications in this research area. 
The possibilities for stem cell research are indeed endless, but yet unpredictable. If 
scientists can master the biochemistry behind stem cell development, stem cell techno-
logy could be used, e.g. to produce replaceable tissues or organs. 
 A contribution to the stem cell development is the subject of the present work. In the 
first part of this thesis, the in vitro development of cardiomyocytes from ES cells induced 
by small molecules is described. 
 
Organic compounds such as pharmaceuticals, agrochemicals, flavors and fragrances 
play an improtant role in modern life. These compounds possess biological activity 
which arises from the interaction of the organic compound with a biological target. 
These biomolecules are single enantiomers of chiral compounds since they are con-
structed from chiral building blocks such as amino acids or carbohydrates, which are 
present in nature as a single enantiomer. 
Besides ex chiral pool syntheses (Scheme 2-2 (a)), there are two general methods 
for obtaining enantiomerically enriched compounds: (Scheme 2-2 (b)) they may be syn-
thesised in racemic form and resolved into their optical antipodes, or (Scheme 2-2 (c)) 
the synthesis may be directly performed in an enantioselective manner. 
(b) An example for the separation of enantiomers by chemical resolution based on 
the selective crystallisation of one enantiomer by diastereomeric salt formation. Al-
though this method is not generally applicable, it is still quite popular for the large scale 
preparation of enantiomerically pure acids or amines. Other approaches of resolution 
involve the formation of covalent bonds between the racemic substrate and an enan-
tiomerically pure compound. The resulting diastareomeric compounds can be separated 
by chromatographic technics and the desired enantiomer can be regenerated from the 
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appropriate diastereomer by chemical transformations. However, these methods yield 
only up to 50 % of the desired enantiomer. 
(c) For asymmetric syntheses, i.e. the generation of enantio-enriched compounds 
from achiral precursors, chiral auxilaries, chiral reagents or chiral catalysts, all in 
enantio-pure form, can be employed. There are prominent auxiliar-based synthesis, e.g. 
Ender’s SAMP/RAMP16 or Schöllkopf’s bislactim ether17 syntheses. However, the 
covalent binding to and cleaving from the substrate makes these procedures less 
efficient. Chiral enantio-pure reagents, e.g. BINAL-H,18 must be employed in stoichio-
metric quantities, this likewise decreases the efficiency of the synthesis. Hence, 
enantioselective catalyses with small amounts of “chiral information” are the most 
efficient procedures to obtain enantiopure chiral compounds. There are three different 
kinds of chiral catalysts employed in asymmetric synthesis, biocatalysts,19 metal ligand 
complexes derived from chiral ligands,20 and chiral organocatalysts.21 Enzymes as bio-
catalysts are very selective and efficient, but often tolerate only small temperature 
ranges, few solvents and a narrow range of sustrates. Metal complex catalysts are 
widely applied in organic chemistry, although the ligands and metals are often quite 
expensive. Catalysis by small organic molecules, e.g. proline, complements enantio-
selective synthesis, as such catalysts are often cheap, easy to modify and less toxic. 
 
chiral enantio-enriched product
achiral starting material
ex chiral pool
derivatisation
nature
non 
stereoselective
synthesis
racemic
mixture
racemic
resolution
enantioselective
synthesis
chiral auxilary
chiral reagent
chiral catalyst
a b c
 
Scheme 2-2 Three methods to obtain chiral, enantio-enriched compounds. 
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Altough impressive results were achieved in the field of asymmetric catalysis in the 
last decades, there is still the need for the development of highly selective and effective 
catalytic systems.  
A contribution to this is the subject of the present work. In the second and third part 
of this thesis, an improved two step synthesis of a prominent organocatalyst as well as 
the devopment of a new catalytic system for an established C-C coupling is described. 
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3 Chemically Induced Cardiomyogenesis of  mES Cells 
3.1 Background 
Cardiomyopathy results from the loss of functional heart muscle cells, impairing the 
ability of the heart to maintain adequate blood circulation. As adult differentiated cardio-
myocytes lack prominent regenerative capacity, heart transplantation remains the only 
effective causal treatment. An increasing number of patients suffer from severe heart 
failure, and the shortage of available donor organs emphasise the demand for 
alternative therapy methods, such as cellular cardiomyoplasty. In this context, several 
animal studies demonstrated a successful engraftment of cardiac myocytes into the 
adult heart.22,23 However, the limiting factor for a general application of cell therapy for 
the treatment of cardiovascular diseases still is the insufficient number of donor cells.  
Embryonic stem (ES) cells isolated from the inner cell mass of early blastocyst-stage 
embryos are pluripotent. They are capable of differentiating in vitro into any somatic cell 
type, including cardiomyocytes, haematopoietic progenitors, skeletal myocytes, smooth 
muscle cells, adipocytes, chondrocytes, endothelial cells, neurons and glia and pan-
creatic islet cells.15 When cultured in the presence of leukaemia inhibitory factor (LIF), 
ES cells remain undifferentiated and can be propagated indefinitely. Upon withdrawal of 
LIF, ES cells spontaneously and irreversibly differentiate into multicellular aggregates, 
so-called embryoid bodies (EBs). These aggregates resemble early post-implantation 
embryos and contain derivatives of all three germ layers.24  
So far, the in vitro differentiation of ES cells into cardiomyocytes offers a new approach 
for cellular therapy of degenerative heart diseases. Therefore, the development of new 
approaches allowing a direct differentiation of ES cells into cardiomyocytes is of growing 
interest.25 
 
The differentiation programs of ES cells can be shifted toward cardiomyogenic or 
neuronal differentiation by treatment with small molecules, such as retinoic acid 1 or 
dimethyl sulfoxide (DMSO) 2 (Scheme 3-1), at specific stages of differentiation.26,27 
 
 
 
 
Scheme 3-1: Retinoic acid 1 (left) and DMSO 2 (right). 
Me
S
Me
O
2Me
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1
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However, this approach is not very efficient, and normaly requires selection to enrich 
specific cell lineages. Several small molecules have recently been found to control the 
differentiation of ES cell into a specific cell lineage as well as to affect the self renewal 
of ES cells: 
 
Ascorbic acid. In 2003 Takashi et al.28 screened 880 compounds of the FDA2000 Drug 
Library, which were approved for human use, for their potential to induce cardiac 
differentiation of mouse ES cells in a monolayer culture. They used CGR8 mouse ES 
cells stably transfected with the cardiac muscle-specific α-MHC promotor driven EGFP 
as a reporter. They found that upon treatment with ascorbic acid 3 (vitamin C, Scheme 
3-2, p. 14) increased cardiac differentiation of ES cells in a dose-dependent manner. It 
can be assumed that this effect of ascorbic acid is independent of its antioxidative pro-
perty29, because antioxidants normally inhibit ES cell differentiation into cardiac myocy-
tes, whereas ROS (reactive oxygen species) like H2O2 or radical-generating menadione 
enhance cardiogenesis30. Other antioxidative agents such as N-acetylcystein, Tiron 
(brenzcatechine-3,5-disulfonic acid disodiumsalt) or vitamin E also do not mimic the 
effect of ascorbic acid on the cardiac differentiation. In addition, there was no significant 
effect of vitamin C 3 on the cardiomyogenesis via embryoid body formation. This sug-
gests that ascorbic acid induces permissive changes that occur during the formation of 
embryoid bodies, rather than induction of autonomous commitment of ES cells to car-
diac myocytes. 
 
5-Aza-2’-deoxycytidine. Based on the results of Fukuda et al.31, who ascertained an 
increased cardiomyogenesis of mesenchymal stem cells by adding the DNA-demethyla-
ting agent 5-aza-2’-deoxycytidine 4 (Scheme 3-2, p. 14), Xu et al.32 tested the effect of 
this compound on the differentiation of human ES cells into cardiomyocytes via embry-
oid body formation. Using immunostaining and real-time PCR they observed an in-
crease of cardiomyocyte formation by treating the human ES cells with 5-aza-2’-deoxy-
cytidine 4. Interestingly, DMSO and retinoic acid, which have been shown to induce car-
diomyocyte differentiation in mouse ES cells (see above), did not enhance human ES 
cell cardiomyocyte differentiation.  
 
Cardiogenol C. Schultz et al.33 screened a 100.000 compound library of so called 
privileged heterocycles34  using a stable engineered mouse embryonic carcinoma cell 
line P19 expressing luciferase under the control of the ANF promoter under monolayer 
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conditions. Like ES cells, P19 cells are pluripotent and are capable of differentiating into 
cardiac cells under specific culture conditions.35 They identified 80 compounds that 
increased luciferase activity. In addition, 35 compounds induced a parallel expression of 
sarcomeric α-MHC, a cardiac specific protein. In particular, these compounds share 
significant structure similarities possessing a 2-hydroxylamino substitution at the C-4 
position and large, hydrophobic groups at the C-2 position. To confirm that these com-
pounds are general cardiomyogenesis inducing agents, they analysed their effects on 
undifferentiated R1 mouse ES cells also in a monolayer culture. They detected more 
than 90 % positive cardiomyocyte formation of ES cells treated with Cardiogenol C 5 
(Scheme 3-2, p.14). Furthermore, they observed that compound treatment slowed down 
cellular proliferation with no significant cell death, indicating that this process is not 
simply a selection for cardiac precursor cells with the death of cells in other lineages. 
 
Verapamil, Ryanodine, Cyclosporin. Sachinidis et al.4 investigated the effects of 33 
small molecules interfering with several signalling cascades on cardiomyognesis. They 
used a transgenic ES cell lines expressing enhanced green fluorescent protein (EGFP) 
under the conrol of the α-myosin heavy chain promoter (pαMHC). In this screening, 
especially the L-type Ca2+ channel blocker Verapamil 6 as well as Ryanodine 7, an 
inhibitor of the protein phosphatase 2B, and Cyclosporin A 8, an Calcineurin inhibitor 
(Scheme 3-2, p. 14), exerted the most striking pro-cardiomyogenic effect. Treatment of 
the EBs with Verapamil 6 caused a pronounced 94 % increase and treatment with 
Ryanodine 7 resulted in a significant 75 % increase of the EGFP fluorescence com-
pared to untreated cells. Ryanodine 7 is a natural compound acting through binding to 
the Ryanodine receptor (RyR), the Ca2+ channel of the sarcoplasmatic reticulum (SR), 
resulting in the release of Ca2+ into the sarcoplasm. Depending on the cell type and 
concentration, Ryanodine 7 induces an inhibition or activation of the release of Ca2+ 
from SR.36 Verapamil 6 is an antagonist of the plasma membrane L-type Ca2+ channel 
thereby inhibiting the influx of extracellular Ca2+ into the cytosol.37 Furthermore, 
Sachinidis et al. observed that spontaneous contractions of ES cell derived cardiomyo-
cytes were totally inhibited when Verapamil 6 was present at late stages of cardiac dif-
ferentiation. From these results, Sachinidis et al. concluded that cyctosolic Ca2+ is invol-
ved in the differentiation of cardiomyocytes from ES cells and that [Ca2+]i lowering 
agents promote cardiomyogenesis even if the physiological activity of beating is 
inhibited. 
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Exposure of EBs to Cyclosporin A 8 caused an increase of the EGFP fluorescence up 
to 140 %. Cyclosporin A 8 is an amino acid cyclic peptide used as immunosuppressant 
compound. Complexes of Cyclosporin A 8 with the immunophilin Cyclophilin A within 
the cell inhibit the Ca2+- and calmodulin-dependent protein phosphatase 2B (Calcineu-
rin). Futhermore there is an accumulating evidence that Calcineurin is also involved in 
the regulation of other cellular processes such as embryonic development and cancer, 
as well as cardiac valve formation and cardiac hypertrophy.38  
 
 
 
 
  3          4                      5 
 
 
 
    6 
 
 
 
 
   7     8 
Scheme 3-2  Cardiomyogenesis inducing substances: ascorbic acid 3, 5-aza-2’deoxycytidine 4, Cardio-
genol C 5, Verapamil 6, Ryanodine 7 and Cyclosporine A 8. 
 
3.2 Concept 
3.2.1 Forward Chemical Genetics Approach 
 
The in vitro differentiation of ES cells into cardiomyocytes offers a new approach for 
cellular therapy of degenerative heart diseases. For a direct differentiation of ES cells 
into cardiomyocytes experimental methods are required allowing rapid and “easy to 
handle” parallel testing of small molecules which may influence the differentiation of ES 
cells towards cardiomyocytes. For this aim, a transgenic ES cell lineage is used, 
expressing enhanced green fluorescent protein (EGFP) under the control of the heart 
specific promoter α−myosine heavy chain (pα-MHC) to test selected substances for 
their cardiomyogenesis inducing activity (Scheme 3-3, p. 15).39,40 
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Scheme 3-3 Forward chemical genetics approach. After culturing of transgenic ES cells in multi-well 
plates, a library of small molecules can be screened by addition of one single compound per well. After 
differentiation, small molecules can be identified participating in the generation of the desired phenotype. 
Further modifications based on the structure of these active test substrates should lead to an enhanced 
differentiation potential of the tested compounds. 
 
In general, two strategies exist for the identification of cardiomyogenesis stimulating 
substances: structure based drug design (SBDD), or rational drug design (RDD).41,42,43 
The SBDD involves the search for a small molecule that perfectly fits in the binding 
pocket of a target protein, and thus influences the signalling pathway. An application of 
this method requires knowledge about the signalling pathways, the proteins involved 
and their structures.  
The RDD describes the relationship between chemical structures and their biological 
effects. For a successful correlation all tested compounds must bind to the same target. 
To fulfil this requirement, the test substrates must have very similar chemical structures. 
To find a capable lead structure for the RDD, a foregoing diversity orientated screening 
(DOS) is performed. Within this screening, substances are tested which cover a broad 
structural spectrum with fixed core structures. 
absence of the  
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As the structures of the proteins involved in the signalling pathways - which are 
assumed to promote cardiomyogenesis of ES cells - are mostly unknown, the require-
ments for a SBDD approach are not fulfiled. Therefore a RDD with a preliminary DOS 
was performed focused on the synthesis and screening of (thio)urea and cinchona-
alkaloid based compound libraries.   
 
3.2.2 Selection of Substrates 
 
Stem cells and cancer cells share the similarity that both cell types exhibit high 
proliferation rates. According to the cancer stem cell theory, drugs which induce 
differentiation of stem cells thereby also decrease their proliferation rates. If the same 
applies for cancer cells, drugs for cell differentiation could be used for anti-cancer thera-
pies and vice versa. The prominent anti cancer drug Nexavar® (Sorafenib) harbours a 
thiourea moiety (Scheme 3-4).2 Therefore, the selection of substances has been 
focused first on (thio)urea derivatives.  
 
Scheme 3-4 Chemical structure of the prominet anti cancer drug Nexavar®. 
 
A second selection of substances has concentrated on ammonium salts derived from 
cinchona alkaloids, as they are well known for their phase transfer abilities44 which 
should promote membrane permeation by drugs. Furthermore, quinidine is a pharma-
ceutical agent that acts as a class I antiarrhythmic agent in the heart. The effect of 
quinidine on the ion channels is to prolong the cardiac action potential and thereby 
prolonging the QT interval on the surface electrocardiogram (ECG).3 
 
3.3 Results and Discussion 
3.3.1 Substance Screening 
 
For the identification of a cardiomyogenesis stimulating substance, a rational drug 
design with a preliminary DOS focused on the synthesis and screening of (thio)urea and 
cinchona-alkaloid based compound libraries was performed.  
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Differentiation Protocol – for DOS, RDD45. A transgenic murine ES cell lineage 
expressing enhanced green fluorescent protein (EGFP) under control of α-myosine 
heavy chain (α-MHC) promoter (pα-MHC- EGFP) was used to investigate the effects of 
(thio)urea and cinchona-alkaloid derivatives on cardiomyogenesis. To start differentia-
tion, ES cells were cultured in suspension for 12 h to form EBs. About fifty EBs were 
transferred to each well of bacterial 6-well plates and the test compounds were added. 
On day 7, fresh medium and fresh test compounds were added. On day 14, EBs on 
each plate were counted, lysed and the EGFP fluorescence in the lysates was 
measured at an excitation wavelength of 476 nm and an emission wavelength of 
508 nm.  
 
Diversity Orientated Screening (DOS). For a first DOS, two substance libraries I and 
II containing (thio)urea (I) or cinchona-alkaloid (II) derivatives with extensivly modified 
substitution patterns (Scheme 3-5 and Scheme 3-6, p. 18-19) were synthesised and 
tested for their cardiomyogenesis inducing efficiency. 
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Scheme 3-5 Structures contained in the (thio)urea-based library I. 
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Scheme 3-6 Structures contained in the cinchona-alkaloid-based library II. 
 
The cardiomyogenic effect of the substances is expressed as percent of the EGFP 
fluorescence of the vehicle treated cells (100%). An increased production of cardio-
myocytes gives percent of control values higher then 100 %, a decreased production of 
cardiomyocytes lower than 100 %. 
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Among the (thio)urea derivatives (library I) tested, especially the bis-ureas I-6 and I-15 
induced an increase of 80 % or 50 %, respectively, of the EGFP fluorescence which 
correlates with a positive cardiomoygenic effect. In the cinchona-alkaloid based library II 
the best result could be obtained with the quinidine based salt II-16 which induced a 
60 % increase (Scheme 3-7). 
 
 
 
 
 
        I-6 
 
 
 
 
 
 
 
 
      I-15 
 
 
 
 
 
 
 
     II-16 
 
 
Scheme 3-7 Influence of the compounds I-6, I-15 and II-16 on the expression of EGFP, normalised to the 
number of EBs. Values from four independent experiments (mean ± SD, n=4), each performed in 
triplicate, are displayed as percent of control values (=100 %, only vehicle, without test substrate). Both a 
significant increase and decrease of values, compared to controls, represent an effect on the generation 
of cardiac cells. 
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Rational Drug Design (RDD). On the basis of the three lead structures (I-6, I-15, II-16) 
found in the foregoing diversity orientated screening, a focused (thio)urea (III, Scheme 
3-8) and a focused cinchona-alkaloid based library (IV,Scheme 3-9) were created. 
These libraries were tested for their cardiomyogenic activity and analysed in a rational 
drug design. As mentioned before, a meaningful RDD requires binding to the same 
target protein. Therefore, analogues were synthesised which differ only slightly com-
pared to the starting compounds, as smaller structural differences can be assumed to 
lead to a higher probability of binding to the same target protein. 
The substrates III-1, III-3 and III-5 (Scheme 3-8) are based on the lead structure I-6. 
They differ from this lead compound in the thiourea moiety (III-1) or in the aromatic 3,5-
subtituents (III-3, III-5). Test compounds III-2, III-4 and III-7 were evolved from the lead 
structure I-15. Substrate III-2 harbours a thiourea function instead of the urea moiety 
and the test compounds III-4 and III-7 exhibit additional aromatic 3,5-subtituents. 
Variation of the chiral diamino backbone led to the test compounds III-6 and III-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-8 Structures contained in the focused (thio)urea-based library III. Differences to the lead 
structures I-6 resp. I-15 are coloured in red. 
 
The substrates in library IV (Scheme 3-9) differ from the lead structure II-16 in the 
methylated hydroxyfunction (IV-1), the hydrogenated double bond (IV-2), the inversion 
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of the stereocenters at C8 and C9 (IV-9), a variation in the alkoxy group (IV-4 and IV-5) 
or in the quaternary ammonium moiety (IV-3, IV-6, IV-7, IV-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-9 Structures contained in the focused cinchona alkaloid-based library IV. Differences to the 
lead structure II-16 are coloured in red. 
 
The cardiomyogenesis inducing effect of the lead structures I-6, I-15, identified in the 
DOS, could not be reproduced in the RDD screening, despite the fact that the same 
screening method (see differentiation protocol) was used (Scheme 3-10, p. 23). 
Consequently, (thio)ureas and their structural variations appear not to provide a 
sufficiently solid and reliable basis for a meaningful structure-activity relationship (in this 
case of small molecule-induced cardiomyogenesis).            
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Scheme 3-10 Influence of the compounds I-6 and I-15 on the expression of EGFP, normalised to the 
number of EBs. Values from four independent experiments (mean ± SD, n=4), each performed in 
triplicate, are displayed as percent of control values (=100 %, only vehicle, without test substrate). Both a 
significant increase and decrease of values, compared to controls, represent an effect on the generation 
of cardiac cells (left – results of the physiological screening of compound I-6; right – results of the 
physiological screening of compound I-15). 
 
A possible explanation for these results might be that the thio(urea)-substrate binding is 
not specific, but rather depends on medium parameters, such as pH value or tempera-
ture, which are influenced by metabolism of the ES cells and therefore can hardly be 
controlled. Such small changes in the experimental environment would then lead to a 
significant influence of a possible (thio)urea induced cardiomyogenesis.  
 
In contrast, in the quinidine based library IV, the positive effect of the lead structure II-16 
on the generation of cardiac cells identified in the DOS could be reproduced in the RDD, 
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i.e. the shapes of the curves are very similar, both show maximal effect (in between 60 
to 80 % increase) at a substrate concentration of 1·10-5 M (Scheme 3-11). 
  
       screening results DOS 
 
 
 
 
           II-16 
 
 
 
                                screening results RDD 
  
 
  
 
 
 
 
 
Scheme 3-11 Influence of the compound II-16 on the expression of EGFP, normalised to the number of 
EBs. Values from four independent experiments (mean ± SD, n=4), each performed in triplicate, are 
displayed as percent of control values (=100 %, only vehicle, without test substrate). Both a significant 
increase and decrease of values, compared to controls, represent an effect on generation of cardiac cells 
(top – results of the physiological screening for the DOS; bottom – results of the physiological screening 
for the RDD). 
 
RDD analysis of the physiological screening of the cinchona alkaloid based library IV 
shows that, compared to the lead structure II-16, the inversion of the C8 and C9 stereo-
centers (IV-9), the hydrogenation of the double bond (IV-2) or the methylation of the 
hydroxyfunction (IV-1) result in the loss of cardiomyogenesis-inducing activity. In con-
trast, especially variations on the alkoxy group (IV-5) and the quarternary ammonium 
moiety (IV-3,6,7,8) lead to an increased formation of cardiomyocytes. The best hits 
could be obtained with the quinidine derivatives (IV-5) (up to 50 % increase) and (IV-8) 
(up to 70 % increase) (Scheme 3-12, p. 25). 
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       IV-5 
 
 
       II-16 
        
 
 
        IV-8         
 
Scheme 3-12 Influence of the variations on the alkoxy and quarternary ammonium substituents 
(compounds IV-5 and IV-8) on the expression of EGFP, normalised to the number of EBs. Values from 
four independent experiments (mean ± SD, n=4), each performed in triplicate, are displayed as percent of 
control values (=100 %, only vehicle, without test substrate). Both a significant increase and decrease of 
values, compared to controls, represent an effect on generation of cardiac cells.  
 
Based on these positively tested substances (compounds IV-5 and IV-8), a new 
quinidine based substance library V was developed and screened for its cardio-
myogenesis inducing effectivity. This library contains substances which differ either in 
the alkoxy group attached to the quinidine moiety (V-8), or in the quinuclidine N-
substituent (V-1 - V-7) compared to the lead structures IV-5 and IV-8 (Scheme 3-13, p. 
26) 
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Scheme 3-13 Structures contained in the quinidine based library V. Differences to the lead structures IV-
5 resp. IV-8 are coloured in red. 
 
Physiological screenings of the quinidine based library V identified compound V-4 as 
the most effective cardiomyogenesis inducing substance with a maximal 50 % increase 
of the EGFP fluorescence at a concentration of 1·10-6 M (Scheme 3-14). In summary, 
the structural modifications introduced by compounds V-1 – V-8 did not improve the 
cardiomyogenesis inducing effect of the original hit, i.e. compound II-16 (60-80 % in-
crease in cardiomyogenesis). 
 
 
 
 
 
        V-4 
 
 
Scheme 3-14 Influence of compound V-4 on the expression of EGFP, normalised to the number of EBs. 
Values from four independent experiments (mean ± SD, n=4), each performed in triplicate, are displayed 
as percent of control values (=100 %, only vehicle, without test substrate). Both a significant increase and 
decrease of values, compared to controls, represent an effect on the generation of cardiac cells. 
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3.3.2 Identification of Signalling Cascades Involved in Cardiomyogenesis  
 
The best hit of the substance screening II-16 and Verapamil 6, a cardiomyogensis 
inducing agent found in previous studies,4 were used for the identification of signalling 
cascades involved in the cardiomyogenesis by the time-dependent screening approach. 
In contrast to previous screenings, in this approach, the test substrates were only 
applied for 2 instead of 14 days. An increased cardiomyogenesis, detected after 14 
days, indicates interaction of the compound tested with a target expressed at a certain 
point in time during the application time-frame of the test substrate. Thus, time-depen-
dent correlations between cardiomyogenesis and concentrations of the substrates are 
expected to limit the number of potential targets associated to the various developmen-
tal stages (Scheme 3-14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-15 Limitation of potential targets by a time-dependent screening. 
 
Differentiation Protocol - Time Dependent Screening. In contrast to the differentia-
tion protocol described above (p. 16), in time-dependent studies, the test substrates are 
applied at different intervals (day 1-3, 3-5, 5-7, 7-9).  
1   2   3   4    5   6   7   8   9   10   11   12   13    14 
application of the  
test substrate 
expression of a target involved in a 
cardiomyogenesis inducing pathway
measuring of the ratio  
of cardiomyocytes 
1   2   3    4   5   6   7   8   9   10   11   12   13    14 
application of the 
test substrate 
expression of a target involved in a  
cardiomyogenesis inducing pathway 
measuring of the ratio  
of cardiomyocytes 
no change of cardiomyogenesis compared to the vehicle control of 100 %,  
as there is no target-substrate interaction 
higher cardiomyogenesis compared to the vehicle control of 100 %,  
due to target activation by the substrate 
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Time Dependent Screening. For the time-depending screening, the cinchona-alkaloid 
II-16 and (racemic) Verapamil rac-6 were used as test substrates (Scheme 3-16). 
Among all substances tested in the physiological screenings, these two led to the 
highest ratio of cardiomyocytes and may best contribute to the identification of the 
signalling pathways involved in cardiomyogenesis. 
 
 
 
 
              II-16      rac-6  
Scheme 3-16 Cinchona alkaloid II-16 (left), verapamil rac-6 (racemic mixture, right). 
 
For each application time-frame (days 1-3, 3-5, 5-7 and 7-9) three different concen-
trations (10-5 M, 10-6 M and 10-7 M) of the quinidine derivative II-16 and Verapamil  
rac-6 were tested in three identical test series. The cardiomyogenic effect of the sub-
stances is expressed as percent of the EGFP fluorescence of the vehicle treated cells 
(100%). An increased production of stem cells gives percent of control values higher 
then 100 %, a decreased production of stem cells lower than 100 %. 
 
As shown in Scheme 3-17 (p. 29), both substrates exhibit different cardiomyogenesis 
inducing profiles in each test series. Based on these results, the cardiomyogenesis 
inducing effect of the test substrate II-16 and verapamil rac-6 appeared to rely on an 
interaction of the tested substances with several target proteins expressed at different 
points of time. In this case, time-dependent correlations between cardiomyogenesis and 
concentrations of the substrates are not suitable to limit the number of potential targets 
associated to the various developmental stages. 
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Scheme 3-17 Time-dependent effects of quinidine derivative II-16 (left) and Verapamil rac-6 (right) on the 
expression of EGFP, normalised to the number of EBs. Values of three independent test series for four 
application time frames, each performed in triplicate, are displayed as percent of control values (=100 %, 
only vehicle, without test substrate). Both a significant increase and decrease of values, compared to 
controls, represent an effect on generation of cardiac cells. 
 
Conclusions. The substance screening led to the identification of cardiomyogenesis 
inducing compounds with good (IV-5, V-4) to very good activities (II-16, IV-8) 
determined by a 50 to 80 % increase of the EGFP fluorescence compared to untreated 
cells. Time-dependent screenings in which compounds were added at different 
developmental stages of the ES cell were of limited suitability for the identification of 
possible targets addressed by active reagents. Further insight on target binding might 
be achieved by the expression of isolated targets and their induction with test 
substances. 
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3.3.3 Synthesis of the Test Substrates 
 
Substance Library I.  The test substrates of the substance library I were synthesised 
by Dr. M. Brandenburg,46 Dr. F. Cleemann,47 Dr. S. Mukherjee,48 Dr. T. Müller,49 Dr. S. 
Schnippering50 and Dr. K. Roland.51 
 
Substance Library II. The test substrates of the substance library II were synthesised 
by Dr. M. Guixà52 and Dr. F. Schmidt.53 
 
Substance Library III. To generate the (thio)urea based library III the chiral diamino-
backbones, consisting of (1S,2S,4S,5S)-2,5-diamino-bicyclo[2.2.1]heptane (DIANANE) 
9, (1R,3S)-3-aminomethyl-3,5,5-trimethylcyclohexylamine (IPDA) 10 and (1R,2R)-1,2-
diaminocyclohexane (DACH) 11, were synthesised first. 
 
For the synthesis of DIANANE 9, norbornadiene 12 was first hydrated to form the 
corresponding diol 13 in 36 % yield. Oxidation of the hydroxy-functions led to the 
diketone 14 in 61 % yield. Reductive amination of the carbonyl-functions resulted in the 
benzyl protected diamine 15 in 97 % yield and deprotection of 15 afforded the desired 
DIANANE 9 in 98 % yield (Scheme 3-18). 
 
NHBn NHBnNH2 NH2
HO OH
PCC
O O
1) HSiCl3, [Pd(C3H5)Cl]2, (S)-MOP      -3 °C,   3 d
2) MeOH, Et3N, Et2O                               r.t., 16 h
DCM, r.t., 14 h
BnNH2, NaBH4, CH3CO2H
DCM, r.t., 6 h
H2, Pd/C
EtOH, r.t., 24 h
12 13, 36 %
14, 61 %15, 97 %9, 98 %
3) H2O2
 . urea, KHF2, THF/MeOH       60 °C, 16 h
 
Scheme 3-18 Synthesis of (1S,2S,4S,5S)-DIANANE 9. 
 
Commercially available IPDA mix-10 is a mixture of the racemic cis- and trans-dia-
stereomers in a 3 : 1 ratio. The optical resolution of IPDA mix-10 was performed via a 
diastereoselective salification with (R,R)-dibenzoyltartaric acid 16 (Scheme 3-19, p. 31). 
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Scheme 3-19  Synthesis of (1R,3S)-IPDA 10 . 
 
The optical resolution of the commercially available racemic 1,2-diaminocyclohexa-
ne rac-11 was carried out via a diastereoselective salification using L-(+)-tartaric acid 18 
(Scheme 3-20). 
NH2
NH2
OH
OHO
HO
O
OH NH2
NH2
rac-11 11, 13 %
18
H2O/AcOH, 5 h, 5 °C
 
Scheme 3-20 Synthesis of (1R,2R)-DACH 11. 
 
Addition of the chiral diamines (1S,2S,4S,5S)-DIANANE 9, (1R,3S)-IPDA 10 and 
(1R,2R)-DACH 11 to the iso(thio)cyanates, according to a general procedure (Scheme 
3-21), yields the corresponding (thio)urea derivatives of the substance library III.  
 
RNCX
NH2 NH2
NHX
NH
R
HN X
HN
R
NH2
NH2
X = S,O
THF, r.t., 5 min - 72 h
*
+
*
*    IPDA, 
   DIANANE, 
   DACH
=
 
Scheme 3-21 General procedure for the addition of the chirale diamines 9, 10 and 11 to the correspon-
ding iso(thio)cyanates. 
 
The yields of these syntheses are given in Scheme 3-22, p. 32. 
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Scheme 3-22  Compounds contained in the (thio)urea based library III. 
  
Substance Library IV. For the preparation of the cinchona-alkaloid based library IV, 
quinidine 19 was first transformed to the derivatives 20, 21 and 22. 
 
                                            
i Compound III-1 was synthesised by Dr. M. Brandenburg. 
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Methylation of the hydroxy function of quinidine 19 with methyl iodide 23 resulted in the 
quinidine derivative 20 in 90 % yield (Scheme 3-23). 
N
CH2
N
OMe
OMe
N
CH2
N
OMe
OH NaH, MeI 23
DMF, r.t., 15 h
19 20, 90 %  
Scheme 3-23 Synthesis of 9-O-methylquinidine 20. 
 
Hydrogenation of the aliphatic double bond of quinidine 19 with Pd/C led to the 
quinidine derivative 21 in 94 % yield (Scheme 3-24). 
 
N
CH2
N
OMe
OH
N
Me
N
OMe
OHPd/C
EtOH, r.t., 16 h, 20 bar H2
19 21  
Scheme 3-24 Synthesis of 10,11-dihydroquinidine 21. 
 
Quinidine derivative 22 was obtained in 61 % yield by cleavage of the aromatic ether 
function of quinidine 19 with BBr3 (Scheme 3-25). 
 
N
CH2
N
OH
OH
BBr3
N
CH2
N
OMe
OH
DCM, -78 °C       reflux, 13 h
19 22, 61 %  
Scheme 3-25 Synthesis of 6’-hydroxy-cinchonine 22. 
 
Furthermore, the benzyl chloride derivative 9-(chloromethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6, 
7,8-octahydro-1,4:5,8-dimethanoanthracene 24 was synthesised by reduction of the 
aldehyde 25 to the corresponding alcohol 26 in 85 % yield. Subsequent substitution of 
the hydroxy function led to the chloride 24 in 96 % yield (Scheme 3-26, p.34). 
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 HO OH Cl
25 26, 85 % 24, 96 %
NaBH4
MeOH, 0 °C, 3 h
PCl5
toluene, r.t., 18 h
 
Scheme 3-26 Synthesis of the 9-(chloromethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6,7,8-octahydro-1,4:5,8-dimetha-
noanthracene 24. 
 
Accoding to the general procedure in Scheme 3-27, quaternisation of the quinidine 
derivatives with the corresponding benzyl chloride derivatives led to the quinidinium 
chlorides of substance library IV (Scheme 3-28).  
 
N
R3
N
OR1
OR2
THF, 15 h - 18 h, reflux N
R3
N
OR1
OR2Ar Cl
Ar
Cl
 
Scheme 3-27 General synthetic procedure for the quaternisation of the quinidine derivatives. 
 
The yields obtained in the synthesis of these quinidinium chlorides are summarised in 
Scheme 3-28, p.35. 
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Scheme 3-28  Compounds contained in the cinchona alkaloid-based library IV. 
 
 
Substance Library V. For the preparation of the cinchona-alkaloid based library V, 
quinidine 19 was first transformed to the derivative 27. 
 
Cleavage of the aromatic ether function of quinidine 19 with BBr3 led to the 6’-hydroxy-
quinidine 22 in a yield of 61 %. Subsequent etherification with cyclopentylbromide 28 
resulted in the desired quinidine derivative 27 in 84 % yield (Scheme 3-29, p.36). 
 
                                            
ii Test substrate IV-3 was synthesised by Dr. M. Guixà. 
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Scheme 3-29 Synthesis of cyclopentyloxy cinchonine 27. 
 
For the synthesis of the benzyl chloride derivatives, 4-(trifluoromethyl)benzyl alcohol 29 
was converted to the corresponding chloride 30 with PCl5. The crude product was used 
for the synthesis of V-3 without further purification (Scheme 3-30). 
 
CF3
Cl
CF3
OH
PCl5
3029
toluene, r.t., 18 h
 
Scheme 3-30 Synthesis of 4-(trifluoromethyl)benzyl chloride 30. 
 
Reaction of 4-iodobenzyl bromide 31 with tin-(IV)-chloride resulted in the formation of 
the corresponding 4-iodobenzyl chloride 32 (Scheme 3-31). Again, the crude product 
could be used directly in the next step without further purification. 
 
SnCl4
I
Cl
I
Br
-30°C     r.t., 2 h
3231  
Scheme 3-31 Synthesis of 4-iodobenzyl chloride 32. 
 
Conversion of 2,4-difluorobenzylalcohol 33 with PCl5 yielded the desired chloride 34. 
This was directly used in the synthesis of test substrate V-7, without further purification 
(Scheme 3-32).  
 
PCl5
F
Cl F
F
OH F
toluene, r.t., 18 h
3433  
Scheme 3-32 Synthesis of 2,4-difluorobenzyl chloride 34. 
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For the synthesis of the benzylchloride 35, the corresponding aldehyde 36 was first 
reduced to the alcohol derivative 37. Subsequent substitution of the hydroxy function 
with PCl5 led to the benzylchloride 35 (Scheme 3-33). 
 
NaBH4 PCl5
ClOHOH
MeOH, 0 °C, 3 h toluene, r.t., 18 h
36 37, 91% 35, 64%  
Scheme 3-33 Synthesis of 9-(chloromethyl)-1,2,3,4,5,6,7,8-octahydro-1,4:5,8-diethanoantracene 35. 
 
According to the general procedure in Scheme 3-34, quaternisation of the quinidine 
derivatives with the corresponding chlorides led to the quinidinium chlorides of 
substance library V (Scheme 3-36).  
 
N
R3
N
OR1
OR2
N
R3
N
OR1
OR2
R
R Cl Cl
THF, 15 h - 10 d, reflux
 
Scheme 3-34 General synthetic procedure for the quaternisation of the quinidine derivatives. 
 
In contrast to the general procedure, for the synthesis of test substrate V-1, quinidine 19 
was first converted to the quaternary ammonium iodide 38 with methyl iodide in 70 % 
yield. The desired chloride V-1 was obtained by anion exchange with silver chloride in 
75 % yield (Scheme 3-35). 
 
N
CH2
N
OMe
OH
N
CH2
N
OMe
OH
Me
I
MeI 23
N
CH2
N
OMe
OH
Me
Cl
19 38, 70% V-1, 75%
AgCl, NH3
MeOH, r.t., 24 h H2O/MeOH, r.t., 72 h
 
Scheme 3-35 Synthesis of 1N-(methyl)quinidinium chloride V-1. 
 
The synthetic yields of the substances of library V are shown in Scheme 3-36.  
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Cl
N
CH2
MeN
OMe
OH
 
Cl
N
CH2
N
OMe
OH
Me 
V-1, 75 % V-2, 32 % 
  
 
N
CH2
N
OMe
OH Cl
CF3  
 
N
CH2
N
OMe
OH
Cl
F  
V-3, 49 % V-4, 38 % 
  
 
N
CH2
N
OMe
OH
I
Cl
 
 
N
CH2
N
OMe
OH
Cl
 
V-5, 34 % V-6, 17 % 
  
 
N
CH2
N
OMe
OH
Cl
FF  
 
N
CH2
N
O
OH
Cl
 
V-7, 12 % V-8, 38 % 
Scheme 3-36 Compounds contained in the cinchona alkaloid-based library V. 
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3.4 Experimental Part 
3.4.1 Physiological ES cell screenings 
 
The physiological tests were performed using a transgenic murine ES cell lineage 
expressing enhanced green fluorescent protein (EGFP) under the control of α-myosine 
heavy chain promoter (pα-MHC). 
 
Culture of ES cells on mouse embryonic feeder cells. Transgenic mouse ES cells 
(αMHC Cl23) were cultured on 10 cm Petri dishes in Dulbecco’s-modified Eagle’s 
medium (DMEM) supplemented with 15 % fetal calf serum (FCS) and leukaemia 
inhibitory factor (LIF) on a layer of feeder cells (irradiated mouse embryonic fibroblasts). 
Cells were incubated at 37 °C, 7 % CO2 and 95 % humidity. Cells were split every 
second day by trypsinising them to single cell suspension and seeding on a fresh dish 
coated with feeder cells. 
 
ES cell aggregation. ES cells from one or more Petri dish were trypsinised, to obtain a 
single cell suspension, and collected by centrifugation. Cells were resuspended to a 
density of approximately 2·106 cells/ml in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 20 % FCS. 4 ml per 6 cm Petri dish of this suspension were 
incubated on a rocking table at 50 rpm, 37 °C, 5 % CO2 and 95 % humidity for 6 h. After 
this time the suspension was diluted 1:20 in several T25 tissue culture flasks and 
incubated for additional 18 h. Under these conditions ES cell aggregates (embryoid 
bodies) formed, typically around 500 per ml of cell suspension. 
 
ES cell differentiation. The embryoid bodies (EBs) were cultured on 6-well-plates in 
IMDM supplemented with 20 % FCS. The test substrates were dissolved in DMSO  
(10-2 M) and a dilution series was obtained by dilution with IMDM, 20 % FCS (10-3 M,  
10-4 M, 10-5 M, 10-6 M). The EBs were treated with the test substrates and the 
corresponding dilutions and afterwards they were incubated at 37 °C, 5 % CO2 and 
95 % humidity for 14 d. After 7 d fresh IMDM, 20 % FCS and the test substrate were 
added. After 14 d the expressed EGFP was quantified. Therefore the EBs per well were 
counted and subsequently lysed with Triton X. The lysate was transferred to 96-well 
plates and the emitted fluorescence per well was determined. 
 
The physiological ES cell screenings were performed according to the Cell Culture 
Quality Assurance Guide and the Standard Operating Protocols (SOP 3-01: Culture of 
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mES cells; SOP 3-02: Production of EBs by mass culture, SOP 4-01: R.E.Tox Test for 
embryotoxicity) developed by Axiogenesis AG, Köln, Department for cell culture, 
toxicology and assay developments. These procedures cannot be explained in detail, as 
they are subject to privacy regulations. 
 
 
3.4.2 Synthesis of the Test Substrates 
 
General Methods. Flash chromatography was performed on silica gel (Macherey-Nagel 
MN-Kieselgel 60, 230-240 mesh). TLC was performed on aluminium backed silica 
plates (Macherey-Nagel, Polygram© SIL G/UV254) which were developed by using UV 
fluorescence. Melting points were determined on a Büchi melting point apparatus and 
are uncorrected. 1H-NMR spectra were recorded at 300 MHz on Bruker AC 300 and 
DPX 300 instruments, respectively; 13C-NMR spectra were recorded at 75.5 MHz on a 
Bruker DPX 300 instrument. Chemical shifts (δ) are given in parts per million (ppm) 
referenced to TMS. For the fine-structure interpretation the abbreviations of the signals 
are the following: s = singulet, d = doublet, t = triplet, q = quartet, m = multiplet. High re-
solution mass spectra (HR ESI-MS) were recorded on a Finnigan MAT 900 ST spec-
trometer. Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR spec-
trometer using the ATR technique and on a Perkin Elmer 1600 Series FT-IR spectro-
meter. All commerically available chemicals were used without further purification. 
Compounds 25 and 36 were kindly provided by Sarwar Aziz. Anhydrous solvents were 
distilled from appropriate drying agents prior to use. 
All experiments are characterised by a number within the bracket: [XX-SEE-XXX]. The 
roman number in front of the three-letter-code indicates the volume number of the 
laboratory notebook, whereas the number after the three-letter-code indicates the 
experiment number in the corresponding notebook volume. 
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3.4.3 Synthesis of  (1S,2R,4S,5R)-2,5-Dihydroxybicyclo[2.2.1]heptane (13)  
 
 [II-SEE-123] 
 
 
 
 
HO OH
 
12  13 
   
12 
 
  1. HSiCl3, [Pd(C3H5)Cl]2, (S)-MOP        -3 °C, 3 d 
  2. MeOH, Et3N, Et2O,                               r.t, 16 h 
  3. H2O2·H2NCONH2, KHF2, THF/MeOH   60 °C, 16 h 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
 
13, 36 % 
 
A solution of [Pd(C3H5)Cl]2 (14.6 mg, 40 µmol, 0.05 mol%) and (S)-MOP (78.7 mg, 
168 µmol, 0.20 mol%) in dry benzene (2 ml) was placed into a double-jacketed 50 ml 
Schlenk flask under argon. HSiCl3 (19.9 ml, 197 mmol, 2.40 equiv), distilled from 
quinoline, and quinoline (236 µl, 2.00 mmol, 2.43 mol%) were added, and the solution 
was cooled to -3 °C. Norbornadiene 12 (8.34 ml, 82.0 mmol, 1.00 equiv), passed 
through neutral aluminia and subsequently distilled, was added slowly with magnetic 
stirring. The reaction mixture was stirred at -3 °C for 3 d, until it turned into a pale 
yellowish solid. The solvent and excess silane were removed in vacuo at r.t.. The 
residue was dissolved in dry Et2O (50 ml) under argon and cooled to 0 °C. A mixture of 
dry MeOH (59.9 ml, 1.48 mol, 18.0 equiv), dry Et3N (80.0 ml, 574 mmol, 7.00 equiv), 
and dry Et2O (50 ml) was added dropwise. The solution was stirred at r.t. overnight. The 
precipitated salts were filtered off and washed with small quantities of Et2O. The com-
bined filtrates were concentrated in vacuo. To the residue was added KHF2 (32.0 mg, 
410 mmol, 5.00 equiv), THF (80 ml), MeOH (80 ml) and H2O2·urea (57.8 g, 615 mmol, 
7.50 equiv). The resulting white suspension was stirred overnight at 60 °C. After 
addition of a catalytic amount of MnO2, stirring was continued at r.t. for 4 h. The solids 
were filtered off, and the filter cake was washed with MeOH. The combined filtrates 
were concentrated in vacuo. The residue was dissolved in H2O (100 ml) and extracted 
with a CHCl3/iPrOH mixture (5 x 100 ml, 3:1). The combined organic phases were dried 
over MgSO4 and evaporated. The remaining solid was recrystallised from CHCl3/n-
hexane to give 3.82 g (30.0 mmol, 36 %) of the diol 13 as thin colourless crystals. 
 
C7H12O2  (128.17 g/mol) 
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m.p.  157 °C    [m.p. ref.54: 158 °C]  
 
1H NMR  (300 MHz, CH3OH-d4): δ [ppm] = 4.69 (s; 2H), 3.64-3.58 (m; 2H), 2.11-
2.10 (m; 2H), 1.55 (s; 2H), 1.50-1.43 (m; 2H ), 1.26- 1.19 (m; 2H). 
 
13C NMR  (75.5 MHz, CH3OH-d4): δ [ppm] = 72.9, 42.4, 36.0, 29.6. 
 
IR (ATR)  ν~  [cm-1] = 3245, 2958, 2886, 1666, 1439, 1346, 1286, 1184, 1089, 1039, 
991, 930, 877, 813, 781. 
 
GC-MS (HP-5; 100 °C (5 min), 20 °C/min, 200 °C (15 min); He; 1.00 ml/min)            
τR (min) = 6.64 (13): m/z = 128 [M+], 110, 95, 81, 66, 55. 
 
The spectroscopical data are in agreement with the literature.54 
 
 
3.4.4 Synthesis of  (1S,4S)-Bicyclo[2.2.1]heptane-2,5-dione (14)  
 
[II-SEE-124] 
 HO OH
 
 
O O 
13  14 
   
13 
 
PCC, MS 3 Å 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 14 h 
 
14, 61 % 
 
Diol 13 (2.05 g, 16.0 mmol, 1.00 equiv) and powdered 3 Å molecular sieves (10 g) were 
suspended in CH2Cl2 (250 ml). PCC (17.2 g, 80.0 mmol, 5.00 equiv) was added slowly 
and the resulting mixture was stirred at r.t. overnight. Et2O (100 ml) was added with 
vigorous stirring, and stirring was continued for 30 min. The mixture was then allowed to 
stand for 2 h. The liquid was filtered through Florisil (20 g, 80-150 µm). The black 
residue was extracted with CH2Cl2/Et2O (4 x 50 ml, 1:1) in an ultrasonic bath. The 
combined extracts were also filtered through the Florisil pad. Evaporation of the 
combined solutions yielded 1.21 g (9.75 mmol, 61 %) of the diketone 14 as a white 
solid.   
 
C7H8O2    (124.14 g/mol)  
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m.p.  115-126 °C    [m.p. ref.54: 115-133 °C] 
 
1H NMR (300 MHz, CHCl3-d1): δ [ppm] = 2.98 (s; 2H), 2.41-2.33 (m; 2H), 2.16-2.09 
(m; 4H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 212.4, 48.7, 39.0, 36.5. 
 
IR (ATR)  ν~  [cm-1] = 2954, 1732, 1404, 1230, 1186, 1123, 1089, 1053, 999, 960, 
915, 893, 794, 731, 709. 
 
GC-MS  (HP-5, 25 m; 100 °C (5 min), 20 °C/min, 200 °C (15 min); He; 1.00 ml/min) 
τR (min) = 5.55 (14): m/z = 124 [M+], 95, 82, 67, 55. 
 
The spectroscopical data are in agreement with the literature.54 
 
 
3.4.5 Synthesis of  (1S,2S,4S,5S)-2,5-Dibenzylaminobicyclo[2.2.1]heptane (15) 
 
 [II-SEE-125] 
O O 
 
 
NHBn NHBn  
14  15 
   
14 
 
BnNH2, NaBH4, CH3COOH 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 6 h 
 
15, 97 % 
 
Glacial acetic acid (4.38 ml, 76.0 mmol, 8.00 equiv) was added dropwise to a 
suspension of NaBH4 (900 mg, 23.7 mmol, 2.50 equiv) in dry CH2Cl2 (80 ml) and the 
resulting mixture was heated to reflux for 30 min. A mixture of diketone 14 (1.18 g, 
9.51 mmol, 1.00 equiv) in dry CH2Cl2 (20 ml) and freshly distilled BnNH2 (2.59 ml, 
23.7 mmol, 2.50 equiv), was added dropwise at r.t.. After being stirred for 6 h, the 
reaction mixture was quenched by the addition of 5 % aq. NaOH (18.9 ml, 23.7 mmol, 
2.50 equiv). The mixture was extracted with 3 x 50 ml of 2 M HCl and the combined 
aqueous phases were basified by the addition of solid NaOH to pH 9. The resulting sus-
pension was extracted with Et2O (3 x 50 ml) and the combined organic phases were 
dried over MgSO4. After concentration in vacuo a colourless oil remained, which soli-
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dified slowly. This material was purified by Kugelrohr distillation at 150 °C, 3 x 10-
3 mbar, to yield 2.82 g (9.22 mmol, 97 %) of (1S,2S,4S,5S)-2,5-dibenzylaminobicyclo-
[2.2.1]heptane 15 as a white solid. 
 
C21H26N2   (306.44 g/mol) 
 
m.p.  47 °C    [m.p. ref.54: 48-49 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 7.36-7.27 (m; 10H), 3.71 (dd; J = 
12.92 Hz; J = 9.0 Hz, 4H), 3.19-3.14 (m; 2H), 2.31 (s; 2H), 1.80-1.71 (m; 
2H), 1.66 (s; 2H), 1.51 (s; 2H), 1.43 (dd; J  = 12.7 Hz,  J  = 3.8 Hz, 2H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 140.6, 128.2, 128.1, 126.7, 58.4, 52.5, 
39.7, 38.1, 29.2. 
 
IR (ATR)  ν~  [cm-1] = 3312, 3023, 2941, 2866, 2797, 1947, 1806, 1742, 1668, 1601, 
1493, 1451, 1342, 1201, 1132, 1095, 1027, 977, 906, 730, 693. 
 
The spectroscopical data are in agreement with the literature.54 
 
 
3.4.6 Synthesis of (1S,2S,4S,5S)-2,5-Diaminobicyclo[2.2.1]heptane (9) 
 
[II-SEE-126] 
 
NHBn NHBn  
 
NH2 NH2  
15  9 
   
15 
 
H2, Pd/C 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
EtOH, r.t., 24 h 
 
9, 98 % 
 
A suspension of the bis-benzylamine 15 (2.50 g, 8.15 mmol, 1.00 equiv) and Pd(OH)2 
(15-20 % on activated charcoal with 50 % H2O, 2.50 g) in EtOH (70 ml) was stirred 
under H2 -atmospheric pressure (balloon). After stirring for 24 h, the catalyst was filtered 
off and the solution was concentrated in vacuo to afford 1.01 g (8.00 mmol, 98 %) 
DIANANE 9 as colourless oil. 
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C7H14N2 (126.20 g/mol) 
 
1H NMR  (300 MHz, MeOH-d4): δ [ppm] = 3.28-3.22 (m; 2H), 2.07 (t; J  = 4.2 Hz, 
2H), 1.75-1.64 (m; 2H), 1.50 (s; 2H), 1.26-1.20 (m; 2H). 
The NH2-protons could not be detected. 
 
13C NMR  (75.5 MHz, MeOH-d4): δ [ppm] = 54.1, 44.9, 39.6, 30.2. 
 
IR (ATR)  ν~  [cm-1] = 3268, 2951, 2873, 1629, 1558, 1464, 1379, 1326, 820. 
 
GC-MS  (HP-5, 25 m; 100 °C (5 min), 20 °C/min, 280 °C (10 min); He; 1.00 ml/min) 
τR (min) = 6.2 (9): m/z = 126 [M+], 109, 94, 82, 68, 56. 
 
The spectroscopical data are in agreement with the literature.54 
 
 
3.4.7 Synthesis of (2R,3R)-2,3-Bis(benzoyloxy)butanedioic acid (1S,5R)-(5-amino-
1,3,3-trimethylcyclohexyl)-methaneamine salt (1:1) (17) 
 
 [II-SEE-127] 
NH2
Me
MeMe
H2N  
O
O
HO
O
HO
O Ph
O Ph
O
 
Me
NH3
Me
H3N
Me
O
O
O
O
O
O
O
Ph
PhO  
mix-10 iii 
 
16 
 
17 
 
mix-10 iii + 16 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
H2O, r.t., 5 min 
 
17, 25 % 
 
3-Aminomethyl-3,5,5-trimethylcyclohexylamine mix-10 (135 ml, 124 g, 732 mmol, 
2.50 equiv) was added at r.t. to (2R,3R)-dibenzoyl tartaric acid 16 (105 g, 293 mmol, 
1.00 equiv) suspended in distilled water (1.35 L) with vigorous stirring. During the exo-
thermic reaction the solution cleared, and the precipitation of the product started after 
                                            
iii rac-10 cis  + rac-10 trans ca. 3 : 1. 
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about 5 min. The reaction mixture was cooled to 0 °C and left at this temperature for 
1.5 h. The solid was filtered off, washed with iPrOH (3 x 140 ml), and dried under 
reduced pressure over P2O5. Recrystallisation from iPrOH/water (650 ml, 2:1) yielded 
39.0 g (73.7 mmol, 25 % based on the amount of mix-10 used) of (2R,3R)-2,3-bis(ben-
zoyloxy)butanedioic acid (1S,5R)-(5-amino-1,3,3-trimethylcyclohexyl)-methylamine salt 
(1:1) 17 as colourless crystals. 
 
C28H36N2O8  (528.59 g/mol) 
 
m.p.  205 °C    [m.p. ref.55: 205 °C] 
 
1H NMR  (300 MHz, DMSO-d6): δ = 7.99 (d; J = 7.2 Hz, 4H), 7.64-7.59 (m; 2H), 
7.53-7.48 (m; 4H), 5.55 (s; 2H), 3.16-3.09 (m; 1H), 2.31 (s; 2H), 1.61-1.54 
(m; 2H), 1.09-1.00 (m; 1H), 0.84 (s; 3H), 0.78 (s; 3H), 0.71 (s; 3H), 0.96-
0.68 (m; 3H). 
The NH3+-protons could not be detected.  
 
13C NMR  (75.5 MHz, DMSO-d6): δ = 169.6, 165.1, 132.7, 130.8, 129.2, 128.3, 75.5, 
52.6, 45.5, 43.7, 42.1, 40.2, 34.2, 34.1, 30.8, 26.8, 22.1. 
 
IR (ATR)  ν~  [cm-1]  = 3428, 2954, 2713, 1723, 1607, 1512, 1407, 1333, 1280, 1122, 
1025, 736, 716. 
 
The spectroscopical data are in agreement with the literature.55 
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3.4.8 Synthesis of  (1R,3S)-3-Aminomethyl-3,5,5-trimethylcyclohexylamine (10) 
 
[II-SEE-128] 
 
Me
NH3
Me
H3N
Me
O
O
O
O
O
O
O
Ph
PhO  
NH2
Me
MeMe
H2N  
17 
 
 
10 
 
17 
 
NaOH 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
H2O, r.t., 2 min 
 
10, 89 % 
 
(2R,3R)-2,3-Bis(benzoyloxy)butanedioic acid (1S,5R)-(5-amino-1,3,3-trimethylcyclohex-
yl)-methanamine salt (1:1) 17 (1.52 g, 2.88 mmol, 1.00 equiv) was dissolved in 5 M aq. 
NaOH (72 ml). The clear solution was extracted with CH2Cl2 (4 x 20 ml), the combined 
organic phases were dried over Na2SO4, and the main part of the solvent was evapora-
ted. Vacuum destillation gave 437 mg (2.57 mmol, 89 %) of (1R,3S)-3-(aminomethyl)-
3,5,5-trimethylcyclohexylamine 10 as a clear liquid (to be stored under argon). 
 
C10H22N2    (170.3 g/mol) 
 
 1H NMR  (300 MHz, CHCl3-d1): δ = 2.90-2.80 (m; 1H), 2.22 (s; 2H), 1.50-1.44 (m; 
1H), 1.40-1.33 (m; 1H), 1.07-1.03 (m; 1H), 0.97 (s; 4H), 0.89 (s; 3H), 0.86 
(s; 3H), 0.79 (s; 3H), 0.83-0.59 (m; 3H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ = 57.5, 50.4, 47.1, 45.7, 43.9, 36.4, 35.2, 31.9, 
27.9, 23.8. 
 
The spectroscopical data are in agreement with the literature.55 
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3.4.9 Synthesis of  (1R,2R)-1,2-Diaminocyclohexane  (11) 
 
[III-SEE-233] 
 NH2
NH2  
 NH2
NH2  
rac-11 11 
   
rac-11 
 
 OH
OHO
HO
O
OH
18 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
H2O/AcOH, 5 °C, 5 h 
 
11, 13 % 
 
A 2 L beaker is charged with 300 ml of distilled water. L-(+)-tartaric acid 18 (118 g, 
786 mmol, 1.00 equiv) is added with stirring in one portion. The solution is stirred as 
1,2-diaminocyclohexane rac-10 (180 g, 1.57 mol, 2.00 equiv) and glacial acetic acid 
(82 ml) is added. An exothermic reaction was observed and the temperature rose up to 
90 °C. The reaction mixture is allowed to cool to 5 °C, with stirring, over 4 h. The 
temperature is maintained at 5 °C for an additional hour and than the product is isolated 
by filtration. The crude product is washed with cold water (50 ml) followed by MeOH 
(4 x 50 ml). The filter cake is recrystallized from water (1.2 L). The solid is dissolved in 
CH2Cl2 (500 ml) and washed with 6 M aq. NaOH (3 x 100 ml) and brine (500 ml). The 
combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure yielding 12.1 g (106 mmol, 13 %) (1R,2R)-1,2-diaminocyclohexane 10 
as an off-white solid. 
For the determination of the enantiomeric excess, a small amount of the product 10 was 
dissolved in 1 ml CH2Cl2, laced with one drop of trifluoroacetic anhydride, and analysed 
by chiral GC. 
 
C6H14N2     (114.19 g/mol)  
 
m.p.  41 °C    [m.p. ref.56: 42-43 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 2.09-2.07 (m; 2H), 1.70-1.66 (m; 2H), 1.52 
(brs; 2H), 1.21 (s; 4H), 1.15-1.08 (m; 2H), 0.95-0.92 (m; 2H). 
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13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 57.6, 35.4, 25.3. 
 
IR (ATR)  ν~  [cm-1] = 3275, 2922, 2855, 1581, 1447, 1377, 1288, 1163, 1081, 959, 
914, 843. 
 
GC  (CP-Chirasil-DexCB, 1.1 ml/min N2; 60 °C, 15 °C/min 150 °C (30 min)) τR 
(min) = 14.95 (ent-10), 15.57 (10). 
 
The spectroscopical data are in agreement with the literature.7 
 
 
3.4.10 Synthesis of N-Phenyl-N'-[(1R,3S)-3-({[(phenyl)amino]-thioxomethyl}amino)-
methyl-3,5,5-trimethylcyclohexyl]thiourea (III-2) 
 
[II-SEE-158] 
NH2
Me
MeMe
H2N  
 
C
N
S
 
NH
Me
Me
Me
NHS
NH
NH
S
 
10 39 III-2 
   
10 + 39 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 72 h 
 
III-2,  67 % 
 
Phenyl isothiocyanate 39 (1.04 ml, 1.18 g, 8.75 mmol, 2.50 equiv) was added to a 
solution of (1R,3S)-3-(aminomethyl)-3,5,5-trimethylcyclohexylamine 10 (648 µl, 596 mg, 
3.50 mmol, 1.00 equiv) in dry THF (5 ml). The resulting mixture was stirred at r.t. under 
argon for 72 h. The solvent was removed under reduced pressure. Purification of the 
residue by flash chromatography (c-hexane/EtOAc 2:1) afforded 1.04 g (2.36 mmol, 
67 %) of the product III-2 as colourless solid.  
 
C24H32N4S2    (440.67 g/mol) 
 
m.p.  182 °C    [m.p. ref.51: 182 °C] 
 
Rf    0.32 (c-hexane/EtOAc 2:1) 
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1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.51 (s; 1H), 8.40 (s; 1H), 7.36-7.12 (m; 
10 H), 6.11 (s; 1H), 5.78 (s; 1H), 4.56-4.53 (m; 1H), 3.44-3.30 (m; 2H), 
1.87-1.74 (m; 2H), 1.14-0.77 (m; 4H), 1.01 (s; 6H), 0.83 (s; 3H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 180.9, 179.1, 136.2, 136.1, 130.1, 127.3, 
127.0, 125.2, 124.9, 58.9, 48.9, 47.7, 45.3, 41.2, 36.7, 34.9, 32.0, 27.6, 
23.4. 
 
IR (ATR)  ν~  [cm-1] = 3383, 3207, 2953, 2217, 1594, 1519, 1448, 1312, 1240, 1178, 
1071, 1027, 1001, 905, 825, 724. 
 
The spectroscopical data are in agreement with the literature.51 
 
 
3.4.11 Synthesis of  1,1’-[(1S,2S,4S,5S)-Bicyclo[2.2.1]heptane-2,5-diyl]bis{3-[3,5-
dimethoxyphenyl]urea}  (III-3)  
 
[II-SEE-140] 
NH2 NH2 
 
C
N
O
MeO
OMe  
HN
HN
ONH
NH
O
OMe
OMe
OMe
MeO
 
9 40 III-3 
   
9 + 40 
 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 72 h 
 
III-3, 97 % 
 
3,5-Dimethoxyphenyl isocyanate 40 (312 mg, 1.74 mmol, 2.20 equiv) was added to a 
solution of (1S,2S,4S,5S)-2,5-diamino-bicyclo[2.2.1]heptane 9 (100 mg, 792 µmol, 
1.00 equiv) in dry THF (2 ml) and the resulting mixture was stirred at r.t. under argon for 
40 h. The solvent was removed under reduced pressure. Purification of the residue by 
flash chromatography (CHCl3/MeOH 5:1) afforded 372 mg (767 µmol, 97 %) of the 
product III-3 as colourless solid. 
 
C25H32N4O6  (484.54 g/mol) 
 
 Rf  0.83 (CHCl3 /MeOH 5:1) 
                                         3 Chemically Induced Cardiomyogenesis of Mouse Embryonic Stem Cells 
 
51 
m.p.  123 °C 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 6.47 (s; 4H), 6.00 (s; 2H), 3.89-3.83 (m; 
2H), 3.59 (s; 12H), 2.25 (s; 2H), 1.89-1.80 (m; 2H), 1.44 (s; 2H), 1.25-1.18 
(m; 2H). 
NH-protons could not be detected. 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 161.1, 156.7, 141.1, 96.8, 94.1, 54.3, 
51.2, 40.9, 36.9, 28.8. 
 
IR (ATR) ν~  [cm-1] = 3383, 2949, 2473, 1602, 1539, 1456, 1273, 1203, 1153, 1064, 
961, 831, 758, 682. 
 
 HR ESI-MS (m/z): exact mass [M+Na]+: 507.2219 ; found [M+Na]+: 507.222. 
 
 
3.4.12 Synthesis of N-[3,5-Di(methoxy)phenyl]-N’-[(1R,3S)-3-{[({[3,5-bis(methoxy)-
phenyl]amino}oxomethyl)amino]methyl}-3,5,5-trimethylcyclohexyl]urea   
(III-4) 
 
[II-SEE-119] 
NH2
Me
MeMe
H2N  
 
C
N
O
MeO
OMe  
NH
Me
Me
Me
NHO
NH
NH
OMeO
OMe
MeO
OMe
 
10 40 III-4 
   
10 + 40 
 
 
⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 1 h 
 
III-4, 90 % 
 
3,5-Dimethoxyphenyl isocyanate 40 (871 mg, 4.86 mmol, 2.00 equiv) was added to a 
solution of (1R,3S)-3-(aminomethyl)-3,5,5-trimethylcyclohexylamine 10 (450 µl, 414 mg, 
2.43 mmol, 1.00 equiv) in dry THF (0.5 ml) and the resulting mixture was stirred at r.t. 
under argon for 1 h. The solvent was removed under reduced pressure. The residue 
was dried in vacuo and 1.15 g (2.17 mmol, 90 %) of the product III-4 were obtained as 
colourless solid. 
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C28H40N4O6 (528.64 g/mol) 
 
 m.p.  110 °C 
 
 1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.41 (s; 1H), 8.30 (s; 1H), 6.62 (s; 4H), 
6.22-6.20 (m; 1H), 6.06 (s; 2H), 5.97-5.94 (m; 1H), 3.81-3.76 (m; 1H), 3.69 
(s; 12H), 2.95-2.78 (m; 2H), 1.63-1.60 (m; 2H), 1.19-1.15 (m; 1H), 1.05-0.87 
(m; 3H), 1.04 (s; 3H), 1.01 (s; 3H), 0.92 (s; 3H). 
 
 13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 160.4, 155.2, 154.2, 142.1, 95.6, 93.9, 
54.8,  52.6, 46.8, 46.0, 42.3, 41.7, 36.0, 34.8, 31.5, 27.4, 23.1. 
 
 IR (ATR) ν~  [cm-1] = 3339, 2948, 1651, 1607, 1553, 1479, 1455, 1421, 1301, 1256, 
1205, 1150, 1174, 1063, 833. 
 
 
3.4.13 Synthesis of 1,1’-[(1S,2S,4S,5S)-Bicyclo[2.2.1]heptane-2,5-diyl]bisphenyl-
urea (III-5) 
 
[II-SEE-112] 
NH2 NH2  
 
C
N
O
 
HN
HN
ONH
NH
O
 
9 41 III-5 
   
9 + 41 
 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 72 h 
 
III-5, 95 % 
 
Phenyl isocyanate 41 (189 µl, 208 mg, 1.74 mmol, 2.20 equiv) was added to a solution 
of (1S,2S,4S,5S)-2,5-diamino-bicyclo[2.2.1]heptane 9 (100 mg, 792 µmol, 1.00 equiv) in 
dry THF (2 ml) and the resulting mixture was stirred at r.t. under argon for 72 h. The 
solvent was removed under reduced pressure. Purification of the residue by flash 
chromatography (CHCl3/MeOH 7:1) afforded 274 mg (750 µmol, 95 %) of the product 
III-5 as colourless solid. 
 
C21H24N4O2  (364.44 g/mol) 
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Rf  0.24 (CHCl3/MeOH 7:1) 
 
m.p.  164 °C 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 7.30 (s; 2H), 7.22-7.11 (m; 8H), 6.93-6.89 
(m; 2H), 6.17 (s; 2H), 3.98 (s; 2H), 2.32 (s; 2H), 1.86 (brs; 2H), 1.42 (s; 
2H), 1.32-1.28 (m; 2H). 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 156.7, 138.7, 128.9, 123.1, 119.8, 51.5, 
41.0, 37.5, 29.4. 
 
 IR (ATR) ν~  [cm-1] = 3323, 2951, 2875, 2242, 1642, 1594, 1538, 1495, 1438, 1310, 
1276, 1226, 1173, 1119, 1076, 1028, 1002, 906, 861, 725, 689. 
 
HR ESI-MS  (m/z): exact mass [M+Na]+: 387.1797 ; found [M+Na]+: 387.180.  
 
 
3.4.14 Synthesis of 1-[3,5-Bis(trifluoromethyl)phenyl]-3-{(1R,2R)-2-{3-[3,5-bis(tri-
fluoromethyl)phenyl]ureido}cyclohexyl}urea (III-6) 
 
[II-SEE-114] 
 
NH2H2N  
 
C
N
O
F3C
CF3  
 
HN
HN
ONH
NH
O
F3C
CF3 CF3
CF3
11 42 III-6 
   
11 + 42  
 
 
⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 24 h 
 
III-6, 61 % 
 
3,5-Bis(trifluoromethyl)phenyl isocyanate 42 (333 µl, 492 mg, 1.93 mmol, 2.20 equiv) 
was added to a solution of (1R,2R)-1,2-diaminocyclohexane 11 (100 mg, 876 µmol, 
1.00 equiv) in dry THF (2 ml), and the resulting mixture was stirred at r.t. under argon 
for 24 h. The solvent was removed under reduced pressure. Purification of the residue 
by flash chromatography (c-hexane/EtOAc 2:1) afforded 334 mg (535 µmol, 61 %) of 
the product III-6 as colourless solid. 
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C24H20F12N4O2  (624.42 g/mol) 
 
Rf  0.23 (c-hexane/EtOAc  2:1) 
 
m.p.  248 °C    [m.p. ref.8: 249-252 °C] 
 
1H NMR  (300 MHz, MeOH-d4): δ [ppm] = 7.84 (s; 4H), 7.32 (s; 2H), 4.62 (s; 2H), 
2.04-2.02 (m; 2H), 1.82 (s; 2H), 1.41-1.39 (m; 4H). 
NH-protons could not be detected. 
 
13C NMR  (75.5 MHz, MeOH-d4): δ [ppm] = 156.1, 141.6, 131.5 (q; 2JC-F = 33.2 Hz), 
123.2 (d; 1JC-F = 271.9 Hz), 117.3, 114.0,  54.3, 32.2, 24.7. 
 
IR (ATR) ν~  [cm-1] = 3315, 2938, 2859, 2476, 1634, 1557, 1476, 1449, 1377, 1276, 
1117, 1055, 1000, 973, 936, 881, 847, 728, 701, 681. 
 
HR ESI-MS (m/z): exact mass [M+Na]+: 647.1292; found [M+Na]+: 647.129.  
 
The spectroscopical data are in agreement with the literature.8 
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3.4.15 Synthesis of N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[(1R,3S)-3-{[({[3,5-bis(tri-
fluoromethyl)phenyl]amino}thioxomethyl)amino]methyl}-3,5,5-trimethyl-
cyclohexyl]thiourea (III-7) 
 
[II-SEE-157] 
NH2
Me
MeMe
H2N  
 
C
N
S
F3C
CF3  
NH
Me
Me
Me
NHS
NH
NH
SF3C
CF3
F3C
CF3
 
10 43 III-7 
   
10 + 43 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 4 d 
 
III-7, 72 % 
 
3,5-Bis(trifluoromethyl)phenyl isothiocyanate 43 (1.39 ml, 2.06 g, 7.60 mmol, 
2.10 equiv) was added to a solution of (1R,3S)-3-(aminomethyl)-3,5,5-trimethylcyclo-
hexylamine 10 (670 µl, 616 mg, 3.62 mmol, 1.00 equiv) in dry THF (5 ml) and the 
resulting mixture was stirred at r.t. under argon for 4 d. The solvent was removed under 
reduced pressure. Purification of the residue by flash chromatography (c-hexane/EtOAc 
2:1) afforded 1.87 g (2.62 mmol, 72 %) of the product III-7 as yellowish solid. 
 
C28H28F12N4S2 (712.66 g/mol) 
 
Rf  0.35 (c-hexane/EtOAc 2:1) 
 
m.p.  125 °C     [m.p. ref.51: 120-122 °C] 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 10.09 (s; 1H), 9.86 (s; 1H), 8.31-8.11 (m; 
6H), 7.68 (s; 2H), 4.60 (s; 1H), 3.45-3.40 (m; 2H), 1.83-1.71 (m; 2H), 1.33-
1.29 (m; 1H), 1.18-1.06 (m; 3H), 1.14 (s; 3H), 1.09 (s; 3H), 0.96 (s; 3H). 
 
 13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 181.7, 179.8, 142.4, 130.6 (q; 2JC-F = 
32.6 Hz), 130.5 (q; 2JC-F = 32.6 Hz), 123.7 (q; 2JC-F = 272.5 Hz), 122.3, 
121.9, 116.3, 116.2, 57.7, 47.8, 44.8, 44.3, 40.8, 36.9, 35.2, 32.1, 27.8, 
23.6. 
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IR (ATR) ν~  [cm-1] = 3234, 2964, 1621, 1539, 1466, 1380, 1303, 1274, 1176, 1134,  
1107, 951, 889, 847, 702  681.  
 
The spectroscopical data are in agreement with the literature.8 
 
 
3.4.16 Synthesis of 1-[3,5-Bis(trifluoromethyl)phenyl]-3-{(1R,2R)-2-[3-[3,5-bis(tri-
fluoromethyl)phenyl)thioureido]cyclohexyl}thiourea (III-8) 
 
[II-SEE-115] 
 
NH2H2N  
 
C
N
S
F3C
CF3  
 
HN
HN
SNH
NH
S
F3C
CF3 CF3
CF3
 
11 43 III-8 
   
11 + 43  
 
 
⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 24 h 
 
III-8, 65 % 
 
3,5-Bis-(trifluoromethyl)phenyl isocyanate 43 (352 µl, 523 mg, 1.93 mmol, 2.20 equiv) 
was added to a solution of (1R,2R)-1,2-diaminocyclohexane 11 (100 mg, 876 µmol, 
1.00 equiv) in dry THF (2 ml), and the resulting mixture was stirred at r.t. under argon 
for 24 h. The solvent was removed under reduced pressure. Purification of the residue 
by flash chromatography (c-hexane/EtOAc 2:1) afforded 376 mg (573 µmol, 65 %) of 
the product III-8 as colourless solid.  
 
C24H20F12N4S2 (656.55 g/mol) 
 
Rf   0.40 (c-hexane/EtOAc  2:1) 
 
m.p.  131-132 °C  [m.p. ref.57: 132-133 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.41 (s; 2H), 7.84 (s; 4H), 7.68 (s; 2H), 
7.19 (s; 2H), 4.38 (brs; 2H), 2.19 (brs; 2H), 1.80 (brs; 2H), 1.33 (brs; 4H). 
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13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 180.4, 138.8, 132.6 (q; 2JC-F = 30.1 Hz), 
123.9, 122.7 (d; 1JC-F = 274.1 Hz), 119.5, 59.3, 31.3, 24.4. 
 
IR (ATR) ν~  [cm-1] = 3245, 3048, 2942, 2860, 1791, 1699, 1621, 1538, 1471, 1373, 
1266, 1183, 999, 974, 956, 885, 847, 787, 731, 681. 
 
HR ESI-MS  (m/z): exact mass [M+H]+: 657.1016; found [M+H]+: 657.101. 
 
The spectroscopical data are in agreement with the literature.57 
 
 
3.4.17 Synthesis of 9-(Hydroxymethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6,7,8-octahydro-1,4: 
5,8-dimethanoanthracene (26) 
 
[II-SEE-163] 
 HO
 
 OH
 
25 26 
   
25 
 
NaBH4 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeOH, 0 °C, 3 h 
 
26, 85 % 
 
Under argon atmosphere, NaBH4 (845 mg, 22.3 mmol, 5.20 equiv) was slowly added to 
a solution of aldehyde 25 (1.02 g, 4.30 mmol, 1.00 eq) in dry MeOH (40 ml) at 0 °C and 
the reaction mixture was stirred for 3 h. 4 M HCl (32 ml) was added and the precipitate 
was filtered off, washed with distilled water (3 x 10 ml) and dried under vacuo to give 
877 mg (3.65 mmol, 85 %) of the alcohol 26 as colourless solid. 
 
C17H20O   (240.34 g/mol) 
 
m.p.  120-123 °C    [m.p. ref.58: 120-122°C]  
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 6.94 (s; 1H), 4.78-4.69 (m; 2H), 3.54 (s; 
2H), 3.28 (s; 2H), 1.89-1.85 (m; 4H), 1.71-1.68 (m; 2H), 1.48-1.45 (m; 2H), 
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1.10-1.07 (m; 4H). 
 The OH-proton could not be detected. 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 145.7, 143.9, 125.1, 113.5, 60.4, 49.1, 
43.9, 41.3, 27.2, 27.1. 
 
IR (ATR)  ν~  [cm-1] = 3322, 2960, 2864, 1688, 1471, 1444, 1327, 1300, 1269, 1142, 
1106, 1044, 1003, 972, 945, 867, 734. 
 
GC MS  (HP-5; 100 °C (5 min), 20 °C/min, 200 °C (15 min); He; 1.00 ml/min) τR 
(min) = 12.67 (26): m/z = 240 [M+], 212, 194, 184, 166, 153, 141, 128, 115, 
96, 89, 76, 63, 51. 
 
The spectroscopical data are in agreement with the literature.58 
 
 
3.4.18 Synthesis of 9-(Chloromethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6,7,8-octahydro-1,4: 
5,8-dimethanoanthracene (24) 
 
[II-SEE-165] 
 OH
 
 Cl
 
26 24 
   
26 
 
PCl5 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
toluene, r.t., 18 h 
 
24, 96 % 
 
Under argon atmosphere, alcohol 26 (730 mg, 3.04 mmol, 1.00 equiv) was dissolved in 
dry toluene (30 ml). The mixture was cooled to 0 °C and PCl5 (1.06 g, 5.16 mmol, 
1.70 equiv) was added. After stirring at r.t. for 18 h, saturated aq. NaHCO3 (30 ml) was 
added at 0 °C, and the mixture was stirred for 10 min. The phases were seperated and 
the aqueous layer was extracted with toluene (20 ml). The combined organic phases 
were washed with water (20 ml), dried over Na2SO4, filtered, and concentrated under 
reduced pressure to obtain 753 mg (2.91 mmol, 96 %) of the chloride 24 as colourless 
solid. 
                                         3 Chemically Induced Cardiomyogenesis of Mouse Embryonic Stem Cells 
 
59 
C17H19Cl   (258.79 g/mol) 
 
m.p.  110-112 °C    [m.p. ref.58: 111-112 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 6.96 (s; 1H), 4.77-4.65 (m; 2H), 3.54 (s; 
2H), 3.30 (s; 2H), 1.95-1.83 (m; 4H), 1.74-1.72 (m; 2H), 1.51-1.48 (m; 2H), 
1.20-1.08 (m; 4H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 145.8, 144.2, 122.4, 114.1, 49.1, 44.0, 
41.3, 41.2, 27.2, 26.7. 
 
IR (ATR)  ν~  [cm-1] = 2966, 2863, 1464, 1443, 1329, 1302, 1290, 1271, 1256, 1141, 
1105, 1038, 941, 909, 883, 865, 815, 737, 711, 683. 
 
GC MS  (HP-5; 100 °C (5 min), 20 °C/min, 200 °C (15 min); He, 1.00 ml/min) τR 
(min) = 12.60 (24): m/z = 258 [M+], 230, 202, 178, 167, 152, 139, 128, 
115, 96, 89, 76, 63, 51. 
 
The spectroscopical data are in agreement with the literature.58 
 
 
3.4.19 Synthesis of 9-O-Methylquinidine (20) 
 
[II-SEE-122] 
 
N
CH2
N
OMe
OH
 
 
N
CH2
N
OMe
OMe
 
19 20 
   
19 
 
NaH, MeI 23 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
DMF, r.t., 15 h 
 
20, 90 % 
 
Under argon atmosphere, NaH (55 % dispersion in mineral oil) (336 mg, 7.70 mmol, 
2.50 equiv) was added to a solution of quinidine 19 (1.00 g, 3.08 mmol, 1.00 equiv) in 
DMF (10 ml) and the suspension was stirred at r.t. for 2 h. Methyliodide 23 (211 µl, 
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481 mg, 3.39 mmol, 1.10 eq) was added dropwise within 10 min and the mixture was 
stirred for 13 h at r.t. The reaction was quenched with brine (10 ml) and the phases 
were separated. The aqueous layer was extracted with EtOAc (3 x 7 ml) and the 
organic layer was washed with brine (20 ml). The combined organic layers were dried 
over Na2SO4 and the solvent was removed under reduced pressure. The residue was 
purified by flash chromatography (CHCl3/MeOH 5:1) to yield 940 mg (2.78 mmol, 90 %) 
of the product 29 as yellow oil. 
 
C21H26N2O2  (338.44 g/mol) 
 
Rf  0.42 (CHCl3/MeOH = 5:1) 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.71 (d; J = 4.5 Hz, 1H), 8.00 (d; J = 
8.8 Hz, 1H), 7.40 (d; J = 4.5 Hz, 1H), 7.35-7.32 (m; 2H),  6.11-5.99 (m; 
1H), 5.18 (s; 1H), 5.09-5.04 (m; 2H), 3.92 (s; 3H), 3.39-3.35 (m; 1H), 3.31 
(s; 3H), 3.02-2.95 (m; 2H), 2.89-2.81 (m; 1H), 2.79-2.71 (m; 1H), 2.29-2.20 
(m; 1H), 2.13-2.05 (m; 1H), 1.73 (s; 1H), 1.57-1.39 (m; 2H), 1.15-1.05 (m; 
1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 162.3, 147.2, 144.3, 143.9, 140.1, 131.5, 
127.1, 121.6, 118.3, 114.5, 100.8, 82.4, 59.4, 57.0, 55.6, 49.8, 49.2, 39.7, 
28.0, 26.0, 20.8. 
 
IR (ATR)  ν~  [cm-1] = 2930, 2866, 1673, 1618, 1589, 1505, 1470, 1430, 1359, 1302, 
1238, 1226, 1117, 1065, 1027, 911, 882, 827, 759, 728, 715. 
 
HR ESI-MS  (m/z): exact mass [M+H]+: 339.2072; found [M+H]+: 339.207. 
 
The spectroscopical data are in agreement with the literature.59 
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3.4.20 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]-9-O-methylquinidinium chloride (IV-1) 
 
[II-SEE-148] 
 
N
CH2
N
OMe
OMe
 
 Cl
 
 
N
CH2
N
OMe
OMe
Cl
 
20 24 IV-1 
   
20 + 24 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
DMF/EtOH/CHCl3, 100°C, 5 h 
 
IV-1, 32 % 
 
Under argon atmosphere, 9-(chloromethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6,7,8-octahydro-
1,4:5,8-dimethanoanthracene 24 (250 mg, 966 µmmol, 1.10 equiv) and 9-O-methyl-
quinidine 20 (297 mg, 878 µmol, 1.00 equiv) were dissolved in a mixture of DMF/ 
EtOH/CHCl3 (8 ml, 9:4:1). The solution was stirred at 100 °C for 5 h. The solvent was 
removed under reduced pressure and the residue was purified by flash chromatography 
(CHCl3/MeOH 9:1→ 5:1). 170 mg (284 µmol, 32 %) of the product IV-1 were obtained 
as off-white solid. 
 
C38H45N2O2Cl  (597.23 g/mol) 
 
Rf  0.25 (CHCl3/MeOH 9:1) 
 
m.p.  150 °C (decomposition) 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 8.85 (d; J = 4.3 Hz, 1H), 8.03 (d; J = 
9.2 Hz, 1H), 7.64 (d; J = 4.3 Hz, 1H), 7.50-7.47 (s; 2H), 7.25 (s; 1H), 6.43 
(s; 1H), 6.12-6.00 (m; 1H), 5.31-5.20 (m; 2H), 5.01 (d; J = 12.7 Hz, 1H), 
4.60 (d; J = 12.7 Hz, 1H), 4.30-4.19 (m; 2H), 4.11-4.05 (m; 4H), 3.91 (brs; 
1H), 3.54 (s; 3H), 3.52-3.31 (m; 4H), 3.27-3.17 (m; 1H), 2.80-2.77 (m; 1H), 
2.51-2.41 (m; 1H), 1.97-1.58 (m; 11H), 1.24-0.99 (m; 5H). 
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13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 157.2, 147.6, 147.4, 147.3, 144.0, 138.6, 
137.3, 131.1, 126.1, 122.2, 119.6, 116.8, 116.5, 113.8, 101.8, 74.5, 66.6, 
59.6, 56.2, 55.1, 55.0, 54.9, 43.8, 43.3, 42.2, 36.5, 26.3, 26.0, 25.8, 23.3, 
20.9. 
 
IR (ATR) ν~  [cm-1] = 2956, 2865, 1620, 1506, 1473, 1428, 1353, 1328, 1294, 1240, 
1205, 1109, 1073, 1023, 999, 949, 923, 867  828, 772, 717. 
 
HR ESI-MS (m/z): exact mass [M-Cl]+: 561.3481; found [M-Cl]+: 561.348. 
 
 
3.4.21 Synthesis of 10,11-Dihydroquinidine (21) 
 
[II-SEE-116] 
N
CH2
N
OMe
OH
  
N
Me
N
OMe
OH
 
19 21 
   
19 
 
Pd/C 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
EtOH, r.t., 16 h, 20 bar H2  
 
21, 94 % 
 
Palladium on charcoal (300 mg, 5 % Pd/C, 55 % H2O) was added to a solution of 
quinidine 19 (400 mg, 1.23 mmol, 1.00 equiv) in ethanol (40 ml), and the resulting 
suspension was stirred for 16 h at 20 bar H2-pressure. The reaction mixture was filtered 
through a pad of celite, the filtrate was concentrated under reduced pressure and the 
residue was dried in vacuo to yield 378 mg (1.16 mmol, 94 %) of the product 21 as 
colourless solid  
 
C20H26N2O2  (326.43 g/mol) 
 
m.p.  167-168 °C  [m.p. ref.53: 166-167 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.51 (d; J = 4.5 Hz, 1H), 7.86 (d; J = 
9.2 Hz, 1H), 7.52 (d; J = 4.5 Hz, 1H), 7.20 (d; J  = 9.2 Hz, 1H), 7.05 (s; 
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1H), 5.57 (s; 1H), 3.71 (s; 3H), 3.22-3.16 (m; 1H), 2.94-2.66 (m; 4H), 2.05-
1.98 (m; 1H), 1.65 (s; 1H), 1.65-1.36 (m; 5H), 1.00-0.93 (m; 1H), 0.87 (t; J 
= 7.2 Hz, 3H). 
  The OH-proton could not be detected. 
 
 13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.5, 148.3, 147.2, 143.7, 131.1, 126.3, 
121.4, 118.3, 101.0, 71.4, 59.6, 55.4, 51.1, 50.2, 37.3, 27.1, 26.2 25.1, 
20.1, 12.0. 
 
 IR (ATR)  ν~  [cm-1] = 3134, 2933, 2866, 2216, 1919, 1620, 1589, 1505, 1469, 1430, 
1363, 1329, 1239, 1226, 1201, 1113, 1082, 1030, 998, 977, 909, 884, 
859, 828, 729, 640. 
 
 HR ESI-MS  (m/z): exact mass [M+H]+: 327.2072; found [M+H]+: 327.207. 
 
The spectroscopical data are in agreement with the literature.53 
 
 
3.4.22 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]10,11-dihydroquinidinium chloride (IV-2) 
 
[II-SEE-149] 
N
Me
N
OMe
OH
 
Cl
 
N
Me
N
OMe
OH Cl
 
21 24 IV-2 
   
21 + 24 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→
THF, reflux, 18 h 
 
IV-2, 49 % 
 
Under argon atmosphere, 9-(chloromethyl)-(1,8-R;4,5-S)-1,2,3,4,5,6,7,8-octahydro-
1,4:5,8-dimethanoanthracene 24 (250 mg, 966 µmmol, 1.10 equiv) and 10,11-dihydro-
quinidine 21 (287 mg, 878 µmol, 1.00 equiv) were dissolved in dry THF (7 ml), and the 
solution was refluxed for 20 h. The solvent was removed under reduced pressure. The 
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residue was dissolved in MeOH (5 ml) and added dropwise to Et2O (200 ml). The 
suspension was stirred for 15 min, the precipitate was filtered off and dried in vacuo to 
yield 252 mg (431 µmol, 49 %) of the product IV-2 as off-white solid. 
 
C37H45ClN2O2 (585.22 g/mol) 
 
m.p.  210 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.66 (d; J = 4.5 Hz, 1H), 7.95 (d; J = 
9.2 Hz, 1H), 7.76 (d; J = 4.5 Hz, 1H), 7.59 (d; J = 5.5 Hz, 1H), 7.29 (d; J = 
9.2 Hz, 1H), 7.12 (s; 1H), 7.06 (s; 1H), 6.59 (d; J = 5.5 Hz, 1H), 5.88 (d; J 
= 12.7 Hz, 1H), 4.39 (d; J = 12.7 Hz, 1H), 3.95 (s; 3H), 3.78-3.64 (m; 2H), 
3.55-3.48 (m; 1H), 3.29-3.26 (m; 4H), 3.05-2.95 (m; 1H), 2.81 (brs; 1H), 
2.47-2.40 (m; 1H), 1.88-1.47 (m; 14H), 1.25 (brs; 1H), 1.03-0.95 (m; 4H), 
0.86 (t; J = 6.8 Hz, 3H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.9, 148.6, 148.5, 147.6, 144.1, 143.6, 
131.9, 125.6, 121.2, 120.5, 117.3, 113.3, 100.7, 69.3, 64.4, 60.1, 56.9, 
56.0, 55.5, 48.4, 44.4, 43.3, 36.4, 27.2, 26.3, 25.0, 24.9, 24.8, 21.2, 11.6. 
 
IR (ATR)  ν~  [cm-1] = 2958, 2866, 2197, 1619, 1590, 1506, 1457, 1429, 1329, 1254, 
1238, 1225, 1110, 1027, 996, 949, 906, 864, 825, 718. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 549.3481; found [M-Cl]+: 549.348.  
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3.4.23 Synthesis of 6’-Hydroxy-cinchonine (22) 
 
[II-SEE-100] 
N
CH2
N
OMe
OH
 
N
CH2
N
OH
OH
 
19 22 
   
19 
BBr3 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, -78 °C → reflux, 13 h 
22, 61 % 
 
In a Schlenk flask, boron tribromide (3.09 g, 12.3 mmol, 4.00 equiv) in dry CH2Cl2 
(12 ml) was slowly added under vigorous stirring to a solution of quinidine 19 (1.00 g, 
3.08 mmol, 1.00 equiv) in dry CH2Cl2 (100 ml) at -78 °C. The reaction mixture was 
allowed to warm up to r. t.. It was refluxed at 40 °C for 1 h and then cooled to 5 °C. 
While stirring and maintaining the temperature aq. NaOH (10 %, 30 ml) was added. The 
aqueous solution was separated from the organic phase and was washed with CH2Cl2 
(30 ml). HCl (2 M) was added dropwise until a colourless solid precipitated (approx. pH 
8). Extraction with CHCl3, drying of the organic phase over MgSO4 and evaporating to 
dryness yielded 580 mg (1.87 mmol, 61 %) of the desired product 22 as yellowish solid.  
 
C19H22N2O2 (310.39 g/mol) 
 
m.p.  >168 °C (decomposition)    [m.p. ref.53: >165 °C (decomposition)] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.57 (brs; 1H), 7.91 (d; J = 8.5 Hz, 1H), 
7.60 (s; 1H), 7.41 (s; 1H), 7.29 (d; J = 8.5 Hz, 1H), 6.04 (brs; 2H), 4.99-4.87 
(m; 2H), 3.91-3.72 (m; 1H), 3.06-2.90 (m; 1H), 2.88-2.69 (m; 1H), 2.61-2.43 
(m; 1H), 2.35-2.14 (m; 2H), 2.11-1.99 (m; 1H), 1.64 (s; 1H), 1.40-1.12 (m; 
2H), 0.90-0.74 (m; 1H). 
 The OH-protons could not be detected. 
 
13C NMR  (75 MHz, CHCl3-d1): δ [ppm] = 158.0, 147.2, 146.1, 142.7, 139.7, 131.3, 
126.6, 123.5, 117.8, 115.2, 104.0, 70.4, 59.3, 49.2, 49.0, 39.5, 28.0, 25.5, 
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18.4. 
 
IR (ATR)  ν~  [cm-1] = 3000, 2868, 1708, 1652, 1614, 1590, 1557, 1506, 1455, 1405, 
1325, 1226, 1129, 1103, 996, 907, 881, 854, 829, 795, 761, 725. 
 
HR ESI-MS (m/z): exact mass [M+H]+: 311.1760; found [M+H]+: 311.176. 
 
The spectroscopical data are in agreement with the literature.53 
 
 
3.4.24 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]- 6’-hydroxycinchoninium chloride (IV-4)  
 
[II-SEE-150] 
N
CH2
N
OH
OH
 
Cl
 
N
CH2
N
OH
OH
Cl
 
22 24 IV-4 
   
22 + 24 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 18 h 
 
IV-4,  42 % 
 
Under argon atmosphere, 9-(chloromethyl)-(1,8-S;4,5-R)-1,2,3,4,5,6,7,8-octahydro-
1,4:5,8-dimethanoanthracene 24 (250 mg, 966 µmmol, 1.10 equiv) and 6’-hydroxy-
cinchonine 22 (273 mg, 878 µmol, 1.00 equiv) were dissolved in dry THF (7 ml) and the 
solution was refluxed for 18 h. The precipitate was filtered off and washed with THF to 
yield 210 mg (369 µmol, 42 %) of the product as light red solid. 
 
C36H41ClN2O2 (569.18  g/mol) 
 
m.p.  210 °C 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 10.53 (s; 1H), 8.73 (d; J = 4.3 Hz, 1H), 
7.93 (d; J = 9.2 Hz, 1H), 7.85 (s; 1H), 7.69 (d; J = 4.3 Hz, 1H), 7.38 (d; J = 
9.2 Hz, 1H), 7.22 (s; 1H), 7.10 (s; 1H), 6.47 (s; 1H), 6.12-6.01 (m; 1H), 
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5.29-5.13 (m; 3H), 4.94 (d; J = 12.8 Hz, 1H), 4.25-4.18 (m; 3H), 4.00-3.74 
(m; 2H), 3.61-3.22 (m; 4H), 2.71-2.64 (m; 1H), 2.30-2.22 (m; 1H), 1.92-
1.50 (m; 11H), 1.14-1.04 (m; 5H). 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 156.2, 148.1, 148.0, 146.3, 142.5, 142.3, 
135.7, 130.5, 124.9, 121.6, 119.2, 117.7, 116.9, 114.1, 104.6, 66.3, 66.1, 
58.2, 56.3, 54.2, 48.4, 44.2, 44.1, 38.0, 26.9, 26.8, 26.6, 24.0, 21.5. 
 
IR (ATR)  ν~  [cm-1] = 2963, 2868, 1619, 1531, 1464, 1403, 1328, 1225, 1110, 1000, 
924, 864, 832. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 533.3161; found [M-Cl]+: 533.316. 
 
 
3.4.25 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]-6’-isopropoxy-cinchoninium chloride (IV-5) 
 
[II-SEE-164] 
N
CH2
N
OiPr
OH
 
Cl
 
N
CH2
N
OiPr
OH
Cl
 
44 24 IV-5 
   
44 + 24 
 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 18 h 
 
IV-5, 20 % 
 
Under argon atmosphere, 9-(chloromethyl)-(1,8-S;4,5-R)-1,2,3,4,5,6,7,8-octahydro-
1,4:5,8-dimethanoanthracene 24 (250 mg, 966 µmmol, 1.10 equiv) and 6’-isopropoxy-
cinchonine 44 (309 mg, 878 µmol, 1.00 equiv)  were dissolved in dry THF (7 ml) and the 
solution was refluxed for 18 h. The solvent was removed under reduced pressure. The 
residue was dissolved in MeOH (5 ml) and added dropwise to Et2O (200 ml). The 
suspension was stirred for 15 min, the precipitate was filtered off and dried in vacuo to 
yield 106 mg (173 mmol, 20 %) of the product as off-white solid. 
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C39H47ClN2O2 (611.26 g/mol) 
 
m.p.  170 °C (decomposition) 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.64 (d; J = 4.3 Hz, 1H), 7.99 (d; J = 
9.2 Hz, 1H), 7.77 (d; J = 4.3 Hz, 1H), 7.70 (s; 1H), 7.30 (d; J = 9.2 Hz, 1H), 
7.20 (s; 1H), 7.04 (s; 1H), 6.60 (s; 1H), 6.03-5.91 (m; 2H), 5.19-5.11 (m; 
2H), 4.73-4.60 (m; 2H), 4.41 (d; J = 12.7 Hz, 1H), 4.07 (brs; 1H), 3.71-3.65 
(m; 1H), 3.57-3.47 (m; 3H), 3.28 (brs; 2H), 3.09-2.99 (m; 1H), 2.52-2.33 
(m; 2H), 1.96-1.72 (m; 6H), 1.67 (d; J = 8.6 Hz, 2H), 1.46 (d; J = 8.7 Hz, 
2H), 1.35-0.98 (m; 12H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 156.0, 148.8, 147.7, 145.6, 143.7, 143.1, 
135.5, 132.0, 125.7, 120.8, 120.5, 118.3, 117.0, 113.2, 104.9, 70.5, 69.4, 
64.6, 60.1, 56.1, 54.9, 48.4, 44.2, 43.8, 38.4, 26.8, 26.8, 26.7, 24.4, 22.2, 
21.3. 
 
IR (ATR) ν~  [cm-1] = 2962, 2866, 1616, 1504, 1457, 1383, 1326, 1238, 1110, 1003, 
968, 926, 863, 826. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 575.3638; found [M-Cl]+: 575.364. 
 
 
3.4.26 Synthesis of 1-N-(9-Anthrylmethyl)quinidinium chloride (IV-6) 
 
[II-SEE-117] 
N
CH2
N
OMe
OH
 
Cl
 
N
CH2
N
OMe
OH
Cl
 
19 45 IV-6 
   
19 + 45 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 16 h 
 
IV-6, 36 % 
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Under argon atmosphere, quinidine 19 (1.00 g, 3.08 mmol, 1.00 equiv) and 9-chloro-
methylanthracene 45 (768 mg, 3.08 mmol, 1.00 equiv) were dissolved in dry THF 
(25 ml), and the solution was refluxed for 16 h. The precipitate was filtered off and was 
washed with THF. The solid was redissolved in CH2Cl2 (10 ml) and was added dropwise 
to Et2O (150 ml). The suspension was stirred for 15 min, the precipitate was filtered off 
and was dried in vacuo. The crude product was purified by flash chromatography 
(CHCl3/MeOH 9:1→ 6:1) to yield 617 mg (1.12 mmol, 36 %) of the product IV-6 as a 
yellow solid. 
 
C35H35ClN2O2 (551.12 g/mol) 
 
 Rf  0.53 (CHCl3/MeOH = 6:1) 
 
m.p.  160 °C (decomposition)   [m.p. ref.52: >155 °C (decomposition)] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 9.04 (d; J = 8.9 Hz, 1H), 8.43 (d; J = 
8.9 Hz, 1H), 8.29-8.21 (m; 3H), 8.06 (d; J = 4.5 Hz, 1H), 8.07 (s; 1H), 7.87 
(d; J = 9.2 Hz, 1H), 7.63 (d; J = 7.5 Hz, 1H), 7.54 (d; J = 8.5 Hz, 1H), 7.36-
23 (m; 3H), 7.14-7.10 (m; 2H), 7.01 (s; 1H), 6.87 (d, J = 13.5 Hz, 1H), 6.45 
(d; J = 13.5 Hz, 1H), 5.74-5.60 (m; 1H), 5.07-4.90 (m; 2H), 4.77-4.72 (m; 
1H), 4.52-4.45 (m; 1H), 4.22-4.14 (m; 1H), 3.83 (s; 3H), 2.71-2.64 (m; 1H), 
2.28-2.18 (m; 2H), 1.85-1.69 (m; 2H), 1.59 (s; 1H), 1.41-1.31 (m; 1H), 
0.95-0.86 (m; 1H). 
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 157.6, 147.0, 144.3, 143.1, 135.7, 132.8, 
131.1, 130.3, 128.6, 127.6, 127.4, 127.3, 126.1, 124.8, 121.3, 120.5, 
118.1, 117.2, 104.2, 70.2, 68.0, 56.8, 56.2, 54.3, 54.2, 38.0, 26.2, 24.2, 
22.5. 
 
IR (ATR) ν~  [cm-1] = 3078, 2200, 1620, 1584, 1539, 1506, 1471, 1447, 1430, 1353, 
1239, 1225, 1124, 1081, 1027, 997, 908, 867, 825, 792, 724. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 515.2701; found [M-Cl]+: 515.270. 
 
The spectroscopical data are in agreement with the literature.52 
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3.4.27 Synthesis of 1-N-(1-Naphthylmethyl)quinidinium chloride (IV-7)  
 
[II-SEE-103] 
N
CH2
N
OMe
OH
 
Cl
 
N
CH2
N
OMe
OH
Cl
 
19 46 IV-7 
   
19 + 46 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 15 h 
 
IV-7, 82 % 
 
Under argon atmosphere, 1-chloromethylnaphthaline 46 (465 µl, 544 mg, 3.08 mmol, 
1.00 equiv) was added to a solution of quinidine 19 (1.00 g, 3.08 mmol, 1.00 equiv) in 
dry THF (20 ml), and the solution was refluxed for 15 h. The precipitate was filtered off 
and was washed with THF. The solid was redissolved in MeOH (10 ml) and added 
dropwise to Et2O (200 ml). The suspension was stirred for 15 min, the precipitate was 
filtered off and dried in vacuo to yield 1.27 g (2.53 mmol, 82 %) of the product IV-7 as 
colourless solid. 
 
C31H33ClN2O2 (501.06 g/mol) 
 
m.p.  187 °C (decomposition)    [m.p. ref.52: >186 °C (decomposition)] 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 8.83 (d; J = 4.1 Hz, 1H), 8.58 (d; J = 
8.2 Hz, 1H), 8.18 (d; J = 8.1 Hz, 1H), 8.12-8.08 (m; 2H), 8.03 (d; J = 
9.2 Hz, 1H), 7.84 (d; J = 4.1 Hz, 1H), 7.73-7.62 (m; 5H) 7.50 (d; J = 
9.13 Hz, 1H), 6.76 (s; 1H), 6.13-6.00 (m; 1H), 5.95 (d; J = 12.8 Hz, 1H), 
5.30 (d; J = 12.8 Hz, 1H), 5.28-5.14 (m; 2H), 4.49-4.43 (m; 1H), 4.21-4.16 
(m; 5H), 3.45-3.40 (m; 1H), 2.89-2.85 (m; 1H), 2.57-2.54 (m; 1H), 2.44-
2.41 (m; 1H), 1.85 (s; 1H), 1.71 (brs; 2H), 1.11 (s; 1H). 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 157.8, 147.8, 144.3, 144.2, 137.8, 134.9, 
134.2, 133.5, 131.7, 131.7, 129.6, 127.8, 126.7, 126.0, 125.8, 124.5, 
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124.4, 122.3, 120.9, 117.4, 102.8, 68.0, 65.0, 59.1, 56.8, 56.0, 54.7, 37.5, 
26.5, 23.9, 21.4. 
 
IR (ATR)  ν~  [cm-1] = 3376, 3124, 1623, 1539, 1515, 1474, 1433, 1365, 1336, 1260, 
1241, 1227, 1173, 1122, 1080, 1026, 994, 967, 930, 866, 850, 834, 807. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 465.254; found [M-Cl]+: 465.254.  
 
The spectroscopical data are in agreement with the literature.52 
 
 
3.4.28 Synthesis of 1-N-(Benzyl)quinidinium chloride (IV-8) 
 
[II-SEE-108] 
N
CH2
N
OMe
OH
  
Cl
 
N
CH2
N
OMe
OH Cl
 
19 47 IV-8 
   
19 + 47  
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 16 h 
 
IV-8, 68 % 
 
Under argon atmosphere, benzyl chloride 47 (496 µl, 546 mg, 4.31 mmol, 1.40 equiv) 
was added to a solution of quinidine 19 (1.00 g, 3.08 mmol, 1.00 equiv) in dry THF 
(15 ml), and the solution was refluxed for 16 h. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography (CHCl3/MeOH 9:1→1:1) 
to yield 944 mg (2.09 mmol, 68 %) of the product IV-8 as colourless solid.  
 
C27H31ClN2O2 (451.00 g/mol) 
 
Rf  0.28 (CHCl3/MeOH 9 :1) 
 
m.p.  178 °C  [m.p. ref.60: 180 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.51 (d; J = 4.5 Hz, 1H), 7.83 (d; J = 
9.2 Hz, 1H), 7.68-7.65 (m; 3H), 7.49 (d; J = 5.7 Hz, 1H), 7.63-7.14 (m; 5H), 
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6.38 (brs; 1H), 5.94-5.83 (m; 1H), 5.66 (d, J = 11.9 Hz, 1H), 5.17-5.11 (m, 
3H), 4.53-4.46 (m, 1H), 4.31 (brs; 1H), 3.99-3.90 (m; 4H), 3.33-3.26 (m; 
1H), 2.80-2.70 (m; 1H), 2.37-2.26 (m; 2H), 1.71 (s; 1H), 1.56 (brs; 2H), 
0.82 (brs, 1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.9, 147.1, 144.0, 143.3, 135.8, 133.9, 
131.4, 130.1, 128.9, 127.3, 126.1, 121.4, 120.7, 117.9, 102.1, 67.8, 65.9, 
62.2, 56.3, 56.1, 53.7, 38.1, 27.2, 23.9, 21.5. 
 
IR (ATR)  ν~  [cm-1] = 3135, 2834, 2201, 1921, 1828, 1616, 1587, 1505, 1472, 1430, 
1356, 1255, 1239, 1173, 1117, 1088, 1024, 1000, 904, 867, 827, 717, 
643. 
 
HR ESI-MS (m/z): exact mass [M-Cl]+: 415.2385; found [M-Cl]+: 415.239. 
 
 
3.4.29 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]quininium chloride (IV-9) 
 
[II-SEE-151] 
N
CH2
N
OMe
OH
 
Cl
 
N
CH2
N
OMe
OH
Cl
 
48 24 IV-9 
   
48 + 24 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
toluene, reflux, 15 h 
 
IV-9, 55 % 
 
Under argon atmosphere, a solution of quinine 48 (285 mg, 878 µmol, 1.00 equiv) and 
9-(chloromethyl)-(1,8-S;4,5-R)-1,2,3,4,5,6,7,8-octahydro-1,4:5,8-dimethanoanthrace-
ne 24 (250 mg, 966 µmmol, 1.10 equiv) in toluene (10 ml) was refluxed for 15 h. The 
precipitate was filtered off, washed with toluene, and dried in vacuo to yield 281 mg 
(483 µmol, 55 %) of the product IV-9 as colourless solid.  
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C37H43ClN2O2 (583.20 g/mol) 
 
m.p.  >207 °C (decomposition)    [m.p. ref.52: >205 °C (decomposition)] 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 8.82 (d; J = 4.4 Hz, 1H), 8.02 (d; J = 
9.1 Hz, 1H), 7.83 (d; J = 4.4 Hz, 1H), 7.55-7.50 (m; 3H), 7.27-7.14 (m; 1H), 
6.68 (s; 1H), 5.87-5.76 (m; 1H), 5.48 (d; J = 12.7 Hz, 1H), 5.12-5.00 (m; 
2H), 4.74-4.63 (m; 2H), 4.31 (brs; 1H), 4.04 (s; 3H), 3.91 (s; 2H), 3.64 (brs; 
1H), 3.41-3.30 (m; 5H), 2.75 (brs; 1H), 2.23 (brs; 2H), 2.00 (s; 1H), 1.87 
(brs; 5H), 1.52-1.50 (m; 4H), 1.10 (brs; 4H). 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 156.9, 147.4, 147.3, 144.3, 143.6, 138.0, 
131.1, 125.3, 121.4,120.3, 116.3, 116.2, 114.3, 102.6, 68.3, 63.5, 59.6, 
59.3, 55.1, 50.4, 45.4, 43.6, 41.9, 37.0, 26.5, 26.4, 25.7, 24.4, 20.5. 
 
IR (ATR)  ν~  [cm-1] = 2961, 2866, 1619, 1507, 1471, 1329, 1239, 1110, 1060, 1027, 
946, 910, 860, 826, 713. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 547.3325; found [M-Cl]+: 547.332. 
 
The spectroscopical data are in agreement with the literature.52 
 
 
3.4.30 Synthesis of N-Methyl-quinidinium iodide (38) 
 
[III-SEE-208] 
 
N
CH2
N
OMe
OH
 
I
N
CH2
MeN
OMe
OH
 
19 38 
   
19 
MeI 23 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeOH, r.t., 24 h 
38, 70 % 
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Under argon atmosphere, methyl iodide 23 (437 µl, 1.00 g, 7.09 mmol, 1.15 equiv) was 
added to a solution of quinidine 19 (2.00 g, 6.18 mmol, 1.00 equiv) in MeOH (60 ml), 
and the reaction mixture was stirred for 24 h at r.t.. The solvent was removed under 
reduced pressure and the residue was washed with THF. The crude product was 
dissolved at reflux in a mixture of MeOH/H2O (30 ml, 1:1). Activated charcoal was 
added and the suspension was stirred for 15 min before it was filtered hot. The filtrate 
was concentrated under reduced pressure, and the residue was dried in vacuo to yield 
2.02 g (4.32 mmol, 70 %) of the product 38 as off-white solid. 
 
C21H27IN2O2 (466.36 g/mol) 
 
m.p.  235 °C (decomposition) [m.p. ref.61: 236-237 °C (decomposition)] 
 
1H NMR  (300 MHz, MeOH-d4): δ [ppm] = 8.76 (d; J = 4.7 Hz, 1H), 7.99 (d; J = 
9.3 Hz, 1H), 7.51 (d; J = 4.7 Hz, 1H), 7.53-7.47 (m; 1H), 7.34-7.29 (m; 1H), 
6.37 (brs; 1H), 6.16-6.04 (m; 1H), 5.36-5.28 (m; 2H), 4.53-4.45 (m; 1H), 
4.11 (s; 3H), 3.85-3.61 (m; 4H), 3.52 (s; 3H), 2.95-2.86 (m; 1H), 2.52-2.45 
(m; 1H), 2.04-1.93 (m; 3H), 1.16-1.08 (m; 1H).  
The OH-proton could not be detected. 
 
13C NMR  (75.5 MHz, MeOH-d4): δ [ppm] = 158.6, 146.8, 144.24, 143.3, 136.3, 
130.3, 125.9, 122.0, 119.9, 116.5, 100.9, 66.5, 65.6, 60.8, 59.2, 48.5, 
38.0, 26.9, 23.7, 19.9. 
 
IR (ATR)  ν~  [cm-1] = 3509, 2992, 2947, 2830, 1621, 1589, 1511, 1472, 1451, 1432, 
1359, 1243, 1227, 1205, 1133, 1115, 1023, 921, 902, 876, 826, 718. 
 
HR ESI-MS  (m/z): exact mass [M-I]+: 339.2072; found [M-I]+: 339.208. 
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3.4.31 Synthesis of N-Methyl-quinidinium chloride (V-1) 
 
[III-SEE-238] 
I
N
CH2
MeN
OMe
OH
 
Cl
N
CH2
MeN
OMe
OH
 
38 V-1 
   
38 
AgCl, NH3 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
H2O/MeOH, r.t., 72 h 
V-1, 75 % 
 
Aqueous ammonia was added dropwise to a suspension of silver(I)chloride (138 mg, 
965 µmol, 1.50 equiv) in dist. H2O (5 ml) until the silver(I)chloride was dissolved 
completely. This solution was added slowly to a solution of N-methyl-quinidinium iodide 
38 (300 mg, 643 µmol, 1.00 equiv) in MeOH (5 ml), and the reaction mixture was stirred 
for 72 h at r.t. The solvents were removed under reduced pressure and the residue was 
dissolved in CHCl3 (5 ml). Insoluble components were filtered off and the filtrate was 
concentrated under reduced pressure. The residue was dried in vacuo to yield 180 mg 
(481 µmol, 75 %) of the product V-1 as off-white solid. 
 
C21H27ClN2O2 (374.91 g/mol) 
 
m.p.  255 °C (decomposition)    [m.p. ref.60: 250-251 °C (decomposition)] 
 
1H NMR  (300 MHz, MeOH-d4): δ [ppm] = 8.76 (d; J = 4.7 Hz, 1H), 8.01 (d; J = 
9.3 Hz, 1H), 7.85 (d; J = 4.7 Hz, 1H), 7.52-7.48 (m; 1H), 7.35-7.29 (m; 1H), 
6.37 (brs; 1H), 6.16-6.04 (m; 1H), 5.36-5.28 (m; 2H), 4.55-4.47 (m; 1H), 
4.09 (s; 3H), 3.83-3.56 (m; 4H), 3.46 (s; 3H), 2.93-2.85 (m; 1H), 2.53-2.45 
(m; 1H), 2.04-1.92 (m; 3H), 1.16-1.08 (m; 1H). 
The OH-proton could not be detected. 
 
13C NMR  (75.5 MHz, MeOH-d4): δ [ppm] = 158.6, 146.8, 144.32, 143.3, 136.3, 130.3, 
125.9, 122.0, 119.9, 116.5, 100.9, 66.5, 65.5, 60.7, 59.2, 48.2, 38.0, 27.0, 
23.7, 19.9. 
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IR (ATR)  ν~  [cm-1] = 3356, 2953, 2510, 1619, 1589, 1507, 1472, 1451, 1430, 1353, 
1290, 1226, 1178, 1134, 1100, 1019, 918, 861, 828, 717. 
 
HR ESI-MS (m/z): exact mass [M-Cl]+: 339.2072; found [M-Cl]+: 339.208. 
 
 
3.4.32 Synthesis of N-1-Butyl-quinidinium chloride (V-2) 
 
[III-SEE-218] 
 
N
CH2
N
OMe
OH
 
MeCl  
Cl
N
CH2
N
OMe
OH
Me 
19 49 V-2 
   
19 + 49  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, 70 °C, 10 d 
V-2, 32 % 
 
Under argon atmosphere, 1-butyl chloride 49 (10.0 ml, 8.00 g, 95.1 mmol, 15.4 equiv) 
was added to a solution of quinidine 19 (2.00 g, 6.18 mmol, 1.00 equiv) in dry THF 
(30 ml), and the solution was stirred for 10 d at 70 °C. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
5:1) to yield 834 mg (2.00 mmol, 32 %) of the product V-2 as off-white solid. 
 
C24H33ClN2O2 (416.98 g/mol) 
 
Rf  0.55 (CHCl3/MeOH 5:1) 
 
m.p.  140 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.76 (d; J = 4.7 Hz, 1H), 8.02 (d; J = 
9.4 Hz, 1H), 7.86 (d; J = 4.7 Hz, 1H), 7.52-7.48 (m; 1H), 7.30-7.27 (m; 1H), 
6.29 (brs; 1H), 6.14-6.02 (m; 1H), 5.36-5.28 (m; 2H), 4.87 (s; 1H), 4.47-
4.39 (m; 1H), 4.08 (s; 3H), 3.86-3.58 (m; 5H), 3.58-3.48 (m; 1H), 2.91-2.82 
(m; 1H), 2.49-2.37 (m; 1H), 2.15-1.88 (m; 5H), 1.68-1.61 (m; 2H), 1.14-
1.08 (m; 4H). 
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13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 158.5, 146.8, 144.4, 143.3, 136.3, 130.3, 
126.0, 122.0, 120.2, 116.5, 101.0, 65.7, 65.5, 60.2, 57.1, 56.0, 55.1, 37.9, 
26.8 , 24.8, 23.5, 20.7, 20.1, 12.8. 
 
IR (ATR)  ν~  [cm-1] = 3140, 2960, 2928, 2869, 2830, 2197, 1619, 1588, 1506, 1470, 
1430, 1362, 1323, 1254, 1238, 1225, 1173, 1132, 1095, 1079, 1026, 997, 
917, 865, 827, 728, 639. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 381.2542; found [M-Cl]+: 381.254. 
 
 
3.4.33 Synthesis of 4-(Trifluoromethyl)benzyl chloride (30) 
 
[III-SEE-244] 
 OH
CF3  
 Cl
CF3  
29 30 
   
29  
PCl5  
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
toluene, r.t., 18 h 
30 
 
Under argon atmosphere, PCl5 (4.02 g, 19.3 mmol, 1.70 equiv) was added to 4-
(trifluoromethyl)benzyl alcohol 29 (1.56 ml, 2.00 g, 11.4 mmol, 1.00 equiv) in dry toluene 
(100 ml) and the reaction mixture was stirred for 18 h at r.t.. Saturated aqueous 
NaHCO3 solution (100 ml) was added and the mixture was stirred for 15 min. The 
organic layer was separated and dried over Na2SO4. The solvent was removed under 
reduced pressure and the residue was used for the synthesis of 1-N-(4-trifluoromethyl-
benzyl)quinidinium chloride V-3 without further purification. 
 
C8H6ClF3     (194.58 g/mol) 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 7.68 (d; J = 8.1 Hz, 2H), 7.56 (d; J = 
8.1 Hz, 2H), 4.66 (s; 2H). 
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13C NMR  (75 MHz, CHCl3-d1): δ [ppm] = 141.3, 130.6 (q; 2JC-F = 32.1 Hz), 128.8, 
125.7, 124.0 (q; 1J C-F = 273.1 Hz), 45.1. 
 
 
3.4.34 Synthesis of 1-N-(4-Trifluoromethylbenzyl)quinidinium chloride (V-3) 
 
[III-SEE-245] 
 
N
CH2
N
OMe
OH
 
 Cl
CF3  
 
N
CH2
N
OMe
OH
Cl
CF3  
19 30 V-3 
   
19 + 30  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 48 h 
V-3, 49 % 
 
Under argon atmosphere, quinidine 19 (2.23 g, 6.87 mmol, 1.00 equiv) and 4-(trifluoro-
methyl)benzyl chloride 30 (2.00 g, 10.3 mmol, 1.50 equiv) were dissolved in dry THF 
(60 ml). The reaction mixture was refluxed for 48 h. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
7:1) to yield 1.75 g (3.37 mmol, 49 %) of the product V-3 as off-white solid. 
 
C28H30ClF3N2O2 (519.00 g/mol) 
 
Rf  0.47 (CHCl3/MeOH 7:1) 
 
m.p.  195 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.47 (d; J = 4.2 Hz, 1H), 7.88 (d; J = 
7.9 Hz, 2H), 7.76 (d; J = 9.2 Hz, 1H), 7.60 (d; J = 4.2 Hz, 1H), 7.41-7.35 
(m; 4H), 6.97 (d; J = 9.2 Hz, 1H), 6.32 (brs; 1H), 5.86-5.74 (m; 2H), 5.58 
(d; J = 12.1 Hz, 1H), 5.15-5.08 (m; 2H), 4.52-4.45 (m; 1H), 4.31 (brs; 1H), 
4.07-4.01 (m; 1H), 3.77 (s; 3H), 3.19-3.12 (m; 1H), 2.66-2.56 (m; 1H), 
2.30-2.16 (m; 2H), 1.69 (s; 1H), 1.51 (brs; 1H), 0.78-0.73 (m; 1H). 
The OH-proton could not be detected. 
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13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.9, 146.9, 143.9, 142.8, 135.3, 134.4, 
132.1 (q; 2JC-F = 32.7 Hz), 131.6, 131.4, 125.9, 125.5, 123.4 (q; 1JC-F = 
272.2 Hz), 120.4, 120.4, 118.1, 102.4, 67.6, 66.4, 60.9, 56.0, 56.1, 54.0, 
38.0, 27.0, 23.7, 21.7. 
 
IR (ATR) ν~  [cm-1] = 3131, 2962, 1619, 1587, 1506, 1471, 1427, 1322, 1238, 1225, 
1168, 1126, 1067, 1020, 1003, 927, 864, 829, 750, 661. 
 
HR ESI-MS (m/z): exact mass [M-Cl]+: 483.2259; found [M-Cl]+: 483.225. 
 
 
3.4.35 Synthesis of 1-N-(4-Fluorobenzyl)quinidinium chloride (V-4) 
 
[III-SEE-205] 
 
N
CH2
N
OMe
OH
 
 
F
Cl
 
 
N
CH2
N
OMe
OH
F
Cl
 
19 50 V-4 
   
19 + 50  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 46 h 
V-4, 38 % 
 
Under argon atmosphere, 4-fluorobenzylchloride 50 (1.04 ml, 1.25 g, 8.65 mmol, 1.40 
equiv) was added to a solution of quinidine 19 (2.00 g, 6.18 mmol, 1.00 equiv) in dry 
THF (30 ml) and the reaction mixture was refluxed for 46 h. The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography 
(CHCl3/MeOH 7:1). 1.10 g (2.35 mmol, 38 %) of the product V-4 were isolated as violet 
solid. 
 
C27H30ClFN2O2 (468.99 g/mol) 
 
Rf  0.29 (CHCl3/MeOH 7:1) 
 
m.p.  166-168 °C (decomposition) 
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1H NMR  (300 MHz, MeOH-d4): δ [ppm] = 8.77 (d; J = 4.6 Hz, 1H), 8.02 (d; J = 
10.1 Hz, 1H), 7.92 (d; J = 4.3 Hz, 1H), 7.83-7.79 (m; 2H), 7.53-7.50 (m; 
2H), 7.36-7.30 (m; 2H), 6.64 (s; 1H) 6.17-6.05 (m; 1H), 5.35-5.18 (m; 3H) 
4.92 (s; 1H), 4.49-4.42 (m; 1H), 4.10 (s; 3H), 4.02-3.97 (m; 2H), 3.66-3.58 
(m; 1H), 3.18-3.08 (m; 1H), 2.72-2.53 (m; 2H), 1.98-1.88 (m; 3H), 1.20-
1.11 (m; 1H). 
The OH-proton could not be detected. 
 
13C NMR  (75.5 MHz, MeOH-d4): δ [ppm] = 164.1 (d; 1JC-F = 250.0 Hz), 158.6, 146.8, 
144.3, 143.4, 136.4, 135.8 (d; 2JC-F = 22.0 Hz), 130.3, 126.1, 123.5, 121.7, 
120.3, 116.5, 115.9 (d; 3JC-F = 8.7 Hz), 101.6, 67.8, 65.6, 62.9, 56.7, 55.2, 
54.3, 37.5, 27.1, 23.4, 21.0. 
 
IR (ATR)  ν~  [cm-1] = 3371, 3148, 2942, 2830, 1616, 1601, 1557, 1538, 1506, 1471, 
1453, 1430, 1354, 1256, 1239, 1225, 1163, 1117, 1084, 1023, 1001, 933, 
917, 867, 828, 784, 759, 718, 638, 620. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 433.2291; found [M-Cl]+: 433.229. 
 
 
3.4.36 Synthesis of 4-Iodobenzyl chloride (32) 
 
[III-SEE-222] 
 Br
I  
 Cl
I  
31 32 
   
31  
SnCl4 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
-30 °C → r.t., 2h 
32 
 
4-Iodobenzyl bromide 31 (445 mg, 1.50 mmol, 1.00 equiv) was added portionwise at  
-30 °C to tin(IV)chloride (1.58 ml, 3.51 g, 13.5 mmol, 9.00 eq). The reaction mixture was 
allowed to warm up to r.t. within 2 h. It was then added to ice water (5 ml). The mixture 
was extracted with Et2O (3 x 3 ml) and the combined organic layers were dried over 
MgSO4. The solvent was removed under reduced pressure, and the residue was used 
                                         3 Chemically Induced Cardiomyogenesis of Mouse Embryonic Stem Cells 
 
81 
for the synthesis of 1-N-(4-iodobenzyl)quinidinium chloride V-5 without further purify-
cation. 
 
C7H6ClI     (252.48 g/mol) 
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 7.73 (d; J = 8.2 Hz, 2H), 7.23 (d; J = 
8.2 Hz, 2H), 4.69 (s; 2H). 
 
13C NMR  (75.5 MHz, DMSO-d6): δ [ppm] = 137.6, 137.6, 131.2, 94.7, 45.5. 
 
GC MS (HP-5; 100 °C, 20 °C/min, 200 °C (15 min); He; 1.00 ml/min), τR (min) = 
8.49 (32): m/z = 252 [M+], 217, 127, 90, 63. 
 
 
3.4.37 Synthesis of 1-N-(4-Iodobenzyl)quinidinium chloride (V-5) 
 
[III-SEE-235] 
 
N
CH2
N
OMe
OH
 
 Cl
I  
 
N
CH2
N
OMe
OH
Cl
I  
19 32 V-5 
   
19 + 32  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 72 h 
V-5, 34 % 
 
Under argon atmosphere, 4-iodobenzylchloride 32 (200 mg, 792 µmol, 1.10 equiv)  was 
added to a solution of quinidine 19 (234 mg, 720 µmol, 1.00 equiv) in dry THF (5 ml), 
and the reaction mixture was refluxed for 72 h. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography (CHCl3/MeOH 5:1) to 
yield 140 mg (243 µmol, 34 %) of the product as yellow solid. 
 
C27H30ClIN2O2 (576.99 g/mol) 
 
Rf  0.47 (CHCl3/MeOH 5:1) 
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m.p.  >210 °C (decomposition) 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.40 (d; J = 4.5 Hz, 1H), 7.73 (d; J = 
9.2 Hz, 1H), 7.67-7.63 (m; 1H), 7.50 (d; J = 7.8 Hz, 2H), 7.43-7.33 (m; 4H), 
7.00 (d; J = 7.2 Hz, 1H), 6.29 (s; 1H), 5.85-5.74 (m; 1H), 5.61 (brs; 1H), 
5.37 (brs; 1H), 5.15-5.09 (m; 2H), 4.42-4.38 (m; 1H), 3.99 (brs; 1H), 3.80 
(s; 3H), 3.64-3.59 (m; 1H), 3.22-3.14 (m; 1H), 2.70-2.67 (m; 1H), 2.31-2.13 
(m; 2H), 1.72-1.61 (m; 3H), 0.81-0.77 (m; 1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.8, 146.9, 143.7, 143.0, 138.0, 135.5, 
135.3, 131.3, 126.9, 126.0, 120.5, 120.4, 118.0, 102.8, 97.3,  67.5, 65.6, 
61.2, 56.2, 56.1, 53.8, 38.0, 27.1, 23.8, 21.8. 
 
IR (ATR)  ν~  [cm-1] = 3123, 2956, 2206, 1721, 1619, 1588, 1506, 1460, 1429, 1598, 
1239, 1225, 1122, 1078, 1024, 1008, 904, 863, 821, 725, 642, 620. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 541.1351; found [M-Cl]+: 541.135. 
 
 
3.4.38 Synthesis of 1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-diethano-9-anthracenemetha-
nol (37) 
 
[III-SEE-227] 
 OH
 
 OH
 
36 37 
   
36  
NaBH4  
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeOH, 0 °C, 3 h 
37, 91 % 
 
Under argon atmosphere, NaBH4 (96.0 mg, 2.54 mmol, 5.20 equiv) was slowly added to 
a solution of 1,2,3,4,5,6,7,8-octahydro-1,4:5,8-diethano-9-anthracenecarboxaldehy-
de 36 (130 mg, 488 µmol, 1.00 eq) in dry MeOH (40 ml) at 0 °C and the reaction 
mixture was stirred for 3 h. 4 M HCl (4 ml) was added and the precipitate was filtered 
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off, washed with distilled water (3 x 1 ml) and dried under vacuo to give 119 mg 
(443 µmol, 91 %) of the alcohol 37 as colourless solid. This was used for the synthesis 
of the chloride 35 without further purification 
 
C19H24O  (268.39 g/mol)  
 
GC-MS (HP-5; 100 °C, 20 °C/min, 200 °C (15 min); He; 1.00 ml/min),  τR (min) = 
14.00 (37): m/z = 268 [M+], 237, 221, 193, 165, 141, 115, 89, 76. 
 
 
3.4.39 Synthesis of 9-(Chloromethyl)-1,2,3,4,5,6,7,8-octahydro-1,4:5,8-diethanoan-
thracene  (35) 
 
[III-SEE-228] 
 OH
 
 Cl
 
37 35 
   
37 
PCl5  
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
toluene, r.t., 18 h 
35, 64 % 
 
Under argon atmosphere, alcohol 37 (119 mg, 443 µmol, 1.00 equiv) was dissolved in 
dry toluene (5 ml). The mixture was cooled to 0 °C and PCl5 (156 mg, 753 µmol, 
1.70 equiv) was added. After stirring at r.t. for 18 h, saturated aq. NaHCO3 (5 ml) was 
added at 0 °C, and the mixture was stirred for 10 min. The phases were separated and 
the aqueous layer was extracted with toluene (4 ml). The combined organic phases 
were washed with water (4 ml) and dried over Na2SO4. The solvent was removed under 
reduced pressure to obtain 80.6 mg (282 µmol, 64 %) of the chloride 35 as colourless 
solid. 
 
C19H23Cl     (286.84 g/mol) 
 
1H NMR   (300 MHz, CHCl3-d1): δ [ppm] = 6.94 (s; 1H), 4.82 (s; 2H), 3.37 (s; 2H), 
2.98 (s; 2H), 1.83-1.78 (m; 8H), 1.42-1.40 (m; 8H). 
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IR (ATR)  ν~  [cm-1] = 2938, 2858, 2352, 1606, 1450, 1358, 1325, 1281, 1252, 1220, 
1182, 1135, 1110, 1026, 910, 859, 810, 733, 695.  
 
GC MS  (HP-5; 100 °C, 20 °C/min, 200 °C (15 min); He; 1.00 ml/min) τR (min) = 
13.58 (35): m/z = 286 [M+], 258, 221, 179, 155, 89, 63. 
 
 
3.4.40 Synthesis of (9S)-9-Hydroxy-6’-methoxy-1-[(1,2,3,4,5,6,7,8-octahydro-1,4: 
5,8-diethano-9-anthraceny)methyl]quinidinium chloride (V-6) 
 
[III-SEE-224] 
 
N
CH2
N
OMe
OH
 
 Cl
 
 
N
CH2
N
OMe
OH
Cl
 
19 35 V-6 
   
19 + 35  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 48 h 
V-6, 17 % 
 
Under argon atmosphere, quinidine 19 (79.0 mg, 244 µmol, 1.00 equiv) and the 
corresponding chloride 35 (70.0 mg, 244 µmol, 1.00 equiv) were dissolved in dry THF 
(6 ml) and the reaction mixture was refluxed for 48 h. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
10:1) yielding 25.0 mg (40.7 µmol, 17 %) of the product V-6 as off white-solid. 
 
C39H47ClN2O2 (613.27 g/mol) 
 
Rf  0.28 (CHCl3/MeOH 10:1) 
 
m.p.  >210 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.59 (s; 1H), 8.01-7.98 (m; 2H), 7.87 (d; J 
= 4.5 Hz; 1H), 7.35-7.32 (m; 2H), 7.09 (s; 1H), 6.80 (s; 1H), 6.13 (d; J = 
12.5 Hz; 1H), 6.07-5.95 (m, 1H), 5.23-5.14 (m; 2H), 4.94 (d; J = 12.5 Hz, 
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1H), 4.73-4.66 (m; 1H), 3.97 (s; 3H), 3.80-3.70 (m; 2H), 3.52-3.41 (m; 3H, 
3.05-2.99 (m; 2H), 2.58-2.50 (m; 1H), 2.45-2.37 (m; 1H), 1.95-1.80 (m; 
9H), 1.68-1.62 (m; 2H), 1.45-1.20 (m; 9H), 1.05-0.97 (m; 1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 157.2, 147.8, 144.4, 144.2, 143.9,  143.4, 
142.5, 141.9, 135.7, 132.2, 125.9, 123.3, 121.1, 120.7, 118.2, 116.3, 
101.2, 69.5, 57.2, 55.8, 55.5, 54.4, 38.7, 35.0, 34.6, 31.1, 25.9, 25.7,  
25.5,  25.4, 24.4, 21.6. 
 
IR (ATR) ν~  [cm-1] = 2954, 2858, 1721, 1619, 1585, 1505, 1469, 1432, 1357, 1321, 
1288, 1239, 1176, 1133, 1090, 1074, 1025, 999, 928, 864, 825, 746, 715, 
657. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 575.3638; found [M-Cl]+: 575.364. 
 
 
3.4.41 Synthesis of 2,4-Difluorobenzyl chloride (34) 
 
[III-SEE-243] 
 
OH
F
F
 
 
Cl
F
F
 
33 34 
   
33  
PCl5  
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
toluene, r.t., 18 h 
34 
 
Under argon atmosphere, PCl5 (2.95 g, 14.1 mmol, 1.70 equiv) was added to a solution 
of 2,4-difluorobenzyl alcohol 33 (930 µl, 1.20 g, 8.33 mmol, 1.00 equiv) in toluene 
(70 ml), and the reaction mixture was stirred at r.t. for 18 h. Saturated aqueous NaHCO3 
(70 ml) was added and the mixture was stirred for additional 15 min. The organic layer 
was separated and dried over Na2SO4. The solvent was removed under reduced 
pressure and the residue was used for the synthesis of 1-N-(2,4-difluorobenzyl)quini-
dinium chloride V-7 without further purification or characterisation. 
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3.4.42 Synthesis of 1-N-(2,4-Difluorobenzyl)quinidinium chloride (V-7)  
 
[III-SEE-246] 
 
N
CH2
N
OMe
OH
 
 
F
Cl F
 
 
N
CH2
N
OMe
OH
F
Cl
F
 
19 34 V-7 
   
19 + 34  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 48 h 
V-7, 12 % 
 
Under argon atmosphere, quinidine 19 (665 mg 2.05 mmol, 1.00 equiv) and 2,4-
difluorobenzyl chloride 34 (500 mg 3.08 mmol, 1.50 equiv) were dissolved in dry THF 
(10 ml). The reaction mixture was refluxed for 48 h. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
7:1) yielding 117 mg (240 µmol, 12 %) of the product V-7 as off-white solid. 
 
C27H29ClF2N2O2  (486.98 g/mol) 
 
Rf   0.61 (CHCl3/MeOH 7:1) 
 
m.p.  175 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.51 (d; J = 4.4 Hz, 1H), 8.08-8.00 (m; 
1H), 7.81 (d; J = 9.2 Hz, 1H), 7.68 (d; J = 4.4 Hz, 1H), 7.44 (s; 1H), 7.19 
(s; 1H), 7.12 (d; J = 9.3 Hz, 1H), 6.87-6.83 (m; 1H), 6.76-6.73 (m; 1H), 
6.40 (s; 1H), 5.91-5.76 (m; 2H), 5.17-5.11 (m; 3H), 4.56-4.50 (m; 1H), 
4.02-3.89 (m; 2H), 3.78 (s; 3H), 3.20-3.12 (m; 1H), 2.83-2.73 (m; 1H), 
2.42-2.26 (m; 2H), 1.78 - 1.68 (m; 3H), 0.84-0.76 (m; 1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 164.4 (dd; 3JC-F = 12.3 Hz, 1JC-F = 
255.1 Hz), 162.1 (dd; 3JC-F = 12.3 Hz, 1JC-F = 252.7 Hz), 158.0, 147.1, 
143.9, 143.0, 137.5 (d; 3JC-F = 7.4 Hz), 135.4, 131.5, 125.8, 121.0, 120.4, 
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118.1, 112.7 (d; 2JC-F = 21.7 Hz), 111.1 (d; 2JC-F = 13.6 Hz), 104.5 (t; 2JC-F 
= 25.8 Hz), 101.6, 68.4, 65.8, 56.1, 55.9, 55.5, 54.3, 38.1, 26.9, 23.9, 21.5 
  
IR (ATR) ν~  [cm-1] = 3107, 2204, 1617, 1505, 1471, 1430, 1324, 1287, 1239, 1225, 
1144, 1101, 1024, 1002, 966, 912, 853, 826, 729, 661, 639. 
 
HR ESI-MS (m/z): exact mass [M-Cl]+: 451.2197; found [M-Cl]+: 451.219. 
 
 
3.4.43 Synthesis of 6’-Cyclopentyloxy-cinchonine (27)  
 
[III-SEE-203] 
 
N
CH2
N
OH
OH
 
 Br
 
 
N
CH2
N
O
OH
 
22 28 27 
   
22 + 28  
Cs2CO3  
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
DMF, 60 °C, 40 h 
27, 84 % 
 
Under argon atmosphere, cesium carbonate (1.31 g, 4.03 mmol, 2.50 equiv) and 
cyclopentyl bromide 28 (345 µl, 450 mg, 3.22 mmol, 2.00 eq) were added to a solution 
of 6’-hydroxycinchonine 22 (500 mg, 1.61 mmol, 1.00 equiv) in dry DMF (60 ml). The 
reaction mixture was stirred for 40 h at 60 °C. After cooling to r.t., the solids were filtered 
off and the filtrate was concentrated under reduced pressure. The residue was 
dissolved in CHCl3 (20 ml) and was washed with dist. H2O (20 ml). The solvent was 
removed under reduced pressure and the residue was dried in vacuo to yield 510 mg 
(1.35 mmol, 84 %) of the product 27 as light orange solid. 
 
C24H30N2O2 (378.23 g/mol) 
 
m.p.  173 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.43 (d; J = 4.3 Hz, 1H), 7.80 (d; J = 
9.2 Hz, 1H), 7.42 (d; J = 4.3 Hz, 1H), 7.20-7.06 (m; 2H), 6.04-5.92 (m; 1H), 
                                     3  Chemically Induced Cardiomyogenesis of Mouse Embryonic Stem Cells 
88 
5.53 (s; 1H), 5.30 (brs; 1H), 4.99-4.94 (m; 2H), 4.62 (s; 1H), 3.36-3.29 (m; 
1H), 2.94-2.92 (m; 1H), 2.84-2.61 (m; 3H), 2.17-2.09 (m; 1H), 1.99-1.92 
(m; 1H), 1.73-1.40 (m; 11H), 1.03-0.97 (m; 1H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 155.9, 147.8, 147.1, 143.7, 140.6, 131.2, 
126.4, 122.5, 118.5, 114.4, 103.0, 79.5, 71.9, 59.7, 50.3, 49.7, 40.1, 32.9, 
32.5, 28.3, 26.4, 24.1, 21.0. 
 
IR (ATR)  ν~  [cm-1] = 3064, 2936, 2868, 1723, 1616, 1588, 1505, 1456, 1353, 1238, 
1218, 1196, 1168, 1107, 1078, 1047, 986, 906, 858, 828, 729, 641. 
 
HR ESI-MS  (m/z): exact mass [M+H]+: 379.2385; found [M+H]+: 379.239. 
 
 
3.4.44 Synthesis of 1-N-[9-((1,8-R;4,5-S)-1,2,3,4,5,6,7,8-Octahydro-1,4:5,8-dimetha-
noanthracenyl)methyl]-6’-(cyclopentyloxy)cinchonine (V-8) 
 
[III-SEE-204] 
 
N
CH2
N
O
OH
 
 Cl
 
 
N
CH2
N
O
OH Cl
 
27 24 V-8 
   
27 + 24  
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, reflux, 18 h 
V-8, 38 % 
 
Under argon atmosphere, 6’-cyclopentyloxy-cinchonine 27 (200 mg, 536 µmol, 
1.00 equiv) and 9-chloromethyl-[(1,8-S;4,5-R)-1,2,3,4,5,6,7,8-octahydro-1,4;5,8-dime-
thanoanthracene 24 (153 mg 590 µmol, 1.10 equiv) were dissolved in dry THF (5 ml) 
and refluxed for 18 h. The solvent was removed under reduced pressure. The residue 
was dissolved in MeOH (1 ml) and was added dropwise to Et2O (100 ml). The 
suspension was stirred for 15 min. The precipitate was filtered off and was further 
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purified by flash chromatography (CHCl3/MeOH 8:1) to yield 129 mg (203 µmol, 38 %) 
of the product V-8 as off-white solid. 
 
C41H49ClN2O2 (637.29 g/mol) 
 
Rf  0.40 (CHCl3/MeOH 8:1) 
 
m.p.  181 °C 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.62 (d; J = 4.2 Hz, 1H), 7.96 (d; J = 
9.2 Hz, 1H), 7.76 (d; J = 4.2 Hz, 1H), 7.26 (brs; 1H), 7.28 (d; J = 9.2 Hz, 
1H), 7.17 (s; 1H), 7.04 (s; 1H), 6.61 (s; 1H), 6.00-5.81 (m; 2H), 5.18-5.11 
(m; 2H), 4.91 (s; 1H), 4.61-4.55 (m; 1H), 4.40 (d; J = 12.8 Hz, 1H), 3.96 
(brs; 1H), 3.73-3.67 (m; 1H), 3.57-3.50 (m; 1H), 3.31 (brs; 4H), 3.10-3.04 
(m; 1H), 2.47-37 (m; 2H), 1.88-59 (m; 17H), 1.48-1.45 (m; 2H), 1.18-0.90 
(m; 5H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 156.4, 148.8, 147.4, 145.7, 143.6, 143.3, 
135.6, 131.8, 125.8, 121.4, 120.5, 118.1, 117.1, 113.3, 103.9, 79.8, 69.1, 
65.0, 60.0, 56.4, 54.0, 50.5, 48.4, 44.1, 43.0, 38.3, 33.0, 26.9, 26.7, 26.5, 
24.5, 24.2, 21.7. 
 
IR (ATR)  ν~  [cm-1] = 2957, 2868, 2200, 1706, 1617, 1586, 1504, 1459, 1350, 1328, 
1256, 1238, 1220, 1169, 1110, 1090, 1045, 988, 907, 864, 826, 723. 
 
HR ESI-MS  (m/z): exact mass [M-Cl]+: 601.3794; found [M-Cl]+: 601.380.  
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4 A Simplified Synthesis of Takemoto’s Catalyst 
4.1 Background 
Urea and thiourea derivatives have been subject to extensive investigations in the area 
of molecular recognition due to their strong hydrogen-bonding ability. Kelly62 and Etter63 
reported that (thio)urea not only recognise organic compounds but also activate 
substrates by acting as general acidic catalysts. Since then, novel urea and thiourea 
derivatives have been developed for a variety of diastereo- and enantioselective 
reactions. Their versatility as general acids has been successfully demonstrated by 
several groups.64 However, the use of these catalysts for enantioselective reactions has 
been rather limited as ureas are less acidic than metallic Lewis acids. To address this 
problem, bifunctional thiourea catalysts have been developed, which activate the 
nucleophile by deprotonation and the electrophile by hydrogen bonding (Scheme 4-1). 
Among the bifunctional systems developed, Takemoto’s catalyst is the most prominent.5 
A significant number of C-C couplings, for example, Michael-,65,66 Mannich-,67 aza-
Henry-68 reactions, or the alcoholytic dynamic kinetic resolution of azlactones69 are 
catalysed enantioselectively by Takemoto’s bifunctional aminothiourea derivative 51.  
 
N
R3R2
F3C
CF3
N
H
N
H
S
NMe2X
H H
N N
S
Nu-H
* chiral backbone
51
 
Scheme 4-1 Principle of the dual activation by bifunctional (thio)ureas (left), amino thiourea 51 (Take-
moto’s catalyst, right). 
 
The original synthesis of Takemoto’s catalyst 51 involves the addition of isothio-
cyanate 43 to N,N-dimethyl-trans-1,2-diaminocyclohexane 52 (Scheme 4-2).65  
 
NH2
Me2N
CF3
F3C NCS
CF3
F3C N
H
N
H
S
NMe2
51, 65 %52
43
 
Scheme 4-2 Synthesis of the amino thiourea 51 developed by Takemoto.65 
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The main drawback of this approach is the laborious synthesis of the N,N-dimethyl-
trans-1,2-diaminocyclohexane building block 52, which was first described by Finney 
and coworkers in 2000.6 As shown in Scheme 4-3, condensation of (1R,2R)-1,2-di-
aminocyclohexane 11 with the Pinner salt 53 derived from acetonitrile provides the 
corresponding imidazoline 54. Refluxing a solution of 54 in ethanol-water mixture leads 
to the corresponding mono-acetyl diamine 55. The diamine 55 is converted to the N,N-
dimethyl derivative 56 by reductive amination, followed by acidic cleavage of the acet-
amide 56. 
 
NH2
NH2
Me OEt
NH  HCl N
N
H
Me
NHAc
NMe2
NH2
NMe2
4 M HCl
NHAc
NH2
.
54 55, 90 % from 11
52, quant. 56, 68 %
11
EtOH, r.t., 18 h EtOH/H2O, reflux, 24 h
formaldehyde aq.
NaCNBH3, AcOH
MeCN, 2 h, r.t.reflux, 12 h
53
 
Scheme 4-3 Synthesis of N,N-dimethylamine 52 according to Finney.6 
 
An alternative approach for the synthesis of the N,N-dimethyl-trans-1,2-diaminocyclo-
hexane building block 52 was described in 2003 by Kaik and Gawronski.7 The desired 
compound 52 was synthesised via a monoprotection of the (1R,2R)-1,2-diaminocyclo-
hexane 11 with phthalic anhydride 57. However, this approach also involves a tedious 
four-step procedure (Scheme 4-4). 
N
H2N
OO
NaHCO3
N
Me2N
OO
N
H3N
OO
SO3
Me
NH2
Me2N
NH2
H2N
59, 92 % 60, 83 %
61, 86 %52, 85 %
11
p-TSA 58
phthalic anhydride 57
xylenes, reflux, 3 h CH2Cl2, r.t., 12 h
formaldehyde aq.
HCO2H, reflux, 6 h
hydrazine hydrate
EtOH, reflux, 2 h
 
Scheme 4-4 Synthesis of N,N-dimethylamine 52 reported by Kaik and Gawronski.7 
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In the first step, mono-protection of the (1R,2R)-1,2-diaminocyclohexane 11 is achieved 
by reaction with phthalic anhydride 57 in the presence of p-toluenesulfonic acid 58. 
Deprotonation of the corresponding salt 59 yields the mono-protected diamine 60. 
Reductive amination affords the N’-phthaloyl-protected N,N-dimethylamine 61. Finally, 
deprotection yields the desymmetrized N,N-dimethyl diamine 52.  
 
4.2 Concept 
An improved synthesis of Takemoto’s catalyst 51 could be realised in two steps if the 
readily available and cheap (1R,2R)-1,2-diaminocyclohexane 11 can be transformed to 
the mono-thiourea 62. A subsequent dimethylation would lead to the fully assembled 
catalyst 51. A literature survey afforded valuable information regarding the synthesis of 
mono-thiourea derivatives of diamines: 
 
Connon and coworkers reported the direct addition of the (1R,2R)-1,2-diamino-
cyclohexane 11 to isothiocyanate 43 in 49 % yield (Scheme 4-5).70 
 
CF3
F3C NCS NH2
H2N
CF3
F3C N
H
N
H
S
NH2
62, 49 %43 11
+
CH2Cl2, 0 °C, 6 h
 
Scheme 4-5 Synthesis of the mono-thiourea 62 as reported by Connon.70 
 
However, in our hands, following Connon’s procedure led to the bis-thiourea 63 in 86 % 
yield from equimolar amounts of 43 and 11 (Scheme 4-6). This observation has been 
confirmed by several other working groups.71,72 
 
CF3
F3C NCS NH2
H2N
F3C
F3C
NH
NH
S CF3
CF3
HN
HN
S
+
CH2Cl2, 0 °C, 6 h
63, 86 %43 11
 
Scheme 4-6 Formation of the bis-thiourea derivative 63, following Connon’s protocol.71,72 
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The formation of the corresponding bis-thiourea 63 could be avoided either (1) by 
mono-protection of the diamine 11 or (2) by decreasing the reactivity of the isothiocya-
nate 43.  
 
(1) Since covalent mono-protection of the diamines is normally accompanied by two 
additional protection/deprotection steps, this approach seems to be less favorable. 
In principle, the diamine 11 could be also protected as an ammonium chloride 64, 
since the HCl “protecting group” can be cleaved in situ with NaBH3CN73 in the 
following methylation step (Scheme 4-7).  
 
NCS
CF3
F3C
H2N
NH3
N
H NH3Cl
N
H
S
CF3
F3C
HCHO
Cl
-HCl N
H NMe2
N
H
S
CF3
F3C
reducing agent+
43 64 65 51  
Scheme 4-7 Proposed addition of isothiocyanate 43 to the HCl mono-protected diamine 64 and in 
situ cleavage of the protecting group in the following methylation step. 
 
However, as described by Moreau, the addition of aromatic isothiocyanate 43 to HCl 
mono-protected (1R,2R)-1,2-diaminocyclohexane 64 does not result in the corres-
ponding mono-thiourea 65. Instead, the guanidine derivative 66 is formed by 
cyclisation of the thiourea 65 and elimination of H2S (Scheme 4-8).71,72 
 
NCS
CF3
F3C
Cl
H2N
H3N
N
H
S
CF3
F3C N
H
H3N
Cl
N
H
CF3
F3C N
H
N
65 66, quant.
+
43 64
-H2S / HClCH2Cl2, 0 °C, 6 h
 
Scheme 4-8 Formation of guanidine derivative 66 by addition of isothiocyanate 43 to HCl mono-pro-
tected diamine 64.72 
 
(2) The group of Nagasawa observed that the urea analogue 67 can be prepared by 
condensation of 3,5-bis(trifluoromethyl)aniline 68 with 4-nitrophenylchloroformate 69 
followed by addition of (1R,2R)-1,2-diaminocyclohexane 11 (Scheme 4-9, p. 94).8 
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NH2
CF3
F3C
O
O
Cl
NO2
N
H NH2
N
H
O
CF3
F3C
+ 2) diamine 11, Hünig's base
68 69 67, 73 %
1) pyridine
CH2Cl2, r.t., 15 min
 
Scheme 4-9 Synthesis of the amino urea 67 according to Nagasawa.8 
 
Rivier and coworkers74 reported the reaction of aniline 70 with phenyl chloro-
thiocarbonate 71 to form phenyl thiophenylcarbamate 72 (Scheme 4-10). Further-
more, when stirring the phenyl thiophenylcarbamate 72 in CH2Cl2 at r.t. Schneider75 
observed its slow decomposition to the corresponding isothiocyanate 39 and 
phenol 73 (Scheme 4-10).   
NH2
O
S
Cl
N
H
O
S
NCS OH
+
70 71 72
+
39 73
THF, r.t., 30 min CH2Cl2, r.t.
 
Scheme 4-10 Formation of phenyl thiophenylcarbamat 72 and its decomposition to isothiocyanate 39 
and phenol 73.74,75 
 
Based on the work of Rivier74 and Schneider75 the reaction described by Nagasawa8 
(Scheme 4-9) can be interpreted as follows:  
 
NH2
CF3
F3C
O
O
Cl
NO2
N
H
O
O
NO2
CF3
F3C
NH2H2N
NCO
CF3
F3C
NH2H2NOH
NO2
N
H NH2
N
H
O
CF3
F3C
74
Hünig's base+
 
   pyridine
68 69
11
67, 73 %
+
11
Hünig's base
decomposition
75 42
 
Scheme 4-11 Proposed formation of intermediate 74. 
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The aniline derivative 68 first reacts with 4-nitrophenylchloroformate 69 to form the 
corresponding intermediate 74. Then it reacts either directly with the (1R,2R)-1,2-di-
aminocyclohexane 11 with elimination of the phenolate moiety or first decomposes 
to the isocyanate 42 which adds to (1R,2R)-1,2-diaminocyclohexane 11 (Scheme 
4-11, p. 94). 
 
Since the reaction of intermediate 74 with the diamine 11 yields only the mono-
thiourea, it can be assumed that intermediate 74 represents a less reactive synthetic 
equivalent for isocyanate 43.  
Hence, to obtain the desired thiourea equivalent 62, 4-nitrophenylchloroformate 69 
could be replaced by a suitable, commercially available thio-analogue, e.g. 71, 76, 
and 77 (Scheme 4-12). 
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N NN
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80
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Scheme 4-12 Thiocarbonyl derivatives for the synthesis of thiourea 62. 
 
Finally, methylation of the primary amino function should yield the desired Takemoto’s 
catalyst 51 (Scheme 4-13). 
 
S
N
H NH2
N
H
CF3
F3C
HCHO
CF3
F3C
S
N
H NMe2
N
H
reducing agent
62 51  
Scheme 4-13 Methylation with formaldehyde. 
 
                                                                            4 A Simplified Synthesis of Takemoto’s Catalyst 
96 
4.3 Results and Discussion 
The approach for the synthesis of the thiourea 62 proceeds via the reaction of aniline 
derivative 68 with the Staab-reagent 76, thiophosgene 77 or phenyl chlorothioforma-
te 71 according to the synthetic procedure described by Nagasawa8 (Scheme 4-14).  
 
CF3
F3C NH2
X1 X2
S
NH2
NH2
NN
CF3
F3C N
H NH2
N
H
S+
68
11
62
X1,2 =   Cl
76
77
X1,2 =
X1 = PhO, X2 = Cl 71  
Scheme 4-14 Screening of different thiocarbonyl compounds, i.e. 71, 76 and 77, for the synthesis of 
mono-thiourea 62. 
 
Unfortunately, neither employing thiophosgene 77 nor the Staab-reagent 76 led to the 
desired product 62. Using thiophosgene 77 resulted in the formation of bis-thiourea 63 
in 84 % yield (Scheme 4-15). 
F3C NH2
CF3
Cl Cl
S
F3C
NH
F3C S
NH
CF3
HN
CF3
HN
S
+
68 77 63, 84 %
diamine 11
CH2Cl2, r.t., 15 min
 
Scheme 4-15 Formation of bis-thiourea §§ from thiophosgene §§. 
 
Application of the Staab-reagent 76 led predominantly to the formation of trans-4,5-
tetramethyleneimidazolidine-2-thione 81 (Scheme 4-16). 
 
CF3
F3C NH2
N NN N
S
N
H
H
N
S+
68 81, 70 %76
diamine 11
CH2Cl2, r.t., 15 min
 
Scheme 4-16 Formation of trans-4,5-tetramethyleneimidazolidine-2-thione 81 using Staab-reagent 76. 
 
Using phenyl chlorothioformate 71, the desired mono-thiourea 62 was obtained in 35 % 
yield (Scheme 4-17, p. 97). 
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NH2
CF3
F3C PhO
S
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H NH2
N
H
S
CF3
F3C
+
68 71 62, 35 %
1) pyridine
2) diamine 11, Hünig's base
CH2Cl2, r.t., 15 min
 
Scheme 4-17 Formation of thiourea 62 using phenylchlorothioformate 71. 
 
Based on the different reactivities of the thiocarbonyl compounds 71, 76 and 77 an 
explanation for the observed differences may be as follows: 
The very electrophilic thiophosgene 77 couples with the aniline derivative 68 to the 
highly reactive intermediate 80, which then reacts with the diamine 11 to form the mono-
thiourea 62. After mono-thioacylation, the diaminocyclohexane derivative 62 should ex-
hibit a lower NH2-nucleophilicity than the free diaminocyclohexane 11. Despite of that, 
the high electrophilicity of the intermediate 80 leads to fast bis-thioacylation and there-
fore results in the formation of the bis-thiourea 63 (Scheme 4-18). 
The less electrophilic Staab-reagent 76 does not react with the weakly nucleophilic NH2-
function of the aniline derivative 68, but with the more nucleophilic NH2-function of the 
diamine 11, forming the cyclic thiourea 81 (Scheme 4-18).  
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Scheme 4-18 Different reaction outcomes employing 71, 76 or 77. 
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In contrast, the phenyl chlorothioformate 71 has nucleofuges (Cl, OPh) with rather  
different reactivities. The more reactive Cl-leaving group is substituted by the weakly 
nucleophilic NH2-group of the aniline derivative 68. The intermediate formed 78 is less 
reactive than intermediate 80. Therefore, reaction with diaminocyclohexane 11 leads 
predominantly to the desired mono substituted amino thiourea 62 (Scheme 4-18, p. 97). 
 
To improve the yield of the mono-thiourea 62, different reaction conditions were 
screened, based on the original reaction protocol8 [values in parentheses] (Scheme 
4-19). Stirring the solution of the aniline derivative 68 and phenyl chlorothioformate 71 
for 2 h [5 min] and using a 1.8 M [ 2.7 M] solution of the diamine 11 led to an optimised 
yield of 50 % by using only 1.0 eq of the diamine 11 [3.0 eq] and 1.0 eq of Hünig’s base 
[3.0 eq] (Scheme 4-20). 
 
DCM
DCM
pyridine
11
Hünig's 
base
5 min 
stirring
15 min 
stirring
diamine
aniline 
derivative 68
phenylchloro-
thioformate 71
0.3 M1.0 eq 1.0 eq 1.1 eq
3.0 eq
3.0 eq
2.7 M
62 
35 % yield
 
Scheme 4-19 Reaction protocol according to Nagasawa.8 
 
 
 
DCM
DCM
pyridine
11
Hünig's 
base
2 h 
stirring
15 min 
stirring
diamine
aniline 
derivative 68
phenylchloro-
thioformate 71
0.3 M1.0 eq 1.0 eq 1.1 eq
1.0 eq
1.0 eq
1.8 M
62 
50 % yield
 
Scheme 4-20 Reaction protocol after optimisation. 
 
The final step in the synthesis of Takemoto’s catalyst 51 is the reductive methylation of 
the free primary amino function with formaldehyde. In a screening for the most suitable 
reducing agent (Table 4-1, p. 99), zinc powder proved best (Table 4-1, entry 2, 73 %). 
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Table 4-1 Screening of reducing agents for the reductive methylation of amino thiourea 62. 
N
H NH2
N
H
S
CF3
F3C
H2CO
N
H NMe2
N
H
S
CF3
F3C
62 51, 4-73 %
reducing agent
 
Entry Additive Reducing Agent Time (h) Solvent Temp (°C) Yield (%) 
176 
  
72 toluene 60 27 
277 CH3CO2H Zn 72 dioxane r.t. 73 
378 - NaH2PO3 1 dioxane 60 68 
47 - HCO2H 6 HCO2H reflux 4 
56 CH3CO2H NaCNBH3 2 MeCN r.t. 32 
 
In conclusion, an efficient two-step synthesis of Takemoto’s catalyst 51, using commer-
cially available starting materials has been developed. As the key step, the amino 
thiourea 62 was prepared by condensation of 3,5-bis(trifluoromethyl)aniline 68 with 
phenyl chlorothioformate 71, and substitution of phenol by trans-1,2-diaminocyclohexa-
ne 11. Reductive dimethylation with formaldehyde / zinc yielded Takemoto’s catalyst 51 
in an overall yield of 37 %. 
 
4.4 Experimental Part 
4.4.1 General Experimental Conditions 
 
Flash chromatography was performed on silica gel (Macherey-Nagel, MN-Kieselgel 60, 
230-240 mesh). TLC was performed on aluminium backed silica plates (Macherey-
Nagel, Polygram© SIL G/UV254), detection by UV fluorescence. Melting points were 
determined on a Büchi melting point apparatus and are uncorrected. 1H-NMR spectra 
were recorded at 300 MHz on a Bruker DPX 300 instrument; 13C-NMR spectra at 
75.5 MHz. Chemical shifts (δ) are given in parts per million (ppm) referenced to TMS. 
For the fine-structure interpretation the abbreviations of the signals are the following: s = 
singulet, d = doublet, t = triplet, q = quartet, m = multiplet. High resolution mass spectra 
(HR ESI-MS) were recorded on a Finnigan MAT 900 ST spectrometer. Infrared spectra 
were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer using the ATR 
N
H
CO2EtEtO2C
H3C CH3H2N
S
NH2
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technique and on a Perkin Elmer 1600 Series FT-IR spectrometer. All commercially 
available chemicals were used without further purification.  
All experiments are characterised by a number within the bracket: [XX-SEE-XXX]. The 
roman number in front of the three-letter-code indicates the volume number of the 
laboratory notebook, whereas the number after the three-letter-code indicates the 
experiment number in the corresponding notebook volume. 
 
 
4.4.2 Preparation of trans-4,5-Tetramethyleneimidazolidine-2-thione (81)  
 
[III-SEE-250] 
 CF3
F3C NH2  N
NN N
S
 
 NH2
NH2  N
H
H
N
S
 
68 76 11 81 
   
68 + 76 + 11 
 
  
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 15 min 
 
81, 70 % 
 
1,1’-thiocarbonyl diimidazole 76 (806 mg, 4.52 mmol, 1.00 equiv) was added to a 
solution of 3,5-bis(trifluoromethyl)aniline 68 (700 µl, 1.03 mg, 4.52 mmol, 1.00 equiv) in 
CH2Cl2 (15 ml) at r.t.. The mixture was stirred for 5 min, then added dropwise to a 
solution of (1R,2R)-1,2-diaminocyclohexane 11 (1.54 g, 13.5 mmol, 3.00 equiv) in 
CH2Cl2 (5 ml) and the resulting mixture was stirred for 15 min. Saturated aq. NaHCO3 
(20 ml) was added and the phases were separated. The aqueous layer was extracted 
with CH2Cl2 (3 x 15 ml). The combined organic layers were washed with brine (40 ml) 
and dried over MgSO4. The solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (CHCl3/MeOH 8:1) to give the product 81 
as light yellow crystals (491 mg, 3.14 µmol, 70 %). 
 
C7H12N2S (156.25 g/mol)  
 
m.p.  151 °C [m.p. ref.79:148-150 °C] 
 
Rf   0.68 (CHCl3/MeOH 8:1)  
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1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 6.91 (brs; 2H), 3.28-3.24 (m; 2H), 2.04-
2.01 (m; 2H), 1.82-1.79 (m; 2H), 1.47-1.26 (m; 4H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ  [ppm] = 187.2, 64.9, 28.9, 23.7.  
 
IR (ATR) ν~ [cm-1] =  3430, 2940, 1580, 1350.  
 
X-RAY       yellow crystals from chloroform 
Empirical formula:                  C7H12N2S 
       Formula weight (M):                    156.25 
       Temperature (T):                      100(2) K 
       Wavelength (λ):                       0.71073 A 
       Crystal system:    monoclinic,  P21 
       Unit cell dimensions:            a = 5.9624(13) Å   α = 90 °   
                                          b = 8.6670(9) Å     β = 101.184(6) ° 
                                           c = 8.2615(16) Å   γ = 90 ° 
       Unit cell volume:                           418.82(13) Å3 
       Z:      2  
      Calculated density:              1.239 mg/m3 
       Absorption coefficient:             0.315 mm-1 
       F(000):                              168 
       Crystal size:                       0.3 x 0.3 x 0.07 mm 
       Theta range for data collection:    2.51 ° to 26.98 ° 
       Limiting indices                   -7 ≤ h ≤ 7, -8 ≤ k ≤ 10, -7 ≤ l ≤ 10 
       Reflections collected:   2131 
       unique reflections:    1647 [Rint = 0.0223] 
        Reflection observed [I > 2σ(I)]:  1457 
       Completeness to Θ (= 26.98 °):    99.7 % 
       Refinement method:                  Full-matrix least-squares on F2 
       Data / restraints / parameters:     1647 / 1 / 139 
       Goodness-of-fit on F2:            0.933 
       Final R indices [I > 2σ(I)]     R1 = 0.0312, ωR2 = 0.0651 
       R indices (all data):               R1 = 0.0391, ωR2 = 0.0677 
      Absolute structure parameter:     0.03(8) 
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       Largest diff. peak and hole:       0.263 and -0.225 e.Å -3 
 
The spectroscopical data are in agreement with the literature.79 
 
 
4.4.3  Preparation of  1-(3,5-Bis-trifluoromethyl-phenyl)-3-{(1R,2R)-2-[3-(3,5-bis-
trifluoromethyl-phenyl)-thioureido]-cyclohexyl}-thiourea (63)  
 
[IV-SEE-253] 
 CF3
F3C NH2  
Cl Cl
S
 
 NH2
NH2  
 
F3C
NH
F3C S
NH
CF3
HN
CF3
HN
S
 
68 77 11 63 
   
68 + 77 + 11 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 15 min 
 
63, 84 % 
 
Thiophosgene 77 (344 µl, 520 mg, 4.52 mmol, 1.00 equiv) was added to a solution of 
3,5-bis(trifluoromethyl)aniline 68 (700 µl, 1.03 mg, 4.52 mmol, 1.00 equiv) in CH2Cl2 
(15 ml) at r.t.. The mixture was stirred for 5 min, then added dropwise to a solution of 
(1R,2R)-1,2-diaminocyclohexane 11 (1.54 g, 13.5 mmol, 3.00 equiv) in CH2Cl2 (5 ml). 
The resulting mixture was stirred for 15 min. Saturated aq. NaHCO3 (20 ml) was added, 
the phases were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 
15 ml). The combined organic layers were washed with brine (40 ml) and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified 
by flash chromatography (c-hexane/EtOAc 2:1) to give the product 63 as light yellow 
crystals (1.24 g, 1.89 mmol, 84 %). 
 
C24H20F12N4S2  (656.55 g/mol)  
 
m.p.  128-129 °C  [m.p. ref.57: 131-132 °C] 
 
Rf  0.40 (c-hexane/EtOAc 2:1) 
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1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 8.41 (s; 2H), 7.84 (s; 4H), 7.68 (s; 2H), 
7.19 (s; 2H), 4.38 (s; 2H), 2.19 (s; 2H), 1.80 (s; 2H), 1.33 (s;  4H). 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ [ppm] = 180.4, 138.8, 132.6 (q; 2JC-F = 30.1 Hz), 
123.9, 122.7 (d; 1JC-F = 274.1 Hz), 119.5, 59.3, 312.7, 24.4. 
 
IR (ATR)  ν~ [cm-1] = 3245, 3048, 2942, 2860, 1791, 1699, 1621, 1538, 1471, 1373, 
1266, 1183, 999, 974, 956, 885, 847, 787, 731, 681.  
 
The spectroscopical data are in agreement with the literature.57 
 
 
4.4.4 Preparation of 1-[(1R,2R)-2-Aminocyclohexyl]-3-[3,5-bis(trifluoromethyl)-
phenyl]thiourea (62)  
 
CF3
F3C NH2  
 
O
S
Cl  
NH2
NH2  
CF3
F3C N
H
NH2
N
H
S
 
68 71 11 62 
   
68 + 71 + 11 
 
pyridine 
N,N-diisopropylamine  
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t. 
 
62 
 
[III-SEE-247]  (Scheme 4-19, p. 98)8 
Phenyl chlorothioformate 71 (250 µl, 312 mg, 1.81 mmol, 1.00 equiv) was added to a 
solution of 3,5-bis(trifluoromethyl)aniline 68 (280 µl, 410 mg, 1.82 mmol, 1.00 equiv) 
and pyridine (160 µl, 157 mg, 1.99 mmol, 1.10 equiv) in CH2Cl2 (6 ml) at r.t.. The mix-
ture was stirred for 5 min, then added dropwise to a solution of (1R,2R)-1,2-diamino-
cyclohexane 11 (620 mg, 5.43 mmol, 3.00 equiv) in CH2Cl2 (2 ml). N,N-Diisopropylethyl-
amine (896 µl, 699 mg, 5.43 mmol, 3.00 eq) was added and the mixture was stirred for 
15 min. Saturated aq. NaHCO3 (7 ml) was added, the phases were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 x 5 ml). The combined organic layers were 
washed with brine (10 ml) and dried over MgSO4. The solvent was removed under 
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reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
7:1) to give the product 62 as light yellow crystals (245 mg, 638 µmol, 35 %). 
 
[IV-SEE-288]  (Scheme 4-20, p. 98) 
Phenyl chlorothioformate 78 (250 µl, 312 mg, 1.81 mmol, 1.00 equiv) was added to a 
solution of 3,5-bis(trifluoromethyl)aniline 68 (280 µl, 410 mg, 1.82 mmol, 1.00 equiv) 
and pyridine (160 µl, 157 mg, 1.99 mmol, 1.10 equiv) in CH2Cl2 (6 ml) at r.t.. The 
mixture was stirred for 2 h, then added dropwise to a solution of (1R, 2R)-1,2-diamino-
cyclohexane 11 (207 mg, 1.81 mmol, 1.00 equiv) in CH2Cl2 (1 ml). N,N-Diisopropyl-
ethylamine (300 µl, 234 mg, 1.81 mmol, 1.00 eq) was added and the mixture was stirred 
for 15 min. Saturated aq. NaHCO3 (7 ml) was added, the phases were separated, and 
the aqueous layer was extracted with CH2Cl2 (3 x 5 ml). The combined organic layers 
were washed with brine (10 ml) and dried over MgSO4. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (CHCl3/MeOH 
7:1) to give the product 62 as light yellow crystals (351 mg, 911 µmol, 50 %). 
 
C15H17F6N3S (385.37 g/mol)  
 
m.p.  69 °C [m.p. ref.70: 70-72 °C]  
 
Rf  0.26 (CHCl3/MeOH 7:1)  
 
1H NMR  (300 MHz, DMSO-d6): δ [ppm] = 8.30 (s; 2H), 7.68 (s; 1H), 4.06 (brs; 1H), 
2.76 (s; 1H), 2.04-1.92 (m; 2H), 1.75-1.58 (m; 2H), 1.34-1.20 (m; 4H).  
The NH-protons could not be detected.  
 
13C NMR  (75.5 MHz, DMSO-d6): δ  [ppm] = 180.9, 142.6, 130.50 (q; 2JC-F = 31.9 Hz), 
124.4 (q; 1JC-F = 271.3 Hz), 122.1, 116.2, 58.5, 54.0, 33.2, 31.2, 24.7, 24.5.  
 
IR (ATR) ν~ [cm-1] = 2936, 1539, 1472, 1380, 1332, 1269, 1177, 1129, 1100, 964, 
881, 846, 754, 700, 675.  
 
HR ESI-MS  (m/z): exact mass [M+H]+: 386.1125; found [M+H]+: 386.113. 
 
The spectroscopical data are in agreement with the literature.70 
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4.4.5 1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-2-(dimethylamino)cyclohexyl]-
thiourea (51, Takemoto’s Catalyst) 
 
CF3
F3C N
H
NH2
N
H
S
 
CF3
F3C N
H
NMe2
N
H
S
 
62 51 
   
62 
 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
 
51 
 
[IV-SEE-292] (Table 4-1, Entry 1, p. 99)76 
Under argon atmosphere, a mixture of the aminothiourea 62 (110 mg, 285 µmol, 
1.00 equiv) in toluene (1.5 ml) and aqueous formaldehyde 37 % (55.0 µl, 684 µmol, 
2.40 equiv) was treated with Hantzsch ester (216 mg, 8.55 µmol, 3.00 equiv) and 
thiourea (2.10 mg, 28.5 µmol, 10.0 mol%). The mixture was stirred at 60 °C for 72 h. 
After filtration through celite, the solvent was evaporated and the residue was purified 
by flash chromatography (CHCl3/MeOH 7:1). The product 51 was obtained as an off-
white crystalline solid (32.0 mg, 77.0 µmol, 27 %). 
 
[IV-SEE-296] (Table 4-1, Entry 2, p. 99)77 
Zinc powder (102 mg, 1.56 mmol, 4.00 equiv), AcOH (180 µl, 187 mg, 3.12 mmol, 
8.00 equiv) and aqueous formaldehyde 37 % (95.0 µl, 1.17 mmol, 3.00 equiv) were 
added to a solution the of aminothiourea 62 (150 mg, 389 µmol, 1.00 equiv) in dioxane 
(0.5 ml), and the resulting mixture was stirred for 72 h at r.t.. Aqueous NH3 (500 µl) was 
added, the aqueous phase was extracted with CH2Cl2 (2 x 1 ml) and dried over MgSO4. 
The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (CHCl3/MeOH 7:1). The product 51 was obtained as an off-white 
crystalline solid (117 mg, 283 µmol, 73 %). 
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[IV-SEE-294] (Table 4-1, Entry 3, p. 99)78 
Aqueous NaH2PO3 solution (2 M, 1.4 ml, 2.85 mmol, 10.0 equiv) and aqueous 
formaldehyde 37 % (231 µl, 2.85 mmol, 10.0 equiv) were added to a solution of the 
amino thiourea 62 (110 mg, 285 µmol, 1.00 equiv) in dioxane (1.4 ml). The resulting 
mixture was stirred for 1 h at 60 °C. The pH was adjusted to 8 by addition of aqueous 
NaOH (2 M) and the reaction mixture was extracted with CH2Cl2 (3 x 3 ml). The organic 
layer was dried over MgSO4, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (CHCl3/MeOH 7:1). The product 51 was 
obtained as an off-white crystalline solid (80.0 mg, 193 µmol, 68 %). 
 
[IV-SEE-269] (Table 4-1, Entry 4, p. 99)7 
A mixture of the amino thiourea 62 (313 mg, 812 µmol, 1.00 equiv), formic acid (337 µl, 
8.94 mmol, 11.0 eq) and aqueous formaldehyde 37 % (149 µl, 1.79 mmol, 2.20 equiv) 
was stirred under reflux for 6 h. The solvent was removed under reduced pressure and 
the residue was dissolved in CH2Cl2 (500 µl) and washed with saturated NaHCO3 
(500 µl) solution. The organic layer was dried over MgSO4, the solvent was evaporated 
and the residue was purified by flash chromatography (CHCl3/MeOH 7:1). The pro-
duct 51 was obtained as an off white crystalline solid (15.0 mg, 36.0 µmol, 4 %). 
 
[III-SEE-234] (Table 4-1, Entry 5, p. 99)6 
Aqueous formaldehyde 37 % (252 µl, 3.38 mmol, 5.00 equiv) was added to a solution of 
the amino thiourea 62 (260 mg, 675 µmol, 1.00 equiv) in acetonitrile (5 ml), and the 
resulting mixture was stirred for 15 min at r.t.. NaBH3CN (85.0 mg, 1.35 mmol, 
2.00 equiv) was added, followed by acetic acid (85.0 mg, 1.35 mmol, 2.00 equiv) after 
15 min. After stirring at r.t. for 2 h, the reaction mixture was diluted with 2 % 
MeOH/CHCl3 mixture (10 ml) and washed with 1 N NaOH solution (12 ml). The 
aqueous layer was extracted with CHCl3 (3 x 6 ml), the combined organic layers were 
dried over MgSO4, and the solvent was removed under reduced pressure. The residue 
was purified by flash chromatography (CHCl3/MeOH 7:1). The product 51 was obtained 
as an off-white crystalline solid (90.0 mg, 218 µmol, 32 %). 
 
C17H21F6N3S (413.42 g/mol) 
 
Rf   0.24 (CHCl3/MeOH 7:1)  
 
                                                                            4 A Simplified Synthesis of Takemoto’s Catalyst 
 
107 
m.p.  110 °C [m.p. ref.48: 111-113 °C] 
 
1H NMR  (300 MHz, CHCl3-d1): δ [ppm] = 7.97 (s; 2H), 7.52 (s; 1H), 4.28 (brs; 1H), 
2.90 (brs; 1H), 2.48 (s; 6H), 2.40 (s; 1H), 1.96-1.71 (m; 3H), 1.38-1.19 (m; 
4H).  
The NH-protons could not be detected. 
 
13C NMR  (75.5 MHz, CHCl3-d1): δ  [ppm] = 180.5, 140.6, 131.8 (q; 2JC-F = 33.6 Hz), 
123.1 (q, 1JC-F = 272.8 Hz), 122.2, 117.6, 67.2, 53.9, 39.8, 32.4, 24.4, 24.2, 
22.2. 
 
IR (ATR)  ν~ [cm-1] = 3302, 2939, 2860, 2215, 1617, 1538, 1471, 1381, 1272, 1170, 
1127, 1061, 1040, 993, 963, 907, 883, 847, 730, 696, 679. 
 
HR ESI-MS  (m/z): exact mass [M+H]+: 414.1438; found [M+H]+: 414.145  
 
The spectroscopical data are in agreement with the literature.48
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5 La-linked BINOL Catalysed Asymmetric Aza-BH Reaction  
5.1 Background 
The Morita-Baylis-Hillman reaction has developed to a highly efficient C-C bond forming 
process since it combines two important requirements: atom economy and functional 
group generation. Although it has been discovered as early as 1968 by Morita80 
(phosphine-catalysis) and was successively further improved in 1972 by Baylis and 
Hillman81 (amine-catalysis), the reaction and its applications have received a growing 
interest only since the mid 1990s. 
The Morita-Baylis-Hillman reaction consists of a C-C coupling between the α-position of 
an EWG-substituted olefin and a carbonyl group in the presence of an appropriate 
nucleophilic catalyst, e.g. a tertiary amine or a phosphine. The transformation leads to 
the formation of a multifunctionalised molecule (Scheme 5-1, left). 
 
R H
O
OH
R
Z NPG
R H
EWG
R
Z
NH
PG
EWG
+ + basebase
 
Scheme 5-1 Original Morita-Baylis-Hillman reaction (left), aza-Baylis-Hillman variation (right). 
 
Replacing the carbonyl by an imine leads to the aza-Baylis Hillman reaction (Scheme 
5-1, right). This reaction yields α-methylene-β-amino derivatives and, in particular, β-
amino esters if acrylates are used as Michael acceptors. 
 
5.1.1 Mechanistic Studies 
 
Both the Baylis-Hillman- (BH) and aza-Baylis-Hillman (aza-BH) reactions are based on 
an addition-elimination sequence. The generally accepted mechanism of the aza-Baylis-
Hillman reaction is shown in Scheme 5-2, p.109.82,83 After addition of a nucleophile to 
the olefin (A), the resulting enolate adds to the imine (B). A proton transfer (C), followed 
by the elimination of the catalyst (D) and the release of the aza-Baylis-Hillman adduct.  
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Scheme 5-2 Proposed mechanism of the aza-BH reaction. 
 
Jacobsen et al. reported aza-BH reactions of methyl acrylate and nosylimines in CHCl3 
catalysed by DABCO.83 The initial rates were found to follow Equation (5-1). 
 
         rate =       (5-1) 
 
A prominent primary kinetic isotope effect (kH/kD = 3.81) was observed after com-
parison of the initial reaction rates of methyl acrylate with the corresponding α-deutero-
methyl acrylate, suggesting that deprotonation of the α-H(D) (step C) was rate limiting. 
Leitner et al.82 analysed the PPh3 catalysed aza-Baylis-Hillman reaction between methyl 
vinyl ketone and a fluorinated N-tosylated imine in THF. Initial rates are shown as a 
function of concentration for the individual components (Equation 5-2). The order of 0.5 
for the imine indicates that the rate-determing step (RDS) is influenced by the proton 
transfer. 
 
   rate = kobs[PPh3]1[MVK]1[Imine]0.5    (5-2)    rate = kobs[PPh3]1[MVK]1[Imine]0.5    (5-3) 
 
Examination of the kinetics in the presence of phenol as a prototypical additive revealed 
that the rate law of the reaction changes in the presence of a Brønsted acid, showing 
first order dependence for the imine (Equation (5-3)). Hence, the elimination step is no 
longer involved in the RDS and the proton transfer is accelerated by the protic additive. 
 
 
 
[Imine]b  1
[Imine][Acrylate][DABCO]a
+
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5.1.2 Substrate Diversity 
 
Imines.84 Various activated aromatic aldimines like tosyl- (Ts-) imines, nosyl (Ns-) imi-
nes, 2-trimethylsilylethanesulfonyl- (SES-) imines, chiral sulfinyl- and thiophosphorylimi-
nesiv, diphenylphosphinoyl- (dpp-) imines, and very recently, even in situ generated tert-
butyloxycarbonyl- (Boc-) and carboxybenzyl- (Cbz-) imines can be used as electrophiles 
in aza-BH reactions. However, the reaction outcome strongly depends on the appropri-
ate protecting group, as highly activated imines are required for most aza-BH reactions. 
Tosylimines are the most often employed imines in the aza-BH-reaction. Since the 
Ts-protecting group exhibits a strong electron withdrawing effect, the resulting imines 
are very electrophilic. However, harsh conditions are required to cleave the Ts-
protecting group. This limits the synthetic utility of the amino adducts as many functional 
groups do not tolerate these conditions (Scheme 5-3).85 
 
MeHS
S
Me R
NH
EWG
O O
R
NH2
EWG +
-78 °C, 20 min
Na/NH3
 
Scheme 5-3 Cleavage of the Ts-protecting group. 
 
Although the Ns- and SES-protecting groups also lead to highly electrophilic imines, 
these groups are rarely used in the aza-BH reaction. Even though the SES-protecting 
group can be easily removed under relatively mild conditions (Scheme 5-4, (b)), the 
laborious four step synthesis of SES-imines is the main drawback (Scheme 5-4, (a))85  
 
(a) 
 
 
 
 
 
 
 
 (b) 
 
 
Scheme 5-4 Synthesis (a) and cleavage (b) of the SES-protecting group. 
                                            
iv For the application of chiral imines see: 5.1.3 Development of Asymmetric Aza-Baylis-Hillman Reactions 
Me3Si
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N
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Me3Si
SO3Na
CH2Cl2, r.t., 3 h
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S
EWG
SiMe3
O O
CsF
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The use of Ns-imines is rather unusual as the Ns-protecting group cannot be cleaved off 
from the aza-BH adduct. The cleaving thiol reagents add to the double bond of the pro-
ducts instead of deprotecting the amino function (Scheme 5-5). 
 
S
O2N Ar
NH
EWG
SPh
O O
O2N Ar
NH
S
EWG
O O
PhSH, K2CO3
DMF, r.t., 1h
 
Scheme 5-5 Addition of thiophenol on the double bond of the aza-BH adduct. 
 
Phosphinoylimines can be easily synthesised and their dpp-protecting group can be 
removed under mild conditions. However, dpp-protected imines are rarely used in aza-
BH reactions, since they are weaker electrophiles compared to their sulfonylated 
analogues (Scheme 5-6).85 
 
Ar
HN
P
EWG
Ph
Ph
O
20% HCl
Ar
NH2
EWG
Cl
P
Ph
Ph
O
reflux, 2 h
+
 
Scheme 5-6 Cleavage of the dpp-protecting group. 
 
Recently, several working groups explored the use of in situ generated imines in aza-
BH reactions.86 For example, Gajda et al. described the DABCO catalysed reaction 
between electron deficient alkenes and Boc- or Cbz-protected imines, generated in situ 
from stable N-carbamate protected amidoalkyl-p-tolylsulfones (Scheme 5-7).86a 
 
Ar
HN
PG
Ts
EWG DABCO
Ar
HN
PG
EWG
PG = Boc, Cbz
EWG = CO2Me, CO2Et, CN
+
neat, r.t., 2-8 h
51-79 %  
Scheme 5-7 Application of in situ generated Boc- or Cbz-imines in the aza-BH reaction. 
 
In contrast to aromatic imines the use of aliphatic imines in aza-BH reactions is poorly 
illustrated in literature.87 Indeed, activated aliphatic imines are enolisable, are more tedi-
ous to synthesise, are less stable, and their application in aza-BH reactions gave poorer 
results compared to their aromatic counterparts. 
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It is possible to synthesise the imine electrophile in the aza-BH reaction in situ from the 
corresponding aldehyde and the diphenylphosphinamid,88 SES-NH2,89 tosylamide,87b,90 
or Boc-amide87b as it is shown in Scheme 5-8. 
 
H
O
R
NPG
R H R
NH
EWG
PG
EWG EWG
PG-NH2+ + +
 
Scheme 5-8 One-pot procedure of the aza-BH reaction. 
 
Enone components.84 Vinyl ketones and acrylates are the most frequently employed 
enone components. Vinyl ketones are particulary interesting substrates due to their 
versatile applicability in aza-BH reactions while the use of acrylates in the aza-BH 
reaction gives synthetically valuable β-amino acid esters. The use of cyclic enones,91 
activated allenes,92 alkynes93 and conjugated dienes,94 acrylonitrile,87a nitroalkenes,95 
acrylamide,96 and acroleine97 as enone components in the aza-BH reaction is less 
common. 
 
 
5.1.3 Development of Asymmetric Aza-Baylis-Hillman Reactions 
 
Chiral Imines. The first example of an asymmetric aza-BH reaction has been 
developed by Kündig et al.98 in 1994. Chiral planar Cr-complexes of sulfonylimines 
derived from ortho-substituted aromatic aldehydes were utilised. The chiral aldehydes 
were first transformed into tosylimines and then reacted with Michael acceptors in the 
presence of DABCO to give α-methylene-β-amino esters in good yields and good 
enantiomeric excesses. At the end of the reaction, the Cr(CO)3 group is removed 
oxidatively. The main disadvantage of this method is the applicability only to imines 
derived from ortho-substituted aromatic aldehydes (Scheme 5-9). 
 
NTs
H
OMe
EWG DABCO
Cr(CO)3 Cr(CO)3
OMe
EWG
NH
Ts
NH
EWG
Ts
OMe
96-99 % ee
r.t., 3 h
+ hν
air, MeCN
EWG = CN, CO2Me 90-92 %
 
Scheme 5-9 Diastereoselective aza-BH reaction with enantiopure planar chiral o-substituted Cr(CO)3.98 
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Later on, Aggarwal et al.87c employed enantiopure N-sulfinimines in aza-BH reactions 
with methyl acrylate in the presence of 3-hydroxyquinuclidine (3-HQD) and a Lewis 
acid. The desired products were obtained in good to moderate diastereoselectivities 
(Scheme 5-10). 
 
R1 H
N
S
O
R2
O
OMe R1
HN
SOR2
CO2MeR1
HN
SOR2
CO2Me
+
1.0 eq 3-HQD
5 mol% Lewis acid
r.t., 7 d
+
4-89 %
4:96-45:55 dr
R1 = p-Tol, tBu
R2 = Ph, 4-NO2C6H4, nPr  
Scheme 5-10 Use of enantiopure N-sulfinimines in aza-BH reactions with methyl acrylates.87c 
 
Subsequently, enantiopure sulfinimines were also used by Shi et al.87d for reactions with 
cyclopentenone. Good yields and diastereoselectivities were achieved (Scheme 5-11). 
 
O
R H
N
S
O
p-Tol
R
NH
p-TolOS
O NHp-TolOS
R
O
+
52-83 %
88:12-93:7 dr
R = Ph, C6H5CH2CH2, 4-ClC6H4, 
       4-BrC6H4, 3-FC6H4, Me(CH2)3
+ 10 mol% PPhMe2
toluene, r.t., 3-9 d
 
Scheme 5-11 Diastereoselective aza-BH reation with enantiopure N-sulfinimines according to Shi.87d 
 
The N-sulfinyl groups not only induce high selectivity but also exhibit the advantage of 
being easily removed under relatively mild conditions. Their synthesis usually requires 
several steps99 but a fast one-pot synthesis of chiral N-p-toluenesulfinylimines starting 
from a commercial chiral sulfinate has also been developed.100 
Recently, Zhou et al.101 used BINOL-based N-thiophosphoryl imines as chiral substrates 
in the 1,3,5-triaza-phosphaadamantane (PTA) catalysed aza-BH reaction and obtained 
excellent diastereomeric excesses and good yields (Scheme 5-12). 
 
O
O
P
N
Ar H
S
O
Me
O
O
P
NH
Ar
S
O
MeMeCN, r.t., 2-108 h
+
10 mol% PTA
Ar = Ph, p-Tol,4-MeOC6H4, 2-ClC6H4,
        4-BrC6H4, 4-F3CC6H4
64-75 %
42-99 % de  
Scheme 5-12 BINOL-based N-thiophosphoryl imines in the aza-BH reaction with methyl vinyl ketone.101 
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Chiral Nucleophiles - Amines. The first asymmetric aza-Baylis Hillman reaction with 
chiral amines as catalysts was published by Shi et al.102 in 2002. Based on the work of 
Hatakeyama103 who first employed β-isocupreidine 82 as a chiral catalyst in the MBH-
reaction, Shi and co-workers used this chiral amine quinidine derivative in the reaction 
between N-sulfonyl imines and various activated alkenes. The corresponding adducts 
were obtained in moderate yields with excellent enantiomeric excesses (Scheme 5-13). 
 
Ar H
NPG EWG
EWG
Ar
NH
PG
N
N
OH
Me
O
solvent, r.t., 4-96 h
+
Ar = Ph, p-Tol, 4-FC6H4, 3-FC6H4, 
       3-ClC6H4, 4-ClC6H4, 4-BrC6H4
82
10 mol% 82
*
43-89% ee (S) EWG = CHO, CO2Me,CO2PhPG = Ts, SES
46-99% ee (R) EWG = COMe, COEt
34-84%
 
Scheme 5-13 First enantioselective aza-BH reaction catalysed by β-isocupreidine 82. 
 
Adolffson and Balan90c adopted the same catalyst (82) in the three component reaction 
between acrylates, aldehydes and tosylamines in the presence of Ti(OiPr)4 and mole-
cular sieves as additive. Good yields and enantiomeric excesses were achieved 
(Scheme 5-14). 
 
Ar H
O
TsNH2
O
OR Ar
NH
CO2R
Ts
N
N
OH
Me
O
12-95 %
82
THF, r.t., 48 h, MS
+
Ar = Ph, 3-ClC6H4, 3-NO2C6H4, 4-NO2C6H4, 
        4-MeOC6H4, 2-naphthyl, 2-furyl, 2-pyridyl 49-74 % ee
R = Me, tBu
15 mol% 82
+ 2 mol% Ti(OiPr)4
 
Scheme 5-14 Enantioselective in situ aza-BH reaction catalysed by β-isocupreidine 82.90  
 
This catalyst (82) was also employed by Hatakeyama104 in reactions between dpp-
protected imines and hexafluoroisopropyl acrylate, giving the corresponding aza-BH 
products in moderate yields with good enantiomeric excesses (Scheme 5-15). 
 
Ar H
NP(O)Ph2
Ar
NH O
O
CF3
CF3
N
N
OH
Me
O
O
O
CF3
CF3
Ph2(O)P
DMF,-55 °C, 2-120 h+
54-73 % ee
42-97 %
82
10 mol% 82
Ar = Ph, 4-NO2C6H4, 
       1-naphthyl  
Scheme 5-15 β-Isocupreidine 82 catalysed aza-BH reaction of dpp-imines with HFIPA.104 
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From the work of Shi,103 Adolffson and Balan,90c and Hatakeyama104 it follows that both 
the ridgid structure of the β-isocupreidine 82 and the phenolic OH group are essential 
for a high degree of asymmetric induction and sufficient reactivity. Overall, the nucleo-
philic nitrogen atom in the quinuclidine moiety of 82 acts as a Lewis base to initiate the 
asymmetric aza-BH reaction, whereas the phenolic hydroxyl group acts as a Lewis acid 
to stabilise and organise the enolate intermediate and also to promote the subsequent 
aldol addition.  
For the protected imines employed, it turned out that only those imines that have a 
nitrogen atom attached to electron withdrawing groups were electrophilic enough to 
participate in the aza-BH reaction.  
Recently, modified β-isocupreidine catalysts were reported by Zhu et al..105 In these 
catalysts the 6’-OH moiety was replaced by various amide or thiourea functions. Excel-
lent yields and enantioselectivities were obtained with the modified catalyst 83 in the 
aza-BH reaction of PMPSO2-protected imines with 2-naphthyl acrylate (Scheme 5-16). 
 
Ar H
NSO2PMP
O
O
O
Ar
NH
O
PMPSO2
N
O
NHBoc
N
HN Me
O
84-98 % ee 83
CH2Cl2, -30 °C, 24-80 h
+
38-90 %
20 mol% 83
Ar = p-Tol, 4-ClC6H4, 4-NO2C6H4, 3-furyl, 
       2-MeC6H4, 2-naphthyl, PhCH=CH,
        n-pentyl, n-butyl, iPrCH2, cHexCH2  
Scheme 5-16 Use of the β-isocupreidine derived bifunctional catalyst 83 in the aza-BH reaction.105  
 
The group of Sasai106 developed a chiral tertiary amine derived from BINOL (84). Like 
β-isocupreidine 82, this base contains both a subunit possessing a Lewis basic 
character and two hydroxyl groups exhibiting Lewis acid properties. This ensures the 
stabilisation of the zwitterionic intermediates. The reaction yields and enantioselecti-
vities were good, albeit with rather long reaction times (Scheme 5-17). 
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O
R
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NH O
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N
N
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+
Ar = Ph, 4-MeOC6H4, 4-ClC6H4, 3-ClC6H4,
        4-BrC6H4, 4-NO2C6H4, 2-furyl, 2-naphthyl
R = H, Me, Et
10 mol% 84
-15 °C, 12-168 h
87-95 % ee
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Scheme 5-17 Enantioselective aza-BH reaction catalysed by the BINOL-based tertiary amine 84.106 
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Chiral Nucleophiles - Phosphines. Starting in 2003, Shi et al.107 explored the use of 
chiral phosphines to induce enantioselectivity in the aza-BH reaction. A chiral phosphine 
derived from BINAP 85 was investigated in the reaction of Ts-imines with methyl vinyl 
ketone. Good yields and moderate enantioselectivites were achieved, although long 
reaction times were required. However, poor yields and enantiomeric excesses were 
obtained with acrylates as substrates (Scheme 5-18).  
 
Ar H
NPG O
R Ar
NH O
R
PG
OH
PPh2
10 mol% 85
solvent, r.t.,  2-168 h
+
Ar = Ph, p-Tol, 4-EtC6H4, 3-FC6H4, 4-BrC6H4,
        2-ClC6H4, 2-NO2C6H4, C6H4CH=CH
PG = Ts, SES, Ms
R = H, Me, Et, OMe, OPh, O-1-naphthyl
8518-95 % ee
26-99 %
 
Scheme 5-18 First asymmetric aza-BH reaction catalysed by a chiral phosphine 85 according to Shi.107 
 
Since then, numerous new chiral phosphines have been designed and screened to 
further improve these pioneering results. Some representative chiral phosphine cata-
lysts evolved from 85 are shown in Table 5-1. These catalysts were employed in the 
aza-BH reaction of Ts-protected imines with methyl vinyl ketones as Michael acceptors. 
 
Table 5-1 Enantioselective aza-BH reaction of Ts-imines with methyl vinyl ketone catalysed by chiral 
phosphines.108-111 
R H
NTs
O
Me R
NH O
Me
Ts
+ 10 mol% phosphine
solvent, T, time  
 
OH
PPhBu
NHAc
PPh2
N
H
PPh2
N
H
Ph
S
N
H
PPh2
O
O
H
N
Ph2P
OH
PPh2
HO
HO
O
OH
PPh2
O
OH
89 90 91
86 87 88
 
 
entry phosphine solvent T (°C) time (h) yield (%) ee (%) 
1 86 THF r.t. 1-5 80-99 44-89 
2 87 THF -20 24-48 70-97 90-96 
3 88 THF 0 10-164 71-quant. 87-96 
4 89 CH2Cl2 r.t. 5-80 61-98 67-97 
5 90 DCE r.t. 12-60 75-99 46-93 
6 91 CH2Cl2 0 24-48 72-98 68-87 
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A slight modification of the phosphine 85 by replacement of one phenyl group with an 
alkyl chain led to a dramatic reduction of the reaction time. The best results were 
obtained with phosphine 86, bearing a n-butyl group. However, in most cases, lower 
enantioselectivities were observed (Table 5-1, Entry 1).108 
The group of Shi109 has developed a new chiral phosphine 87 comprising several 
hydroxy groups. These types of catalysts ensure a better stabilization of the zwitterionic 
intermediate by creating more hydrogen bonding interactions. Employing phosphine 87 
as chiral catalyst in the aza-BH reaction resulted in improved enantiomeric excesses 
and good yields (Table 5-1, Entry 2). Further improvements in this family of catalysts 
have been made by Ito et al..110 Replacing the binaphthol unit of 87 by a phenol led to 
the organocatalyst 88 with improved catalytic properties, both in terms of yields and 
enantiomeric excesses (Table 5-1, Entry 3). 
Because of the hydrogen bond donating properties of amide groups or thioureas, the 
group of Shi111 incorporated these functionalities into chiral phosphine ligands. 
However, the phosphine-thiourea catalyst 89 as well as the phosphine-amide cata-
lyst 90 led only to moderate enantioselectivities but good yields were obtained (Table 
5-1, Entry 4,5). The sterically more demanding phosphine-amide bifunctional catalyst 91 
gave similar results as organocatalyst 90 (Table 5-1, Entry 6). 
In summary, the chiral phosphine catalyst 87 showed the best results when used in the 
aza-BH reaction of Ts-protected imines with ketones. However, up to now acrylates 
remain challenging substrates for chiral phosphine catalysts. 
 
Chiral Nucleophiles - Sulfides. Aggarwal et al.86c have applied the chiral sulfide 92 in 
the aza-BH-reaction between in situ generated iminium ions and various α,β-unsatura-
ted ketones. While cyclic enones provided the adducts with good yields and enantio-
selectivities, the latter were very poor when acylic enones were used (Scheme 5-19). 
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Scheme 5-19 First enantioselective aza-BH reaction with in situ generated iminium ions.86c 
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Chiral Nucleophiles - Carbenes. Recently, Ye et al.112 demonstrated that chiral N-
heterocyclic carbene precursors with a proximal hydroxy group can act as catalysts in 
aza-BH reactions of cyclopentenone with a  Ts-protected imine. The corresponding aza-
BH adduct was obtained in good yields but only moderate enantioselectivity (Scheme 
5-20). 
Ph H
NTs
O O
Ph
NH
Ts
N
N
N
Ph
Ar
Ar OR
BF4
+
10 mol% 93/94
toluene, r.t., 36 h
*
93: 54 %, 44 % ee
94: 75 %, 10 % ee
Ar = 3,5-F3CC6H493
R = H
94 Ar = Ph
R = TMS 
Scheme 5-20 First asymmetric aza-BH reaction with chiral N-heterocyclic carbene precursors.112 
 
Chiral Additives - Thioureas. Jacobsen et al.83 have developed highly enantioselec-
tive catalytic aza-BH reactions between nosylimines and methyl acrylate in the 
presence of the chiral thiourea derivative 95 and DABCO as nucleophile (Scheme 
5-21). Good enantioselectivities but only moderate yields were obtained. 
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tBu
tBu
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N
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H
S
N
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N
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10 mol% DABCO
tBu
95
Ar = Ph, 3-MeC6H4, 4-ClC6H4, 4-BrC6H4, 3-MeOC6H4,
        3-ClC6H4,  2-thiophenyl, 1-naphthyl, 3-furyl 87-99 % ee
+
10 mol% 95
xylenes, 4 °C, 16-36 h, MS
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Scheme 5-21 Enantioselective aza-BH reaction catalysed by chiral thiourea derivative 95. 
 
Chiral Solvent - Ionic Liquids. Besides chiral catalysts, chiral reaction media can also 
induce high asymmetric induction. Leitner et al.113 performed reactions in the chiral ionic 
liquid methyltrioctylammonium dimalatoborate 96. In the aza-BH reaction between me-
thyl vinyl ketone and tosylimines, good enantioselectivities but only moderate conver-
sions were observed (Scheme 5-22). 
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Scheme 5-22 Chiral ionic liquid 96 as reaction medium in the aza-BH reaction. 
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5.1.4 Use of Aza-Baylis-Hillman Adducts in Synthesis 
 
The aza-Baylis-Hillman reaction has gained considerable interest because it leads to 
highly functionalised products.114 The synthetic utility of the aza-BH adducts is illustra-
ted in the variety of transformations shown in Scheme 5-23. 
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Scheme 5-23 Some representative synthetic tranformations of aza-BH aduccts. Conditions: (a1) K2CO3, 
DMF; (a2) Grubbs II, CH2Cl2; (b) Et3N, CH2Cl2; (c) H2 (1 atm), MeOH; (d1) K2CO3, DMF; (d2) Pd(OAc)2, 
K2CO3, PEG-OH 3400, DMF; (e) DBU, THF; (f1) 20 % HCl; (f2) BOPCl, Et3N, THF; (g) t-BuOOH, Triton B, 
THF; (h) OsO4, NMO, H2O/acetone; (i1) K2CO3, MeCN; (i2) DBU, MeCN.  
 
Various transformations of Ns-protected α-methylene-β-amino esters to new β-amino 
esters have been described by Jacobsen et al..83 These transformations include [3+2] 
cycloadditions of aldoximines (Scheme 5-23, (b)), conjugate additions of 1,3-dicarbonyl 
compounds (Scheme 5-23, (e)), epoxidations (Scheme 5-23, (g)), and dihydroxylations 
(Scheme 5-23, (h)). 
 
In particular, the synthesis of new β-amino ester analogues by hydrogenation of type-B 
β-amino esters have been intensively investigated by several research groups.115 For 
example, Brown et al.115a have studied the hydrogenation of N-Boc-α-methylene-β-
amino esters. The reaction was performed in the presence of a chiral phosphine and 
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resulted in the kinetic resolution of the starting material, which was recovered with high 
enantiomeric excess (Scheme 5-23, (c)). 
 
Another transformation of aza-BH adducts is the conversion to pyrrolidines, pyrrolines 
and pyrroles.89,116 For example, Lamaty et al.89 concentrated on the synthesis of SES-
protected pyrrolidines using ring closing metathesis as a key step (Scheme 5-23, (a)). 
Kim et al.116d have recently synthesised polysubstituted pyrroles from β-amino-carbonyl 
compounds (Scheme 5-23, (i)). 
 
The syntheses of piperidines, tetrahydropiperidines and pyridines starting from aza-BH 
adducts were described by several groups.94,117 For example, Kim et al.117c transformed 
suitably substituted β-amino esters to tetrahydropyridines by an intramolecular Heck 
reaction using a solvent mixture of PEG and DMF (Scheme 5-23, (d)). 
 
The syntheses of  β-amino alcohols by reduction of the corresponding aza-BH adducts 
with LiAlH4 was published by Shi et al.118 (Scheme 5-23, (j)). 
 
β-Lactams are accessible from aza-BH adducts as illustrated by Hatakeyama et al..119 
The synthesis of β-lactams was carried out from dpp-protected β-amino esters following 
a deprotonation-cyclisation two step procedure (Scheme 5-23, (f)).  
 
5.2 Concept 
The application of acrylates as olefinic component in the aza-BH reaction yields 
enantio-enriched unsaturated β-amino acid esters, which have gained considerable 
interest due to their important biological properties, their occurrence in natural products 
and as potential precursors for β-lactams.9 The most common approach for the 
synthesis of β-amino acid esters via aza-BH reactions is the use of Ts-protected imines 
and chiral Lewis bases as catalysts.84 However, harsh conditions are required to cleave 
the Ts-protecting group (see 5.1.2 Substrate Diversity, p. 110). Therefore, the dpp-
protecting group should be employed as it activates the imine and can be removed 
under mild conditions. Furthermore, using dpp-protected imines in combination with 
various acrylates provide a direct access to β-amino acids by simultaneous removal of 
the dpp-protecting group and hydrolysis of the ester function (Scheme 5-24, p. 121).104 
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Ar O
ONH CF3
CF3 Ar OH
ONH2dpp HCl
.
20 % HCl
reflux, 2 h  
Scheme 5-24 According to Hatakeyama,104 hydrolytic C,N-terminal deprotection provides direct access to 
enantio-enriched α-methylene-β-amino acids. 
 
For the aza-BH reaction between dpp-protected imines and less activated acrylates a 
literature survey revealed that the use of chiral Lewis bases only provides moderate 
enantioselectivities. Alternatively, dpp-protected imines can be activated by Zn-(R,R)-
linked-BINOL complexes as shown by Shibasaki in asymmetric Mannich-type reactions 
(Scheme 5-25).120 
 
Ar H
N
dpp O
OH
OMe
0.1mol% Et2Zn / 97
Ar
ONH
OH
dpp OMe
OH
OH
HO
HO
O
+ THF,  -30°C, 4-24 h, MS
Ar = 4-MeC6H4, 2-MeC6H4, 
        4-Cl-C6H4, 1-naphthyl, 
        2-naphthyl, 2-furyl
95-98 %
97-99 % ee
98:2-95:5 dr
97
 
Scheme 5-25 Asymmetric Mannich–type reactions catalysed by a Zn-BINOL complex. 
 
However, so far no example of an enantioselective protocol with chiral metal Lewis acid 
catalysts is known for the aza-BH reaction.121 The following section describes the first 
applications of non-chiral metal Lewis acids in (aza)-BH reactions: 
 
Adolfsson observed that the in situ aza-BH reaction can be accelerated by La(OTf)3 
(Scheme 5-26).90a  
 
Ar H
O
H2NTs
O
OMe Ar
NH
Ts
OMe
O
+ +
2 mol% La(OTf)3
15 mol% DABCO
24 h, r.t., iPrOH, MS  
Scheme 5-26 In situ aza-BH reaction accelerated by La(OTf)3 according to Adolfsson.90a 
 
Unfortunately, the combination of Lewis acids and tertiary amines in MBH reactions 
causes the formation of amine-Lewis acid complexes. In these adducts, the N-nucleo-
phile is not catalytically active. Therefore, in the classic MBH reaction, Aggarwal made 
use of triethanolamine to liberate the lanthanum-coordinated DABCO, which can then 
act as a nucleophile (Scheme 5-28, p. 122). In addition, the use of oxygen-rich ligands 
leads to more Lewis acidic metal complexes and therefore to a rate acceleration of the 
MBH reaction.122 
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La(OTf)x (DABCO)2
N(C2H4OH)3
La(OTf)y (N(C2H4OH)3)2
N
N  
Scheme 5-27 DABCO-lanthanum, triethanolamine-lanthanum equilibrium.122 
 
 
Ph H
O O
OtBu Ph OtBu
OOH
10 mol% DABCO
neat, r.t., 24 h
+
3.8 % y
15.9 % y
36.5 % y
-
10 mol% La(OTf)3
10 mol% La(OTf)3, N(C2H4OH)3  
Scheme 5-28 Rate acceleration of the MBH reaction by Lewis acidic metal complexes.122  
 
Furthermore, Sasai et al. successfully employed La-BINOL-derived heterobimetallic 
complexes in the MBH reaction (Scheme 5-29).121b 
 
O
O
O O
O
O
La
Li
Li
Li
O
HPh
O
O
Ph
OH
+ 10 mol% P(nBu)3
16 mol% LLB
THF, r.t., 2-48 h
LLB
 75 %, 33 % ee
 
Scheme 5-29 Enantioselective MBH reaction promoted by heterobimetallic complexes. 
 
Based on these results, BINOL-based lanthanum complexes should be tested as 
potential chiral catalysts for aza-Baylis-Hillman reactions of dpp-protected imines. 
 
Shi et al. performed a screening of different nucleophiles for the aza-BH reaction of dpp-
protected imine 98a with methyl acrylate 99a and obtained the highest yields when 
Ph2PMe is employed (Table 5-2, entry 2 and 4, p. 123).123 However, using Ph2PMe in a 
preliminary screening in combination with (R)-LLB (La-Li-(R)-BINOL) resulted in poor 
enantioselectivities, while the less reactive DABCO provided much higher 
enantioselectivities (Table 5-2, entries 1 and 3, p. 123). 
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Table 5-2 Preliminary screening for the best nucleophile in the aza-BH reaction of dpp-imine 98a.a 
Ph H
Ndpp O
OMe Ph
NH O
OMe
dpp
98a
+
LLB
Ph2PMe / DABCO
35 h, r.t., THF 100aa99a  
entry nucleophile (R)-LLB  yield (%)b ee (%)c 
1 DABCO 10 mol% 30 75 
2 DABCO -    7d - 
3 Ph2PMe 10 mol% 33 5 
4 Ph2PMe  -   29d - 
 
a Reactions were carried out at r.t. in THF (1.0 M) using imine 98a (1.0 eq), acrylate 99a 
(2.0 eq), DABCO/Ph2PMe (20 mol%), (R)-LLB (10 mol%). b Isolated yield. c Determined by 
HPLC. d Yields are in agreement with literature values.123 
 
In conclusion, dpp-protected imines combined with various acrylates and DABCO as 
nucleophile should be employed as test system for the screening of Lewis acidic 
BINOL-based lanthanum complexes. 
 
5.3 Results & Discussion 
For the application of chiral Lewis acid complexes in the aza-Baylis-Hillman reaction, an 
initial ligand screening was performed using La(OiPr)3 and various (R)-BINOL-based 
ligands in the reaction of dpp-protected benzaldimine 98a and methyl acrylate 99a as 
test system (Table 5-3, p. 124).v Using ligand 101 ((R)-BINOL), the corresponding aza-
Baylis-Hillman adduct was obtained in 25 % yield and 70 % ee (Table 5-3, entry 1). In-
creasing the ligand to metal ratio from 1:1 to 2:1 yielded the same result (Table 5-3, en-
try 2). Sterically more demanding groups in the BINOL 3,3’-positions, i.e. 2-naphthyl 
102, 8-anthracenyl 103, as well as 3,5-bis-CF3- and 2,4,6-tri-iPr-substituted phenyl 
groups 104 and 105 decreased the yields and enantioselectivities (Table 5-3, entries 3-
6 and 9-12). In contrast, a high enantioselectivity of 89 % ee was achieved with linked-
(R,R)-BINOL 97 (Table 5-3, entry 7). Since increasing the ligand to metal ratio for (R)-
BINOL 101 gave no improvement (Table 5-3, entry 2), it is postulated that the increase 
in enantioselectivity for linked-(R,R)-BINOL 97 complex was due to its higher stability as 
compared to the La-(R)-BINOL complex.124 Similar reactivity and selectivity patterns 
                                            
v Absolute product configuration was rigorously established for the aza-BH adducts 100aa and 100ae by 
comparison of the HPLC elution profiles with those reported by Hatakeyama.104 For all other aza-BH 
products, absolute configuration is drawn in analogy. 
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were observed by replacing methyl acrylate with phenyl acrylate 100ab  (Table 5-3, 
entry 9-14). 
Table 5-3 Screening of (R)-BINOL-based ligands.a 
Ph H
Ndpp
OR
O
DABCO
Ph OR
ONH
dpp
La(OiPr)3
(R)-BINOL-based ligand
35 h, r.t., THF
+
98a 99 100  
entry R ligand yield (%)b ee (%)c 
1 Me 101 25 70 
2d Me 101 27 71 
3 Me 102 19 36 
4 Me 103 17 22 
5 Me 104 22 46 
6 Me 105 13 5 
7 Me 97 36 89 
8e Me 97 32 87 
9 Ph 101 51 19 
10 Ph 102 48 12 
11 Ph 103 55 22 
12 Ph 104 46 rac 
13 Ph 105 61 70 
14e Ph 97 60 74 
 
a Reactions were carried out at r.t. in THF (1.0 M) using imine 98a (1.0 eq), 
acrylate 99a,b (2.0 eq), DABCO (20 mol%), La(OTf)3 (10 mol%), and (R)-BINOL 
based ligand 97, 101-105 (10 mol%). b Isolated yield. c Determined by HPLC. d 
20 mol% ligand. e Catalyst loading: 20 mol% La(OiPr)3-ligand. 
 
F3C CF3
Pr
Pr
iPr
H
OH
OH
R
R
O
OH
OH
HO
HO
R =
i
i
101 102
104 105
103
97  
 
The La-linked-(R,R)-BINOL complex is well known for its dual reactivity as Lewis acid 
and Brønsted base.125 The basicity of the catalyst was increased by deprotonation with 
KHMDS, NaHMDS or n-BuLi. However, applying these heterobimetallic complexes in 
the aza-Baylis-Hillman reaction did not result in higher yields or enantioselectivities 
(Table 5-4, entries 2-4, p. 125) relative to the non-metallated species.  
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Table 5-4 Screening of heterobimetallic La-M-linked-(R,R)-BINOL complexes.a 
        
Ndpp
Ph H
OMe
O DABCO
OMe
ONH
Ph
dpp
La(OiPr)3-(M)-ligand 97
35 h, r.t., THF
98a 100aa
+
99a  
entry M source yield (%)b ee (%)c 
1 - 35 89 
2 KHMDS 28 82 
3 NaHMDS 29 86 
4 n-BuLi 30 75 
 
a Reactions were carried out at r.t. in THF (1.0 M) using imine 
98a (1.0 eq), methyl acrylate 99a (2.0 eq), DABCO (20 mol%), 
La(OTf)3 (10 mol%) and ligand 97 (10 mol%). b Isolated yield. c 
Determined by HPLC. 
 
To vary the catalyst’s Lewis acidity, linked-(R,R)-BINOL 97 was coordinated to several 
M(OiPr)3. The activity and selectivity of the resulting complexes were compared to the 
corresponding La-linked-(R,R)-BINOL complex. The Sm- and Y-complexes showed 
similar reactivity and selectivity patterns (Table 5-5, entries 2,3). In contrast, the more 
Lewis-acidic Ti(iPrO)4 did not lead to a catalytically active complex (Table 5-5, entry 4). 
The increased basicity of the Sr-complex led to poor yields and enantioselectivities 
(Table 5-5, entries 5,6). In the absence of M(OiPr)x, ligand 97 did not show any catalytic 
activity (Table 5-5, entry 7). 
 
Table 5-5 Screening of M(OiPr)x–ligand 97 complexes.a 
          
Ph H
Ndpp
OMe
O DABCO
Ph OMe
ONH
dpp
M(OiPr)x-ligand 97
35 h, r.t., THF
+
98a 99a 100aa  
entry M(OiPr)3 yield (%)b ee  (%)c 
1 La(OiPr)3 35 89 
2 Sm(OiPr)3 35 89 
3 Y(OiPr)3 24 81 
4 Ti(OiPr)4 traces n.d. 
5 Sr(OiPr)2 25 25e 
6d Sr(OiPr)2 42 12e 
7 - traces rac 
 
a Reactions were carried out at r.t. in THF (1.0 M) using imine 98a 
(1.0 eq), methyl acrylate 99a (2.0 eq), DABCO (20 mol%), La(OTf)3 
(10 mol%),  and  ligand 97  (10 mol%).  b Isolated yield.  c Determined  
by HPLC. d 20 mol% Sr(OiPr)2, e The opposite enantiomer was formed 
in excess. 
HO
HO
O
OH
OH
97
HO
HO
O
OH
OH
97
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To further optimise the reaction conditions, a test system consisting of the La-linked-
(R,R)-BINOL complex as catalyst in combination with dpp-protected benzaldimine 98a 
and methyl acrylate 99a as substrates was employed. Among the three solvents tested, 
the best yield was achieved in MeCN (Table 5-6, entry 2), while the highest enantiose-
lectivity was observed in THF (Table 5-6, entry 3). Higher yields were obtained in THF 
upon increasing the substrate concentration, without affecting the ee values (Table 5-6, 
entry 4). No improvements were observed with higher DABCO loadings or addition of 
molecular sieves (Table 5-6, entries 5 and 6). Increased yields resulted from higher 
amounts of methyl acrylate 99a (Table 5-6, entry 7). Raising the temperature from r.t. to 
40 °C only led to a slight increase in yield due to the increased formation of byproducts 
as well, while the enantioselectivity was not adversely affected (Table 5-6, entry 8). 
These conditions could not be applied to phenyl acrylate 99b, due to its limited solubility 
in THF. Instead, the best reaction conditions were found to be a 1 M solution of the 
imine 98a in THF, using 2 eq of the acrylate 99b (Table 5-6, entry 9). 
 
Table 5-6 Optimised reaction conditions of the aza-Baylis-Hillman reaction.a 
       
Ph H
Ndpp
OR
O DABCO
OR
ONH
dpp
Ph
35 h, r.t., solvent
+
98a 99 100
La(OiPr)3-ligand 97
 
entry acrylate R solvent yield  (%)b ee  (%)c 
1 99a (2 eq)  Me (1 M) EtOAc 38 86 
2 99a (2 eq)  Me (1 M) MeCN 40 83 
3 99a (2 eq)  Me (1 M) THF 35 89 
4 99a (2 eq)  Me (2 M) THF 41 89 
5d 99a (2 eq)  Me (2 M) THF 40 88 
6e 99a (2 eq)  Me (2 M) THF 38 89 
7 99a (4 eq)  Me (2 M) THF 46 88 
8f 99a (4 eq)  Me (2 M) THF 50 90 
9f 99b (2 eq)  Ph (1 M) THF 68 70 
 
a Reactions were carried out at r.t. in THF using imine 98a (1.0 eq), acrylate 99a,b, DABCO (20 mol%), 
La(OTf)3 (10 mol%) and ligand 97 (10 mol%). b Isolated yield. c Determined by HPLC. d Molecular sieves 
added (200mg/mmol). e 40 mol% DABCO, f Reaction performed at 40 °C. 
 
Among the acrylates tested in a substrate screening, the highest yields were achieved 
using the very reactive phenyl acrylate 99b and 2-naphthyl acrylate 99d (Table 5-7, 
entries 2,8 and 4,10, p. 127). Employing the even more reactive 1,1,1,3,3,3-hexafluoro-
isopropyl acrylate 99e led to reduced yields, due to the increased formation of bypro-
HO
HO
O
OH
OH
97
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ducts.vi Employing methyl acrylate 99a led to the highest enantioselectivities (Table 5-7, 
entries 1 and 7). Acrylonitrile 99f gave only racemic products, due to its fast background 
reaction (Table 5-7, entry 6). Applying the dpp-protected para-Cl-substituted benzald-
imine derivative 99b instead of the dpp-protected benzaldimine 98a led in most cases to 
higher enantioselectivities at virtually unchanged yields (Table 5-7, entries 7-11 vs. 1-6). 
Aliphatic imines were also tested, but only provided traces of the corresponding aza-BH 
adducts. 
Table 5-7 Substrates screening.a 
         
R H
Ndpp R'
DABCO
R
R'
NH
dpp
La(OiPr)3-ligand 97
35 h, r.t., solvent
+
98 99 100  
entry imine R acrylate R’ yield (%)b ee  (%)c 
1 98a  99a  34 89 
2 98a  99b  59 71 
3 98a  99c  31 70 
4 98a  99d  67 63 
5 98a  99e  41 80 
6 98a  99f  48 rac 
7 98b  99a  39 90 
8 98b  99b  56 69 
9 98b  99c  27 83 
10 98b  99d  59 79 
11 98b  99f  52 11e 
 
a Reactions were carried out at r.t. in THF (1.0 M) using imine 98a,b (1.0 eq), olefin component 99a-f 
(2.0 eq), DABCO (20 mol%), La(OTf)3 (10 mol%) and ligand 97 (10 mol%). b isolated yield, c determined by 
HPLC.e The opposite enantiomer was formed in excess. 
 
Acidic hydrolysis of the aza-Baylis-Hillman products 100 provides a single step access 
to the β-aminoacids (Scheme 5-30, p. 128).104 The viability of this approach to α-
methylene-β-aminoacids 106 was proven by the hydrolysis of the aza-Baylis-Hillman 
adducts 100: After refluxing in 20 % aqueous HCl for 6 h, the corresponding β-amino 
acids 106 were isolated in up to 75 %  yield. 
                                            
vi Therefore, Hatakeyama performed aza-BH reactions with 1,1,1,3,3,3-hexafluoroisopropyl acrylate 99e 
in DMF at -55 °C.104 Unfortunately, these reaction conditions could not be applied for the La-linked-BINOL 
catalysed aza-BH reaction due to solubility problems. 
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Ar OR
ONH
dpp
Ar OR
ONH2
100ab R = Ph, Ar = Ph
100ba R = Me, Ar = pClC6H4
75 % 106a Ar = Ph
62 % 106b Ar = pClC6H4
HCl.20 % HCl
reflux, 6 h
 
Scheme 5-30 Conversion of 100 to β-amino acids 106. 
 
In conclusion, it has been shown for the first time that the aza-Baylis-Hillman reaction 
can be catalysed enantioselectively by a chiral Lewis acidic metal complex. Using the 
La-linked-(R,R)-BINOL complex as catalyst and dpp-protected imines as substrates the 
corresponding aza-BH adducts could be obtained in up to 68 % yield and up to 90 % 
ee. Hydrolytic deprotection of the highly enantio-enriched aza-Baylis-Hillman products 
thus obtained grants access to α-methylene-β-aminoacids. 
 
5.4  Outlook 
In this work, it was shown for the first time that the aza-Baylis-Hillman reaction can be 
catalysed with chiral Lewis acidic complexes. Based on these studies, many different 
Lewis acidic metal complexes, which are known to activate protected imines, should be 
also tested in a future work. For example, the chiral heterobimetallic Cu/Sm/Schiff 
base/OAr complex 107, which has been successfully employed in the asymmetric nitro-
Mannich reaction for the activation of Boc-protected imines might also be used in the 
aza-BH reaction (Scheme 5-31).126 
Ar
NBoc
H
O
OR Ar OR
ONH
Boc
N N
O O
O O
Cu
Sm
OAr
+
107
R3N / R3P
107
*
 
Scheme 5-31 Proposed asymmetric aza-BH reaction with N-Boc-protected imines catalysed by the chiral 
heterobimetallic complex 107. 
 
To further optimise the results of the present work, two main goals should drive future 
researches: (a) simplifying the procedure and (b) improving the yields. 
 
(a) According to Shi, it is possible to synthesise the imine electrophile in situ in the aza-
BH reaction from the corresponding aldehyde and diphenylphosphine amide.88 This 
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in situ protocol should be applied to the system developed in the present thesis 
(Scheme 5-32).  
Ar H
O O
OR
DABCO
Ar OR
ONH
dpp
O
HO
HOOH
OH
+ +
La(OiPr)3-ligand 97
solvent, r.t., 35 h
*dpp-NH2
97  
Scheme 5-32 Proposed asymmetric in situ aza-BH reaction catalysed by the La-linked-(R,R)-BINOL 
complex. 
 
(b) According to previous studies, the low yields observed when employing DABCO as 
catalyst could be improved by replacement with a more reactive phosphine. 
However, in combination with the La-linked-(R,R)-BINOL complex, Ph2PMe led to 
lower enantioselectivities than DABCO. This low selectivity might be due to a fast 
background reaction (see Table 5-2, p. 123). 
 
An intramolecular combination of Ph2PMe and the La-linked-(R,R)-BINOL complex 
might solve this problem and might increase the yield while maintaining high 
enantioselectivities (Scheme 5-33). 
 
O
O
La
O
O Ph2P
 
Scheme 5-33 Complex derived from La(OiPr)3 and a linked-(R,R)-BINOL-diphenylphosphine deriva-
tive. 
 
A further improvement could be the substitution of the diphenylphosphino group by 
the dimethylphosphino group (Scheme 5-34). As shown by Shi, the chiral dimethyl-
phosphino-derived catalyst exhibits much higher reactivity in the aza-BH reaction 
than its corresponding diphenyl analogue.127 
 
O
O
La
O
O Me2P
 
Scheme 5-34 Complex derived from La(OiPr)3 and a linked-(R,R)-BINOL-dimethylphosphine deriva-
tive. 
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However, La-coordination by the phosphine might decrease its nucleophilicity. 
Therefore, designing a chiral ligand with the dimethylphosphine moiety in the 3-
position and a La-coordinating hydroxy group in the 2-position might lead to a highly 
reactive and highly selective bifunctional catalyst (Scheme 5-35). 
 
O
O
O
La
O
O
Me2P
H
2
3
 
Scheme 5-35 La –linked-(R,R)-BINOL complex with non La-coordinated dimethylphosphine group. 
 
 
5.5 Experimental Part 
5.5.1 General Experimental Conditions 
 
Preparative thin layer chromatography was performed with Merck F-254 TLC plates. 
Flash chromatography was performed on silica gel (Macherey-Nagel MN-Kieselgel 60, 
230-240 mesh). Analytical TLC was performed on aluminium backed silica plates 
(Macherey-Nagel, Polygram© SIL G/UV254), detection by using UV fluorescence. Melting 
points were determined on a Büchi melting point apparatus and are uncorrected. 1H-
NMR spectra were recorded at 500 MHz on a JEOL JNM-LA500 spectrometer and at 
300 MHz on Bruker AC 300 and DPX 300 instruments, respectively; 13C NMR spectra 
at 75.5 MHz on a Bruker DPX 300. Chemical shifts (δ) are given in parts per million 
(ppm) referenced to TMS. For the fine-structure interpretation the abbreviations of the 
signals are the following: s = singulet, d = doublet, t = triplet, q = quartet, m = multiplet. 
HPLC analyses were performed using an Agilent 1100 Series or on a JASCO HPLC 
system. High resolution mass spectra (HR ESI-MS) were recorded on a Finnigan MAT 
900 ST spectrometer. Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 
FT-IR spectrometer using ATR technique. All commercially available chemicals were 
used without further purification. Anhydrous solvents were distilled from appropriate 
drying agents prior to use.  
All experiments are characterised by a number within the bracket: [XX-SEE-XXX]. 
The roman number in front of the three-letter-code indicates the volume number of the 
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laboratory notebook, whereas the number after the three-letter-code indicates the 
experiment number in the corresponding notebook volume. 
 
 
5.5.2 Syntheses of the Substrates for the Aza-BH Reaction  
 
5.5.2.1 Synthesis of  P,P-Diphenylphosphinic amide (109)128 
 
[IV-SEE-300] 
 
PPh
Ph
O
Cl
 
 
PPh
Ph
O
NH2  
108 109 
   
108  
NH3 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
EtOH/CH2Cl2, -20 °C → r.t., 12 h 
109, 90 % 
 
A solution of diphenylphosphinic chloride 108 (20.0 g, 84.5 mmol, 1.00 eq) in dry 
CH2Cl2 (40 ml) was added dropwise with stirring to a saturated ethanolic ammonia 
solution (170 ml) and CH2Cl2 (70 ml) at -20 °C. The reaction mixture was stirred for 12 h 
at r.t.. The precipitated solid was filtered off and the solvents were removed under 
reduced pressure. The residue was dissolved in CHCl3 (240 ml) and washed with 5 % 
aqueous K2CO3 (3 x 50 ml) and distilled water (70 ml). The organic layer was 
separated, dried over MgSO4, and the solvent was removed under reduced pressure. 
The residue was recrystallised from toluene to yield 16.6 g (76.0 mmol, 90 %) of P,P-
diphenylphosphinic amide 109 as an off-white solid. 
 
C12H12NOP   (217.2 g/mol) 
 
m.p.  163-164 °C    [m.p. ref.128: 164-166 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.93-7.86 (m; 4H), 7.50-7.37 (m; 6H), 3.53 
(s; 2H). 
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 134.5, 132.7, 131.9, 131.8, 128.5, 128.4. 
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IR (ATR) ν~ [cm-1] = 3288, 3235, 3115, 1557, 1435, 1180, 1123, 909, 750. 
 
The spectroscopical data are in agreement with the literature.128 
 
 
5.5.2.2 Synthesis of P,P-Diphenyl-N-(phenylmethylene)phosphinic amide (98a)128 
 
[IV-SEE-299] 
 
H
O
 
 
PPh
Ph
O
NH2  
N
H
P
O
Ph
Ph
 
110a 109 98a 
   
110a + 109 
TiCl4, Et3N 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, 0 °C, 2 h 
98a, 69 % 
 
P,P-Diphenylphosphinic amide 109 (10.8 g, 50.0 mmol, 1.00 eq) was dissolved in 
CH2Cl2 (190 ml), then benzaldehyde 110a (5.09 ml, 5.31 g, 50.0 mmol, 1.00 eq) and 
Et3N (20.9 ml, 15.2 mg, 150 mmol, 3.00 eq)  were added. The reaction mixture was 
cooled to 0 °C and TiCl4 (3.01 ml, 5.21 g, 27.5 mmol, 55.0 mol%) was added dropwise. 
The mixture was stirred for 2 h at r.t. and the solvent was evaporated under reduced 
pressure. The residue was redissolved in toluene (100 ml), filtrated through a pad of 
celite and the solvent was removed under reduced pressure. The residue was redissol-
ved in EtOAc (70 ml), filtrated, and the solvent was evaporated under reduced pressure. 
The crude product was recrystallised from EtOAc to yield 10.5 g (34.5 mmol, 69 %) of 
P,P-diphenyl-N-(phenylmethylene)phosphinic amide 98a as light yellow crystals. 
 
C19H16NOP   (305.3 g/mol) 
 
m.p.  141-143 °C    [m.p. ref.128: 139-141 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 9.37 (d; J = 32.0 Hz, 1H), 8.06-7.95 (m; 6H), 
7.63-7.47 (m; 9H). 
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 173.8, 173.7, 136.1, 135.7, 133.9, 133.7, 
132.2, 131.8, 131.7, 131.5, 130.2, 128.9, 128.5, 128.4. 
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IR (ATR) ν~ [cm-1] = 1613, 1576, 1451, 1436, 1204, 1124, 1106, 912, 850, 828, 748, 
726. 
 
The spectroscopical data are in agreement with the literature.128 
 
 
5.5.2.3 Synthesis of P,P-Diphenyl-N-(4-chlorophenylmethylene)phosphinic amide 
(98b)128 
 
[IV-SEE-301] 
 
H
O
Cl  
 
PPh
Ph
O
NH2  
 
H
N
P
O
Ph
Ph
Cl  
110b 109 98b 
   
110b + 109 
TiCl4, Et3N 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, 0 °C, 2 h 
98b, 57 % 
 
P,P-Diphenylphosphinic amide 109 (3.70 g, 17.0 mmol, 1.00 eq) was dissolved in 
CH2Cl2 (65 ml), then 4-chlorobenzaldehyde 110b (2.00 ml, 2.38 g, 17.0 mmol, 1.00 eq) 
and Et3N (7.11 ml, 5.16 mg, 51.0 mmol, 3.00 eq)  were added. The reaction mixture 
was cooled to 0 °C and TiCl4 (1.02 ml, 1.77 g, 9.35 mmol, 55.0 mol%) was added 
dropwise. The mixture was stirred for 2 h at r.t. and the solvent was evaporated under 
reduced pressure. The residue was redissolved in toluene (30 ml), filtrated through a 
pad of celite and the solvent was removed under reduced pressure. The residue was 
redissolved in EtOAc (20 ml), filtrated, and the solvent was evaporated under reduced 
pressure. The crude product was recrystallised from EtOAc to yield 3.32 g (9.77 mmol, 
57 %) of P,P-diphenyl-N-(4-chlorophenylmethylene)phosphinic amide 98b as light 
yellow crystals. 
 
C19H15NOPCl   (339.8 g/mol) 
 
m.p.  128-130 °C    [m.p. ref.128:127-130 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 9.21 (d; J = 31.7 Hz, 1H), 7.88-7.82 (m; 6H), 
7.43-7.34 (m; 8H). 
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13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 172.3, 172.2, 134.1, 133.6, 131.9, 131.6, 
131.5, 131.3, 129.4, 128.4, 128.6, 128.5. 
 
IR (ATR) ν~ [cm-1] = 3055, 2225, 1701, 1614, 1591, 1566, 1487, 1436, 1405, 1198, 
1123, 1107, 1087, 1012, 849, 819, 751. 
 
The spectroscopical data are in agreement with the literature.128 
 
 
5.5.2.4 Synthesis of N-[Cyclohexyl[(4-methylphenyl)sulfonyl]methyl]-P,P-diphenylphos-
phinic amide (rac-112)129 
 
[IV-SEE-306] 
 
H
O
 
 
PPh
Ph
O
NH2  
 
S
Me
O
OH  
NH
S
P
O
Ph
Ph
Me
O O
 
110c 109 111 rac-112 
   
110c + 109 + 111 
 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
Et2O, r.t., 12 h 
rac-112, 85 % 
 
Under argon atmosphere, cyclohexane carbaldehyde 110c (1.11 g, 9.90 mmol, 1.50 eq) 
was added to a suspension of P,P-diphenylphosphinic amide 109 (1.43 g, 6.60 mmol, 
1.00 eq) and p-toluene sulfinic acid 111vii (1.76 g, 9.90 mmol, 1.50 eq) in dry Et2O. The 
mixture was stirred for 15 h at r.t.. The precipitate was filtered, washed with Et2O and 
dried in vacuo to yield 2.63 g (5.62 mmol, 85 %) of N-[cyclohexyl[(4-methylphenyl)sul-
fonyl]methyl]-P,P-diphenylphosphinic amide rac-112 as colourless solid.   
 
C26H30NO3PS   (467.6 g/mol) 
 
m.p.  112-114 °C    [m.p. ref.129: 113-115 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.80 (dd; J = 7.2 Hz, J = 12.1 Hz, 2H), 7.68 
                                            
vii p-Toluene sulfinic acid was prepared by dissolving its hydrated sodium salt in 10 % HCl (pH < 3) and 
crystallisation at 4 °C. Filtration and drying under vacuo led to the crude product, which was directly used 
for the synthesis of of N-[cyclohexyl[(4-methylphenyl)sulfonyl]methyl]-P,P-diphenylphosphinic amide 111. 
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(d; J = 8.1 Hz, 2H), 7.55-7.36 (m; 6H), 7.31-7.24 (m; 4H), 4.17 (t; J = 
11.9 Hz, 1H), 3.73-3.66 (m; 1H), 2.47 (s; 3H), 2.39-2.31 (m; 1H), 2.03 (s; 
1H), 1.77-1.73 (m; 2H), 1.66-1.53 (m; 2H), 1.43-1.12 (m; 5H). 
 
13C NMR  (75.5 MHz, CDCl3): δ  [ppm] = 144.8, 134.9, 132.4, 132.1, 131.9, 129.7, 
129.1, 128.7, 128.5, 128.4, 128.3, 76.6, 37.8, 30.7, 26.9, 26.4, 25.8, 21.7. 
 
IR (ATR) ν~ [cm-1] = 3177, 3055, 2926, 2849, 1700, 1592, 1437, 1299, 1184, 1124, 
1081, 1033, 1007, 905, 813, 750, 724. 
 
The spectroscopical data are in agreement with the literature.129  
 
 
5.5.2.5 Synthesis of N-(Cyclohexylmethylene)-P,P-diphenylphosphinic amide (98c)130 
 
[IV-SEE-303] 
NH
S
P
O
Ph
Ph
Me
O O
 
 
H
N
P
O
Ph
Ph
 
rac-112 98c 
   
rac-112  
NaHCO3 
⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 5 h 
98c, 86 % 
 
Saturated aqueous NaHCO3 (43 ml) was added to a mixture of N-[cyclohexyl[(4-
methylphenyl)sulfonyl]methyl]-P,P-diphenylphosphinic amide rac-112 in CH2Cl2 (43 ml). 
The mixture was stirred for 5 h at r.t.. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 30 ml). The combined organic layers 
were dried over Na2SO4. The solvent was removed under reduced pressure and the 
residue was dried in vacuo to obtain 570 mg (1.83 mmol, 86 %) of N-(cyclohexyl-
methylene)-P,P-diphenylphosphinic amide 98c as colourless oil. The crude product was 
used in the aza-BH reaction without further purification. 
 
C19H22NOP   (311.4 g/mol) 
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1H NMR  (300 MHz, CDCl3): δ [ppm] = 8.81 (dd, J = 3.7 Hz, J = 33.3 Hz, 1H), 7.91-
7.85 (m; 4H), 7.51-7.41 (m; 6H), 2.48-2.42 (m; 1H), 1.98-1.95 (m; 2H), 
1.80-1.68 (m; 3H), 1.42-1.22 (m; 5H). 
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 185.6, 185.5, 131.6, 131.5, 131.4, 128.5, 
128.3, 46.6, 46.3, 28.6, 25.9, 25.3. 
 
The spectroscopical data are in agreement with the literature.130  
 
 
5.5.3 Syntheses of Racemic Reference Substances131 
 
5.5.3.1 Synthesis of Methyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanoate (rac-100aa) 
 
[IV-SEE-336] 
 
H
N
P
O
Ph
Ph
 
 
OMe
O
 
NHP
O
Ph
Ph
OMe
O
 
98a 99a rac-100aa 
   
98a + 99a  
Ph2PMe 
⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 72 h 
rac-100aa, 35 % 
 
Under argon atmosphere, methyl acrylate 99a (70.8 µl, 67.6 mg, 786 µmol, 1.20 eq) 
was added to a mixture of imine 98a (200 mg, 655 µmol, 1.00 eq) and diphenylmethyl-
phosphine (24.3 µl, 26.2 mg, 131 µmol, 20.0 mol%) in dry THF (1 ml). The suspension 
was stirred for 72 h at r.t.. The solvent and excess acrylate were removed under 
reduced pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) 
to obtain 90.0 mg (229 µmol, 35 %) of methyl (βS)-β-[(diphenylphosphinoyl)amino]-α-
methylenebenzenepropanoate rac-100aa as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.2 Synthesis of Phenyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanoate (rac-100ab) 
 
[IV-SEE-332] 
 
H
N
P
O
Ph
Ph
 
 
OPh
O
 
NHP
O
Ph
Ph
OPh
O
 
98a 99b rac-100ab 
   
98a + 99b 
Ph3P 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
THF, r.t., 72 h 
rac-100ab, 50 % 
 
Under argon atmosphere, phenyl acrylate 99b (544 µl, 582 mg, 3.93 mmol, 1.20 eq) 
was added to a mixture of imine 98a (1.00 g, 3.26 mmol, 1.00 eq) and triphenylphos-
phine (206 mg, 786 µmol, 20.0 mol%) in dry THF (3 ml). The suspension was stirred for 
72 h at r.t.. The solvent and excess acrylate were removed under reduced pressure. 
The residue was purified by column chromatography (c-hexane/EtOAc 3:1) to obtain 
740 mg (1.63 mmol, 50 %) of phenyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanoate rac-100ab as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.3 Synthesis of 1,1-Dimethylethyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methyle-
nebenzenepropanoate (rac-100ac) 
 
[IV-SEE-311] 
 
H
N
P
O
Ph
Ph
 
 
OtBu
O
 
NHP
O
Ph
Ph
OtBu
O
 
98a 99c rac-100ac 
   
98a + 99c 
Ph2PMe 
⎯⎯⎯⎯⎯⎯⎯→ 
THF, 72 h, r.t. 
rac-100ac, 30 % 
 
Under argon atmosphere, tert-butyl acrylate 99c (580 µl, 512 mg, 4.00 mmol, 4.00 eq) 
was added to a mixture of imine 98a (305 mg, 1.00 mmol, 1.00 eq) and diphenylmethyl-
phosphine (37.0 µl, 40.0 mg, 200 µmol, 20.0 mol%) in dry THF (1 ml). The suspension 
was stirred for 72 h at r.t.. The solvent and excess acrylate were removed under 
reduced pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) 
to obtain 130 mg (300 µmol, 30 %) of 1,1-dimethylethyl (βS)-β-[(diphenylphosphinoyl)-
amino]-α-methylenebenzenepropanoate rac-100ac as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.4 Synthesis of  (βS)-β-[(Diphenylphosphinoyl)amino]-α-methylenebenzenepropa-
nenitrile (rac-100af) 
 
[IV-SEE-323] 
 
H
N
P
O
Ph
Ph
 
 CN
 
NHP
O
Ph
Ph
CN
 
98a 99f rac-100af 
   
98a + 99f  
DABCO 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeCN, r.t., 72 h 
rac-100af, 64 % 
 
Under argon atmosphere, acrylonitrile 99af (99.5 µl, 79.6 mg, 1.50 mmol, 1.50 eq) was 
added to a mixture of imine 98a (305 mg, 1.00 mmol, 1.00 eq) and 1,4-diazabicyclo-
[2.2.2]octane (16.8 mg, 150 µmol, 15.0 mol%) in dry MeCN (1 ml). The suspension was 
stirred for 72 h at r.t.. The solvent and excess acrylate were removed under reduced 
pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) to obtain 
230 mg (642 µmol, 64 %) of (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanenitrile rac-100af as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.5 Synthesis of Methyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanoate (rac-100ba) 
 
[IV-SEE-314] 
 
H
N
P
O
Ph
Ph
Cl  
 
OMe
O
 
NHP
O
Ph
Ph
OMe
O
Cl  
98b 99a rac-100ba 
   
98b + 99a 
Ph2PMe 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 72 h 
rac-100ba, 47 % 
 
Under argon atmosphere, methyl acrylate 99a (360 µl, 344 mg, 4.00 mmol, 4.00 eq) 
was added to a mixture of imine 98b (339 mg, 1.00 mmol, 1.00 eq) and diphenylmethyl-
phosphine (37.0 µl, 40.0 mg, 200 µmol, 20.0 mol%) in dry CH2Cl2 (1 ml). The suspen-
sion was stirred for 72 h at r.t.. The solvent and excess acrylate were removed under 
reduced pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) 
to obtain 200 mg (470 µmol, 47 %) of methyl (βS)-4-chloro-β-[(diphenylphosphinoyl)-
amino]-α-methylenebenzenepropanoate rac-100ba as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.6 Synthesis of Phenyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanoate (rac-100bb) 
 
[IV-SEE-328] 
 
H
N
P
O
Ph
Ph
Cl  
 
OPh
O
 
NHP
O
Ph
Ph
OPh
O
Cl  
98b 99b rac-100bb 
   
98b + 99b 
Ph3P 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeCN, r.t., 72 h 
rac-100bb, 51 % 
 
Under argon atmosphere, phenyl acrylate 99b (345 µl, 370 mg, 2.50 mmol, 2.50 eq) 
was added to a mixture of imine 98b (339 mg, 1.00 mmol, 1.00 eq) and triphenylphos-
phine (39.3 mg, 150 µmol, 15.0 mol%) in dry THF (1 ml). The suspension was stirred for 
72 h at r.t.. The solvent and excess acrylate were removed under reduced pressure. 
The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) to obtain 241 mg 
(510 µmol, 51 %) of phenyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanoate rac-100bb as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.7 Synthesis of 1,1-Dimethylethyl  (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-
methylenebenzenepropanoate (rac-100bc) 
 
[IV-SEE-316] 
 
H
N
P
O
Ph
Ph
Cl  
 
OtBu
O
 
NHP
O
Ph
Ph
OtBu
O
Cl  
98b 99c rac-100bc 
   
98b + 99c   
Ph2PMe 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
CH2Cl2, r.t., 72 h 
rac-100bc, 34 % 
 
Under argon atmosphere, tert-butyl acrylate 99c (580 µl, 512 mg, 4.00 mmol, 4.00 eq) 
was added to a mixture of imine 98b (339 mg, 1.00 mmol, 1.00 eq) and diphenylmehtyl-
phosphine (37.0 µl, 40.0 mg, 200 µmol, 20.0 mol%) in dry CH2Cl2 (1 ml). The suspen-
sion was stirred for 72 h at r.t.. The solvent and excess acrylate were removed under 
reduced pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) 
to obtain 160 mg (342 µmol, 34 %) of 1,1-dimethylethyl  (βS)-4-chloro-β-[(diphenylphos-
phinoyl)amino]-α-methylenebenzenepropanoate rac-100bc as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.3.8 Synthesis of (βS)-4-Chloro-β-[(diphenylphosphinoyl)amino]-α-methylenebenze-
nepropanenitrile (100bf) 
 
[IV-SEE-317] 
 
H
N
P
O
Ph
Ph
Cl  
 CN
 
NHP
O
Ph
Ph
Cl
CN
 
98b 99f rac-100bf 
   
98b + 99f  
DABCO 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
MeCN, r.t., 72 h 
rac-100bf, 51 % 
 
Under argon atmosphere, acrylonitrile 99f (99.5 µl, 79.6 mg, 1.50 mmol, 1.50 eq) was 
added to a mixture of imine 98b (339 mg, 1.00 mmol, 1.00 eq) and 1,4-diazabicyclo-
[2.2.2]octane (22.4 mg, 200 µmol, 20.0 mol%) in dry MeCN (1 ml). The suspension was 
stirred for 72 h at r.t.. The solvent and excess acrylate were removed under reduced 
pressure. The residue was purified by preparative-TLC (c-hexane/EtOAc 3:1) to obtain 
200 mg (509 µmol, 51 %) of (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanenitrile rac-100bf as colourless solid. 
 
The spectroscopical data are in agreement with the data in chapter 5.5.4, p.144 et sqq.. 
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5.5.4 General Procedure for the (R,R)-La-Linked BINOL Catalysed Aza-Baylis-
Hillman Reaction of N-Diphenylphosphinoyl-Protected Imines with Olefins 
 
 
Ar H
N
P
O
Ph
Ph
 
 R
 Ar
NHP
O
Ph
Ph
R
 
98 99 100 
   
98 + 99  
DABCO 
BINOL-based ligand / M(OiPr)x  
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯→ 
solvent, r.t., 35 h 
100 
 
A 0.2 M solution of La(OiPr)3 in THF (150 µl, 30.0 µmol, 10.0 mol%) was added to 
linked-(R,R)-BINOL 97 (18.4 mg, 30.0 µmol, 10.0 mol%) at 0 °C. After stirring for 15 min 
at 0 °C and 2 h at r.t., the iPrOH and THF were removed under reduced pressure. 
DABCO (6.73 mg, 60.0 µmol, 20.0 mol%) and the imine 98 (300 µmol, 1.0 eq) were 
added. The solids were dissolved in THF (300 µl), and the olefin component 99 
(600 µmol, 2.00 eq) was added. After 35 h, the solvent and excess acrylate were 
removed under reduced pressure and the crude mixture was purified by preparative thin 
layer chromatography. The enantiomeric excess was determined by HPLC analysis 
using a chiral column.  
 
5.5.4.1 Methyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzenepropanoate 
(100aa)  
 
Compound 100aa was obtained as a colourless solid from 98a and 99a in 34 % yield. 
The enantiomeric purity was determined to be 89 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 1.0 ml/min; τR = 38.7 min (S), 42.8 min (R)). 
 
C23H22NO3P  (391.2 g/mol) 
 
m.p.   159-160 °C    [m.p. ref.131: 157-160°C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.84-7.76 (m; 4H), 7.41-7.13 (m; 11H), 6.26 
(s; 1H), 5.80 (s; 1H), 5.02 (t; J = 10.9 Hz, 1H), 4.24 (dd; J = 10.9 Hz, J = 
8.6 Hz, 1H), 3.53 (s; 3H). 
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13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 166.2, 141.2, 141.1, 133.0, 132.2, 132.1, 
132.0, 128.7, 128.6, 128.5, 128.4, 127.3, 127.1, 126.5, 57.1, 51.9.  
 
IR (ATR)  ν~  [cm-1] = 3174, 1717, 1436, 1273, 1190, 1151, 1122, 1108, 1068, 907, 
696.  
 
HR ESI-MS  calcd for C23H22NO3P [M+Na]+: 414.1235, found: 414.124. 
 
The spectroscopical data are in agreement with the literature.131 
 
 
5.5.4.2 Phenyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzenepropanoate 
(100ab) 
 
Compound 100ab was obtained as a colourless solid from 98a and 99b in 59 % yield. 
The enantiomeric purity was determined to be 71 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 1.0 ml/min; τR = 35.5 min (S), 45.5 min (R)). 
 
C28H24NO3P (453.5 g/mol) 
 
m.p. 157-159 °C    [m.p. ref.131: 156-157 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.85-7.77 (m; 4H), 7.41-7.17 (m; 13H), 7.09-
7.04 (m; 1H), 6.80-6.77 (m; 2H), 6.50 (s; 1H), 6.03 (s; 1H), 5.14 (t; J = 
10.9 Hz, 1H), 4.18 (dd; J = 10.9 Hz, J = 8.6 Hz, 1H). 
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 164.4, 150.3, 141.1, 141.0, 141.0, 140.9, 
132.8, 132.4, 132.3, 132.1, 132.1, 132.0, 129.4, 128.7, 128.6, 128.5, 
127.5, 126.6, 126.0, 121.5, 57.1. 
 
IR (ATR)  ν~  [cm-1] = 3061, 2916, 2220, 1730, 1590, 1437, 1250, 1187, 1121, 1063, 
906, 847, 688.  
 
HR ESI-MS  calcd for C28H24NO3P [M+Na]+: 476.1392, found: 476.139. 
 
The spectroscopical data are in agreement with the literature.131 
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5.5.4.3 1,1-Dimethylethyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanoate (100ac) 
 
Compound 100ac was obtained as a colourless solid from 98a and 99c in 31 % yield. 
The enantiomeric purity was determined to be 70 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 0.12 ml/min; τR = 138.1 min (S), 144.6 min (R)). 
 
C26H28NO3P  (433.5 g/mol) 
 
 m.p.  121-123 °C   
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.93-7.87 (m; 4H), 7.50-7.38 (m; 8H), 7.34-
7.29 (m; 3H), 6.27 (s; 1H), 5.79 (s; 1H), 5.08 (t; J = 10.9 Hz, 1H), 4.18 (dd; 
J = 10.9 Hz, J = 8.7 Hz, 1H), 1.28 (s; 9H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 165.1, 142.7, 141.7, 133.3, 132.3, 132.2, 
132.1, 132.1, 131.9, 128.6, 128.5, 128.4, 128.3, 127.1, 126.5, 125.9, 81.5, 
57.1, 27.8. 
 
IR (ATR)  ν~  [cm-1] = 3175, 2974, 1708, 1437, 1366, 1275, 1187, 1147, 1122, 1066, 
748, 695.  
 
 HR ESI-MS  calcd for C26H28NO3P [M+Na]+: 456.1705, found: 456.170. 
 
 
5.5.4.4 2-Naphthalenyl (βS)-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanoate (100ad) 
 
Compound 100ad was obtained as a colourless solid from 98a and 99d in 67 % yield. 
The enantiomeric purity was determined to be 63 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 1.0 ml/min; τR = 56.6 min (S), 65.0 min (R)). 
 
C32H26NO3P   (503.5 g/mol) 
 
 m.p.  171-172 °C    
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.99-7.91 (m; 4H), 7.83-7.73 (m; 3H), 7.54-
7.28 (m; 14H), 7.04 (dd; J = 8.9 Hz, J = 2.2 Hz, 1H), 6.68 (s; 1H), 6.18 (s; 
1H), 5.38 (t; J = 10.7 Hz, 1H), 4.29 (dd; J = 10.7 Hz, J = 8.6 Hz, 1H).  
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13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 164.5, 147.9, 141.1, 141.0, 133.6, 133.5, 
132.9, 132.4, 132.3, 132.1, 132.1, 132.0, 131.8, 131.5, 131.2, 129.3, 
128.7, 128.6, 128.6, 128.5, 128.5, 127.7, 127.6, 127.5, 126.6, 126.5, 
125.8, 120.9, 118.5, 57.1. 
 
IR (ATR)  ν~  [cm-1] = 3165, 3065, 1730, 1628, 1599, 1510, 1436, 1238, 1188, 1154, 
1122, 1060, 960, 906, 808, 724, 696. 
 
 HR ESI-MS  calcd for C32H26NO3P [M+Na]+: 526.1548, found: 526.155. 
 
 
5.5.4.5 2,2,2-Trifluoro-1-(trifluoromethyl)ethyl (βS)-β-[(diphenylphosphinoyl)amino]-α-
methylenebenzenepropanoate (100ae)  
 
Compound 100ae was obtained as a colourless solid from 98a and 99e in 41 % yield. 
For the determination of the enantiomeric purity, the 1,1,1,3,3,3-hexafluoroisopropyl 
acrylate was transformed to the corresponding methyl acrylate. To this end, Et3N 
(500 µl, 360 µmol) was added to a stirred solution of the 2,2,2-Trifluoro-1-(trifluoro-
methyl)ethyl (βS)-β-[(diphenylphosphinyl)amino]-α-methylenebenzenepropanate 100ae 
(50 µmol) in MeOH (500 µl) at r.t.. After stirring for 1 h, the mixture was acidified with 
DOWEX 50WX4-200, additionally stirred for 15 min, filtered, and evaporated. The 
enantiomeric purity was determined to be 80 % ee by HPLC (Chiralpak AD-H, 90:10 
iPrOH/n-hexane, 1.0 ml/min; τR = 38.7 min (S), 42.8 min (R)).  
 
C25H20F6NO3P   (527.4 g/mol) 
 
m.p.  190-192 °C    [m.p. ref.104:192-193 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.83-7.74 (m; 4H), 7.47-7.35 (m; 6H), 7.25-
7.19 (m; 5H), 6.49 (s; 1H), 6.13 (s; 1H), 5.57 (hept; J = 6.0 Hz, 1H), 5.11 
(t; J = 10.5 Hz, 1H), 3.77 (dd; J = 10.5 Hz, J = 8.8 Hz, 1H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 162.3, 140.2, 140.0, 139.0, 138.9, 132.9, 
132.5, 132.3, 132.0, 130.7, 128.8, 128.7, 128.6, 128.5, 128.4, 127.9, 
126.4, 121.1 (q; J = 283.4 Hz), 66.6 (hept; J = 35.0 Hz), 56.4, 30.8.  
 
IR (ATR)  ν~  [cm-1] = 3168, 1748, 1436, 1384, 1355, 1287, 1230, 1194, 1107, 904, 
724. 
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HR ESI-MS  calcd for C25H20F6NO3P [M+Na]+: 550.0983, found: 550.098. 
 
The spectroscopical data are in agreement with the literature.104 
 
 
5.5.4.6  (βS)-β-[(Diphenylphosphinoyl)amino]-α-methylenebenzenepropanenitrile 
 (100af)  
 
Compound 100af was obtained as a colourless solid from 98a and 99f in 48 % yield. 
The material was determined to be racemic by HPLC (Chiralpak AD-H, 90:10 iPrOH/n-
hexane, 1.0 ml/min; τR = 39.4 min (S), 47.5 min (R)). 
 
C22H19N2OP   (358.4 g/mol) 
 
m.p.  179-180 °C    [m.p. ref.131: 176-178 °C] 
 
1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.87-7.77 (m; 4H), 7.49-7.33 (m; 6H), 7.30-
7.25 (m; 5H), 5.90 (d; J = 6.8 Hz, 2H), 4.92, (t; J = 9.8 Hz, 1H) 3.52 (dd; 
J = 9.8 Hz, J = 7.5 Hz, 1H)   
 
13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 138.9, 138.8, 132.3, 132.2, 132.1, 131.2, 
129.2, 128.8, 128.7, 128.6, 128.6, 128.5, 126.8, 117.2, 57.5. 
 
 IR (ATR)  ν~  [cm-1] = 3053, 2867, 2221, 1437, 1185, 1123, 1106, 928, 696. 
 
HR ESI-MS  calcd for C22H19N2OP [M+Na]+: 381.1133, found: 381.113. 
 
The spectroscopical data are in agreement with the literature.131 
 
 
5.5.4.7 Methyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylenebenzenepro-
panoate (100ba).  
 
Compound 100ba was obtained as a colourless solid from 98b and 99a in 39 % yield. 
The enantiomeric purity was determined to be 80 % by HPLC (Chiralpak AD-H, 90:10 
iPrOH/n-hexane, 1.0 ml/min; τR = 35.6 min (S), 42.4 min (R)). 
 
C23H21ClNO3P   (425.8 g/mol) 
 
 m.p.  173-174 °C    [m.p. ref.131: 173-175 °C] 
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 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.83-7.74 (m; 4H), 7.43-7.33 (m; 6H), 7.28-
7.18 (m; 4H), 6.25 (s; 1H), 5.78 (s; 1H), 4.97 (t; J = 10.9 Hz, 1H), 4.26 (dd; 
J = 10.9 Hz, J = 8.6 Hz, 1H), 3.56 (s; 3H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 166.1, 140.6, 140.6, 139.8, 139.7, 133.2, 
132.3, 132.2, 132.1, 132.1, 128.7, 128.6, 128.6, 128.4, 127.9, 127.4, 56.8, 
52.0. 
 
 IR (ATR)  ν~  [cm-1] = 3171, 3054, 2954, 1719, 1489, 1436, 1268, 1187, 1122, 1073, 
1014, 751, 696. 
 
 HR ESI-MS  calcd for C23H21ClNO3P [M+Na]+: 448.0846, found: 448.085. 
 
The spectroscopical data are in agreement with the literature.131 
 
 
5.5.4.8 Phenyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylenebenzene-
propanoate (100bb).  
 
Compound 100bb was obtained as a colourless solid from 98b and 99b in 56 % yield. 
The enantiomeric purity was determined to be 69 % by HPLC (Chiralpak AD-H, 90:10 
iPrOH/n-hexane, 1.0 ml/min; τR = 36.3 min (S), 44.9 min (R)). 
 
C28H23ClNO3P   (487.9 g/mol) 
 
m.p.  178-179 °C    [m.p. ref.131: 180-182 °C] 
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.83-7.74 (m; 4H), 7.43-7.17 (m; 12H), 7.12-
7.07 (m; 1H), 6.83 (d; J = 7.6 Hz, 2H), 6.50 (s; 1H), 6.00 (s; 1H), 5.09 (t; 
J = 11.0 Hz, 1H), 4.24 (dd; J = 11.0 Hz, J = 8.7 Hz, 1H). 
 
 13C NMR  (75 MHz, CDCl3): δ [ppm] = 164.2, 150.2, 140.5, 140.5, 139.7, 139.6, 
133.4, 133.2, 132.8, 132.3, 132.2, 132.0, 131.5, 131.1, 129.4, 128.7, 
128.6, 128.6, 128.5, 128.1, 126.1, 121.4, 56.7. 
 
 IR (ATR)  ν~  [cm-1] = 3161, 1731, 1592, 1484, 1435, 1248, 1186, 1159, 1122, 1066, 
1012, 905, 809, 722, 684, 641. 
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 HR ESI-MS  calcd for C28H23ClNO3P [M+Na]+: 510.1002, found: 510.100. 
 
The spectroscopical data are in agreement with the literature.131 
 
 
5.5.4.9 1,1-Dimethylethyl  (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methylene-
benzenepropanoate (100bc).  
 
Compound 100bc was obtained as a colourless solid from 98b and 99c in 27 % yield. 
The enantiomeric purity was determined to be 83 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 0.12 ml/min; τR = 151.3 min (S), 172.8 min (R)). 
 
C26H27ClNO3P   (467.9 g/mol) 
 
 m.p.  136-138 °C   
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.83-7.75 (m; 4H), 7.42-7.33 (m; 6H), 7.27-
7.17 (m; 4H), 6.17 (s; 1H), 5.66 (s; 1H), 4.94 (t; J = 11.0 Hz, 1H), 4.16 (dd; 
J = 11.0 Hz, J = 8.7 Hz, 1H), 1.23 (s; 9H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 164.9, 142.2, 142.1, 140.3, 140.3, 133.2, 
132.9, 132.3, 132.2, 132.0, 128.7, 128.6, 128.5, 128.4, 128.0, 126.4, 81.8, 
56.7, 27.9. 
 
 IR (ATR)  ν~  [cm-1] = 3172, 2975, 1707, 1489, 1436, 1366, 1274, 1186, 1122, 1085, 
1014, 848, 751, 695. 
 
HR ESI-MS  calcd for C26H27ClNO3P [M+Na]+: 490.1315, found: 490.132. 
 
The spectroscopical data are in agreement with the literature.131 
 
 
5.5.4.10 2-Naphthalenyl (βS)-4-chloro-β-[(diphenylphosphinoyl)amino]-α-methyleneben-
zenepropanoate (100bd) 
 
Compound 100bd was obtained as a colourless solid from 98b and 99d in 59 % yield. 
The enantiomeric purity was determined to be 79 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 1.0 ml/min; τR = 58.9 min (S),73.4 min (R)). 
 
C32H25ClNO3P   (537.9 g/mol) 
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 m.p.  190-191 °C    
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.97-7.75 (m; 7H), 7.55-7.33 (m; 13H), 7.09-
7.05 (m; 1H), 6.67 (s; 1H), 6.15 (s; 1H), 5.24 (t; J = 10.8 Hz, 1H), 4.32 (dd; 
J = 10.8 Hz, J = 8.6 Hz, 1H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 164.4, 147.8, 140.6, 140.6, 139.7, 139.6, 
133.6, 132.3, 132.2, 132.0, 131.5, 129.4, 128.9, 128.8, 128.7, 128.6, 
128.5, 128.1, 127.8, 127.7, 126.7, 125.9, 120.8, 118.5, 56.8. 
 
IR (ATR)  ν~  [cm-1] = 3163, 3051, 2914, 1730, 1489, 1437, 1238, 1186, 1155, 1123, 
1065, 907, 725, 697. 
 
 HR ESI-MS  calcd for C32H25ClNO3P [M+Na]+: 560.1159, found: 560.115. 
 
 
5.5.4.11 (βS)-4-Chloro-β-[(diphenylphosphinoyl)amino]-α-methylenebenzenepropane-
nitrile (100bf)  
 
Compound 100bf was obtained as a colourless solid from 98b and 99f in 52 % yield. 
The enantiomeric purity was determined to be 11 % ee by HPLC (Chiralpak AD-H, 
90:10 iPrOH/n-hexane, 1.0 ml/min; τR = 46.8 min (S), 51.3 min (R)). 
 
C22H18ClN2OP   (392.8 g/mol) 
 
 m.p.  142-144 °C    [m.p. ref.131:142-143 °C] 
 
 1H NMR  (300 MHz, CDCl3): δ [ppm] = 7.94-7.84 (m; 4H), 7.58-7.44 (m; 6H), 7.37-
7.30 (m; 4H), 5.98 (d; J = 17.8 Hz, 2H), 4.98 (t; J = 10.2 Hz, 1H), 3.66 (dd; 
J = 10.2 Hz, J = 7.4 Hz, 1H). 
 
 13C NMR  (75.5 MHz, CDCl3): δ [ppm] = 137.4, 137.4, 134.6, 132.5, 132.3, 132.2, 
132.1, 131.9, 131.5, 130.7, 130.5, 129.3, 128.9, 128.8, 128.7, 128.6, 
128.3, 125.4, 125.1, 116.9. 
 
 IR (ATR)  ν~  [cm-1] = 3144, 2866, 2218, 1490, 1436, 1183, 1106, 1090, 751, 725. 
 
 HR ESI-MS  calcd for C22H18ClN2OP [M+Na]+: 415.0743, found: 415.074. 
 
The spectroscopical data are in agreement with the literature.131 
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5.5.5 Hydrolytic C,N Terminal Deprotection104 
 
5.5.5.1 Synthesis of  (βS)-β-Amino-α-methylenebenzenepropionic acid hydrochloride 
(106a) 
 
[IV-SEE-334] 
NHP
O
Ph
Ph
OPh
O
 
NH2
OH
OHCl.
 
100ab 106a 
   
100ab  
20 % HCl 
⎯⎯⎯⎯⎯⎯→ 
reflux, 6 h 
106a, 75 % 
 
A mixture of 100ab (300 mg, 661 µmol, 1.00 eq) in 20 % HCl (7 ml) was refluxed for 
6 h. The reaction mixture as washed with Et2O (3 x 4 ml) and EtOAc (2 x 4 ml) and the 
solvent was evaporated. The residue was dried under vacuo to give amino acid 
hydrochloride 106a (105 mg, 496 µmol, 75 %) as a colourless solid.  
 
C10H12ClNO2   (213.6 g/mol) 
 
m.p.   217-219 °C (decomposition)   
 
 1H NMR  (300 MHz, D2O): δ [ppm] = 7.43-7.34 (m; 5H), 6.59 (s; 1H), 5.97 (s; 1H), 
5.36 (s; 1H). 
The OH- as well as the NH3+- protons could not be detected. 
 
13C NMR  (75.5 MHz, D2O): δ [ppm] = 167.9, 136.1, 134.1, 129.9, 129.5, 129.3, 
127.3. 
 
 IR (ATR)  ν~  [cm-1] = 3385, 2870, 2600, 1962, 1697, 1626, 1577, 1493, 1435, 1395, 
1252, 1164, 1116, 1004, 970, 919, 827, 759. 
 
HR ESI-MS calcd for C10H12ClNO2 [M-Cl]+: 178.087 , found: 178.0868 
 
The spectroscopical data are in agreement with the literature.104 
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5.5.5.2 (βS)-4-Chloro-β-amino-α-methylenebenzenepropionic acid hydrochloride 
(106b)  
 
[IV-SEE-335] 
NHP
O
Ph
Ph
OMe
O
Cl  
NH2
OH
O
Cl
HCl.
 
100ba 106b 
   
100ba 
20 % HCl 
⎯⎯⎯⎯⎯⎯⎯⎯→ 
reflux, 6 h 
106b, 62 % 
 
A mixture of 100ba (200 mg, 470 µmol, 1.00 eq) in 20 % HCl (5 ml) was refluxed for 
6 h. The reaction mixture as washed with Et2O (3 x 3 ml) and EtOAc (2 x 3 ml) and the 
solvent was evaporated. The residue was dried under vacuo to give amino acid hydro-
chloride 106b (72.0 mg, 291 µmol, 62 %) as a colourless solid. 
 
C10H11Cl2NO2     (248.1 g/mol) 
 
m.p.  209-211 °C (decomposition) 
 
 1H NMR  (300 MHz, D2O ) δ [ppm] = 7.60-7.52 (m; 4H), 6.80 (s; 1H), 6.17 (s; 1H), 
5.56 (s; 1H). 
The OH- as well as the NH3+- protons could not be detected. 
 
 13C NMR  (75.5 MHz, D2O) δ [ppm] = 167.8, 135.9, 134.8, 132.8, 130.1, 129.3, 
129.0, 54.3. 
 
 IR (ATR)  ν~  [cm-1] = 3387, 2886, 1962, 1700, 1629, 1595, 1494, 1412, 1198, 1157, 
1092, 1014, 973, 834, 722. 
 
The spectroscopical data are in agreement with the literature.131
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6 Appendix 
6.1 Abbrevations 
For SI units the generally accepted abbreviations were used. 
abs. absolute (distilled and dried) 
Ac Acetyl  
ANF Atrial natriuretic factor 
aq. Aqueous 
Ar Aryl 
ATR Attenuated total reflection 
BH Baylis Hillman 
BINAP 2,2’-Bis(diphenylphosphino)-1,1’-binaphthyl 
BINOL 1,1'-Binaphthalene-2,2'-diol 
Boc tert-butyloxycarbonyl 
BOP (Benzotriazol-1-yloxy)-tris(dimethylamino)-phosphonium 
Bu Butyl 
Cbz Carboxybenzyl 
d Day(s) 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DACH 1,2-Diaminocyclohexane 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-en 
DCE Dichloroethane 
DCM Dichloromethane 
DIANANE 2,5-Diamino-bicyclo[2.2.1]heptane 
DMEM Dulbecco’s-modified eagle’s medium 
DMF N,N-Dimethyl formamide 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DOS Diversity orientated sceening 
dpp Diphenylphosphinoyl 
EB Embryoid bodies 
ECG Electrocardiogram 
ee Enantiomeric excess 
EGFP Enhanced green fluorescence protein 
ent- Enantiomer 
eq(uiv) Equivalent(s) 
(m)ES (murine) Embryonic stem 
Et Ethyl 
et sqq. And the following (et sequentia) 
EWG Electron withdrawing group 
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FCS Fetal calf serum 
FDA Food and Drug Administration 
FT Fourier transformation 
GC Gas chromatography 
GC-MS Gas chromatography connected with mass spectra 
h Hour(s) 
HPLC High performance liquid chromatography 
3-HQD 3-Hydroxyquinuclidine 
HR ESI-MS High resolution electrospray ionisation mass spectra  
Hz Hertz 
IMDM Iscove’s modified dulbecco’s medium 
IPDA 3-Aminomethyl-3,5,5-trimethylcyclohexylamine 
iPr iso-Propyl 
IR Infrared Spectroscopy 
J Spin Coupling 
LLB La-Li-BINOL 
LIF Leukaemia inhibitor factor 
m Meta 
α-MHC α-Myosine heavy chain 
m.p. Melting point 
m/z Mass-to-charge ratio 
Me Methyl 
min Minute 
MOP 2'-(Methoxy-[1,1']-binaphthalin-2-yl)-diphenyl-phosphin 
MS Molecular sieves 
MtOA Methyltrioctylammonium 
MVK Methyl vinyl ketone 
n.d. Not detected 
NMR Nuclear magnetic resonance 
Ns Nosyl 
Nu Nucleophile 
o Ortho 
p Para 
pα-MHC α-Myosine heavy chain promoter 
PCC Pyridinium chlorochromate 
PCR Polymerase chain reaction 
PEG Polyethyleneglycol 
PG Protecting group 
Ph Phenyl 
PMP p-Methoxyphenyl 
PTA  1,3,5-Triaza-phosphaadamantane 
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p-TLC Preparative thin layer chromatography 
quant. quantitative 
r.t.  Room temperature 
rac Racemic 
RDD Rational drug design 
RDS Rate determing step 
ref. Reference 
Rf Retention factor 
ROS Reactive oxygen species 
RyR Ryanidine receptor 
SBDD Structur based drug design 
SES 2-Trimethylsilylethanesulfonyl 
SR Sarcoplasmic reticulum 
tBu tert-Butyl 
Tf Triflate 
THF Tetrahydrofuran 
Tol Toluene 
Ts Tosyl 
TSA Toluene sulfonic acid 
® Trade mark 
τR Retention time 
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6.3  Abstract - Kurzzusammenfassung 
Abstract 
In this work, new substances for the chemical induction of cardiomyogenesis from embryonic stem (ES) 
cells have been developed and contributions to asymmetric C-C couplings were made. 
A transgenic murine ES cell lines was used to investigate the effects of (thio)urea and cinchona-
alkaloid derivatives on cardiomyogenesis. Various compound screenings yielded substances which led to 
a 50 % to 80 % increased cardiomyogenesis compared to untreated cells. In the test system investigated, 
time dependent screening approaches appeared to be of limited suitability for the identification of 
potential cellular targets. 
A facile two-step procedure for the preparation of Takemoto’s catalyst was developed. The thiourea 
moiety was obtained by condensation of 3,5-bis(trifluoromethyl)aniline with phenylchlorothioformate and 
direct reaction with trans-1,2-diaminocyclohexane. Subsequent reductive dimethylation using formalde-
hyde / zinc afforded Takemoto’s catalyst in an overall yield of 36 %. 
For the first time, an enantioselective aza-Baylis-Hillman reaction was catalysed by a chiral Lewis 
acidic metal complex. N-dpp-α-methylene-β-amino acid esters were obtained in up to 68 % yield and up 
to 90 % ee, using a La-linked-(R,R)-BINOL complex as catalyst and N-dpp-protected imines as sub-
strates. The subsequent hydrolytic C,N-terminal deprotection provided direct access to enantio-enriched 
α-methylene-β-amino acids in up to 75 % yield. 
 
Kurzzusammenfassung 
In Rahmen dieser Arbeit wurden neue Substanzen für die chemisch induzierte Kardiomyogenese von 
embryonalen Stammzellen entwickelt und Beiträge zu asymmetrischen C-C Kupplungen geleistet. 
Die Einfüsse von (Thio)Harnstoffderivaten und Cinchona-Alkaloiden auf die Bildung von Kardiomyocyten 
wurden an einer transgenen mausartigen embyronalen Stammzelllinie untersucht. In Screenings dieser 
Testsubstrate wurden Verbindungen identifiziert, welche eine 50 - 80 %ige Zunahme der Kardiomyogene-
se, verglichen zu unbehandelten Stammzellen, bewirken. In den untersuchten Testsystemen konnten 
durch zeitabhängige Screeningverfahren keine Eingrenzung potentieller Targetproteine vorgenommen 
werden. 
Eine vereinfachte zwei-Stufen Synthese zur Darstellung des Takemoto Katalysators wurde entwickelt. 
Die Thioharnstoffeinheit wurde dabei durch Kondensation von 3,5-(Bistrifluormethyl)anilin mit Phenylchlo-
rothioformiat und Reaktion mit trans-1,2-Diaminocyclohexan erhalten. Anschließende reduktive Dime-
thylierung mit Formaldehyd / Zink ergab den Takemoto Katalysator in einer Gesamtausbeute von 36 %. 
Weiterhin wurde eine enantioselektive aza-Baylis-Hillman Reaktion entwickelt, die erstmals durch 
einen chiralen Lewis sauren Metallkomplex katalysiert wurde. Einsatz eines (R,R)-BINOL-basierten La-
Komplexes als Katalysator und dpp - geschützter Imine als Substrate ergab N-dpp-α-Methylen-β-amino-
säureester in bis zu 68 % Ausbeute und bis zu 90 % ee. Hydrolytische C,N-terminale Entschützung führte 
in einem Schritt zu der entsprechenden freien α-Methylen-β-aminosäure in bis zu 75 % Ausbeute. 
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